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Introduction
Stroke is defined as an acute neurological deficit, such as hemiparesis, aphasia or speech 
disturbance, caused by a sudden occlusion (ischemic stroke or transient ischemic attack) 
or rupture of a cerebral artery (hemorrhagic stroke). Worldwide, stroke is the second 
leading cause of death and a major cause of disability,1 which affects about 15 million new 
patients every year,2 with numbers expecting to increase.3 Although stroke is generally 
believed to be a disease of the elderly, approximately 15% of all these strokes occurs in 
adults under the age of 50 and this proportion is also increasing.4 Stroke at a young age 
has a major impact on many aspects of daily life, such as work and social life, but also 
involves uncertainties of suffering recurrent cardiovascular disease, or fear of potential 
risks of future pregnancies. To appropriately counsel and treat the patient, it is of utmost 
importance to gain more insights on the risk factors and long-term prognosis of stroke 
at a young age.
Risk factors and long-term consequences of stroke in young adults
The “traditional” cardiovascular risk factors for stroke, such as diabetes, hypertension, 
smoking and hypercholesterolemia, are also frequent in young stroke patients.5 
However, also other, more age-specific risk factors can play a role, such as arterial 
dissection, clotting disorders and (complications during) pregnancy. Despite extensive 
investigations, the cause of stroke remains unknown in 30-40% of all patients with a 
stroke at a young age,6, 7 especially when the etiology of stroke is classified according to 
a classification system that was originally designed for elderly patients. In contrast, it 
is globally accepted that these “elderly” stroke classification systems are not applicable 
to stroke in children, e.g. pediatric stroke, and for these patients other classification 
systems are constructed.8, 9 However, to date there is no classification system specifically 
designed for stroke in young adults. Proper determination of the specific risk factors 
and causes of young stroke is a first step in unraveling specific mechanisms of stroke 
in young adults, which subsequently will also allow for studies investigating treatment 
for these young patients. Because pediatric stroke classification systems take rare causes 
of stroke more into account, a “pediatric” approach to risk factors and mechanisms of 
stroke could thus also provide more insight in the etiology of stroke in young adults. 
To date, this approach is not often applied.
When focusing on the long-term consequences after stroke, patients who suffer a stroke 
at a young age usually have a life expectancy of many decades ahead. Fortunately, in 
recent years more attention has been paid to the very long term prognosis of young 
stroke patients.10, 11 The risk of recurrent vascular events after stroke in young adults is 
not so favorable as earlier thought: even decades after the qualifying event these patients 
have a cumulative risk of 28-32% of developing at least one recurrent vascular event.10 
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However, the translation of these data towards personalized counseling is limited because 
the specific predictors that put an individual patient at risk for recurrent events have not 
been fully identified yet. 
Pregnancy and stroke in young adults
Among patients with a stroke at a young age there are also women who were pregnant 
during stroke or who want to become pregnant after a stroke. 
The incidence of pregnancy-related ischemic stroke is 12.2 per 100.000 pregnancies.12 
Although rare, in case of a stroke during pregnancy, the clinician should not only take 
care of the affected woman but also of her unborn child. Adequate care in the acute, but 
also later stages of stroke during pregnancy is therefore indispensable, but important 
knowledge gaps remain in current clinical guidelines.13 
Besides the clinical challenge of treating stroke during pregnancy, various pregnancy 
complications such as preeclampsia also increase the risk of future cardiovascular 
disease (CVD) such as stroke, possibly via shared risk factors or a common etiological 
pathway.14, 15 With the current knowledge that pregnancy complications are associated 
with stroke, women with a stroke may have concerns about the course of a subsequent 
pregnancy. However, it has never been investigated whether women are at increased 
risk of pregnancy complications after stroke. Also, the risk of a recurrent stroke during 
a subsequent pregnancy (and the influence of pregnancy complications on this risk) is 
still understudied. 
Patients with a previous stroke at young age are for yet an unknown reason also at 
increased risk for cerebral small vessel disease.16 As recent findings suggested that 
hypertensive disorders in pregnancy are a risk factor for the development of cerebral small 
vessel disease (SVD) later in life,17, 18 we aimed to investigate whether these hypertensive 
disorders in pregnancy also affect early in life SVD.
Answers to these relevant questions may help the clinician to appropriately inform and 
counsel these women. 
Aim of the thesis and study design
The aim of this thesis is to investigate the specific risk factors of stroke in young adults, 
with a special focus on pregnancy and pregnancy related disorders. We also aimed to 
investigate the long-term prognosis after stroke at a young age with respect to the risk 
of recurrent vascular events, SVD and pregnancy complications. 
The studies mentioned in this thesis are based on the Follow-Up of Transient ischemic 
attack and stroke patients and Unelucidated Risk factor Evaluation (FUTURE) study. The 
FUTURE study is a prospective cohort study of 1005 patients and specifically designed to 
investigate risk factors and long-term prognosis of stroke at a young age. All consecutive 
patients aged 18-50 years with an ischemic stroke, transient ischemic attack (TIA) or 
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1
intracerebral hemorrhage, admitted to the Radboud University Medical Center from 
January 1, 1980 until November 1, 2010 were included. Exclusion criteria were cerebral 
venous thrombosis, retinal infarction, subarachnoid hemorrhage, traumatic hemorrhage 
or hemorrhage from a known metastasis or brain tumor.
From November 1, 2009 to January 1, 2012, all patients alive were invited for an extensive 
follow-up assessment, including MRI scanning of the brain. Subsequently, from august 1, 
2014 to January 15, 2015 all patients alive were approached again to assess the occurrence 
of vascular events, and all women were contacted to assess the course and outcome of 
their pregnancies.
Outline of this thesis
In chapter 2 the rationale and design of the FUTURE study is described (part I). In part II 
we describe the specific mechanisms and long-term consequences of young ischemic 
stroke or TIA (chapter 3 and 4). In part III we focus on the management of stroke during 
pregnancy (chapter 5) and the incidence of pregnancy complications in women with 
young stroke compared to the general Dutch population (chapter 6). Furthermore, we 
will focus on the risk of small vessel disease after stroke at a young age, stratified by a 
history of hypertensive disorders of pregnancy (HDP) (chapter 7). In Part IV we describe 
the design and rationale of a new and ongoing prospective multicenter cohort study on 
risk factors and prognosis after a stroke at young age: The Observational Dutch Young 
Symptomatic StrokE studY (ODYSSEY) (chapter 8).
The final part of this thesis (part V) will provide a summary (chapter 9, chapter 11 
in Dutch) and discussion of the main results with implications and recommendations 
for clinical practice (chapter 10). 
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Abstract
Background and objective: Young stroke can have devastating consequences with 
respect to quality of life, the ability to work, plan or run a family, and participate in 
social life. Better insight into risk factors and the long-term prognosis is extremely 
important, especially in young stroke patients with a life expectancy of decades. To 
date, detailed information on risk factors and the long-term prognosis in young stroke 
patients, and more specific risk of mortality or recurrent vascular events, remains 
scarce.
Methods/Design: The FUTURE study is a prospective cohort study on risk factors 
and prognosis of young ischemic and intracerebral hemorrhage among 1006 patients, 
aged 18-50 years, included in our study database between 1-1-1980 and 1-11-2010. Follow-
up visits at our research centre take place from the end of 2009 until the end of 2011. 
Control subjects will be recruited among the patients’ spouses, relatives or social 
environment. Information on mortality and incident vascular events will be retrieved 
via structured questionnaires. In addition, participants are invited to the research 
centre to undergo an extensive sub study including MRI.
Discussion: The FUTURE study has the potential to make an important contribution 
to increase the knowledge on risk factors and long-term prognosis in young stroke 
patients. Our study differs from previous studies by having a maximal follow-up of 
more than 30 years, including not only TIA and ischemic stroke but also intracerebral 
hemorrhage, the addition of healthy controls and prospectively collect data during 
an extensive follow-up visit. Completion of the FUTURE study may provide better 
information for treating physicians and patients with respect to the prognosis of 
young stroke.
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2
Introduction
Up to 12% of all strokes occur in patients between 18-50 years (‘young’ stroke),1 affecting 
about 5000 patients each year in the Netherlands and about 2 million young people 
each year worldwide. In a substantial proportion of roughly one third the etiology 
remains unelucidated. In terms of prognosis a ‘young’ stroke has a dramatic influence 
on independency and quality of life as it occurs in the period of life that people start to 
form families, make decisive career moves, and have an active social life. Uncertainty 
about long-term prognosis affects choices and planning affiliated with these life events.
Whereas risk factors and prognosis in patients who develop a stroke at higher ages 
(usually over 70 years) are among the best studied topics in clinical medicine, this does 
not hold true for young stroke. At higher ages, almost all risk factors have atherosclerosis 
in their final common pathway. However, this cannot simply be extrapolated to young 
stroke as the underlying cause of stroke is usually different from that in elderly and may 
therefore also have a different prognosis both with respect to functional stroke outcome 
as to risks of recurrent stroke or other major vascular events. Even more, the identification 
of risk factors for young stroke so far has often been based on the occurrence of presumed 
risk factors in consecutive series of young stroke patients, without methodological sound 
comparison with controls.
The ‘long-term’ perspective in an on average over 70 years ‘old’ stroke patient differs from 
that of a 30 years ‘young’ stroke patient, and particularly studies with a long-term follow-
up of more than 10 years are lacking in the young stroke field. Studies thus far, usually 
with a mean follow-up duration of less than 7 years, report highly variable post-stroke 
mortality and risk of incident vascular disease.1-6 These large differences across studies 
are well explained because young stroke is a heterogeneous disease and most studies 
were small, had different selection criteria, did not investigate patients in person but 
relied on telephone interviews and outcome assessments and follow-up planning was not 
uniform and often suboptimal. Although stroke includes both ischemic and intracerebral 
hemorrhage, almost all studies have excluded the investigation of etiology and prognosis 
of young intracerebral hemorrhage.
Except for recurrent vascular disease and persistent motor and language impairments, 
post-’young’ stroke quality of life will most likely also be determined by cognitive 
dysfunction, depressive symptoms, fatigue, and specific post-stroke complications such 
as epilepsy, because those determine the ability to (return to) work and to have a normal 
family and social life. Data on those aspects in the very long-term follow-up of young 
stroke patients are even more scarce.
Although the absolute number of young stroke is lower than stroke among the elderly, the 
total number of years that young stroke patients as a whole will live with the consequences 
of the stroke exceeds that of older stroke survivors due to far longer survival.
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This justifies a properly designed and executed study on risk factors and prognosis of 
young stroke, compared with controls. We therefore set up the FUTURE study (Follow-
Up of Transient ischemic attack and stroke patients and Unelucidated Risk factor 
Evaluation study), the largest single-centre prospective cohort study on risk factors 
and prognosis of young TIA, ischemic stroke and intracerebral hemorrhage patients 
(n=1006) and controls.
Methods/Design
The FUTURE study is a prospective cohort study that aims to investigate the causes and 
consequences of a young stroke. The Medical Review Ethics Committee region Arnhem-
Nijmegen approved the study.
Patients
The department of neurology has a long-standing interest in the etiology and prognosis 
of young stroke and therefore maintains a prospective registry of all consecutive young 
stroke patients with a standardized collection of baseline and clinical characteristics (see 
baseline) since the 1970’ies.7 For the current FUTURE study, all consecutive TIA, ischemic 
stroke patients with presumed arterial origin or those with an intracerebral hemorrhage 
that sought medical attention for these disorders at the department of neurology of 
the Radboud University Nijmegen Medical Centre between 1-1-1980 and 1-11-2010 will be 
eligible for participation in the study.
Inclusion criteria
1. TIA, ischemic stroke of presumed arterial origin or intracerebral hemorrhage
2. Date of onset between 1-1-1980 and 1-11-2010
3. Age 18-50 years at onset
Exclusion criteria
1. Traumatic intracerebral hemorrhage
2. Intracerebral hemorrhage in known cerebral metastasis or primary brain tumor
3. Ischemic stroke/intracerebral hemorrhage due to cerebral venous sinus thrombosis
4. Intracerebral hemorrhage due to ruptured cerebral aneurysm
5. Any subarachnoid hemorrhage 
6. Retinal infarct
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TIA was defined as a rapidly evolving focal neurological deficit with no other than a 
vascular cause lasting less than 24 hours. Stroke was defined similarly, but with symptoms 
lasting more than 24 hours. Based on radiological findings, stroke was further subdivided 
into hemorrhagic and ischemic stroke.
As the diagnostic process may have changed during more than 30-year period all initial 
diagnoses were reviewed by a panel of 2 experts from a pool of 4 (FEdL, EvD, RA, LJD) and 
in cases of disagreement a consensus meeting was held to adjudicate the event.
1006 patients who had sought medical attention at our University Medical Centre 
between 1-1-1980 and 1-11-2010 fulfilled inclusion and exclusion criteria for our study. 
Characteristics of our baseline population (at the time of their qualifying event) are 
reported in table 1.
Table 1. Baseline population characteristics
 
Time of index event
Total population 1980-1989 1990-1999 2000-2010
n 1006 223 249 534
Male, n (%) 470 (46.7) 110 (49.3) 128 (51.4) 232 (43.4)
Age at index event, mean (SD) 40.2 (7.9) 39.3 (8.3) 39.7 (8.6) 40.8 (7.4)
Index event
TIA, n (%) 277 (27.5) 52 (23.3) 40 (16.1) 185 (34.6)
Infarction, n (%) 630 (62.6) 146 (65.6) 189 (75.9) 295 (55.2)
Hemorrhage, n (%) 99 (9.8) 25 (11.2) 20 (8.0) 54 (10.1)
Controls
Control subjects will be recruited among the patients’ spouses, relatives or social 
environment.
They must be at least 18 years old without a history of any TIA or stroke before the age 
of 50 at the moment of inclusion.
Baseline
At baseline (during the occurrence of the qualifying event for the study) a minimal 
dataset has been collected that consists of demographics, stroke subtype, risk factors 
and additional investigations (table 2). The completeness of the baseline dataset varies 
among patients due to changes in standard diagnostic procedures over the last 30 years.
Current common rating scales for the severity and cause of stroke did not exist at the 
time when a substantial proportion of our patients experienced their qualifying event. 
Therefore, a rating of both the severity (NIHSS) and cause (TOAST) was done for all cases 
retrospectively by a validated approach.8 
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Follow-up
Information on the vital status will be available either from hospital data or through 
coupling of patient records with data from the municipality registry. All patients alive will 
be approached for the follow-up assessment according to a two-step approach.
First, all patients will be contacted by letter to inform them about the study; subsequently 
they will be contacted by phone. In case the patient has moved, the municipality register of 
the last known residence will be contacted to trace the patient. In cases of an invalid phone 
number, a second letter will be sent asking the patient to contact our centre to provide a 
correct phone number. Subsequently, when a patient does not respond to the second letter, the 
last known general practitioner will be contacted to provide us with updated contact details. 
The patient will be considered lost to follow-up when known alive, but when untraceable via 
the procedure described above.
Subsequently, patients will be given the opportunity to participate in an extensive sub study. If 
they agree to do so, they will be invited to visit our research centre for additional investigations 
including a structured interview, cognitive assessment, physical and neurological examination, 
an extensive MRI protocol, an electrocardiogram and an ultrasonography of the carotid 
arteries (Table 2). In addition, blood samples (serum/plasma/DNA) will be taken for future 
analysis. When patients are not able to visit our research centre the same investigations 
will be performed at their homes, except for the ultrasonography of the carotid arteries, 
electrocardiogram and MRI scan. Controls will undergo the same protocol as patients.
The follow-up has started at the end of 2009 and is planned to finish at the end of 2011. 
All these participants signed an informed consent.
Outcome events
The primary outcome of the study will be all-cause mortality and the composite endpoint 
of death from all vascular causes; non-fatal stroke, non-fatal (silent) myocardial infarction, 
cardiovascular procedures (coronary artery bypass grafting, percutaneous transluminal 
coronary angioplasty, carotid endarterectomy and other arterial revascularization procedures), 
whichever occurred first. We will perform separate analysis for the occurrence of fatal or non-
fatal stroke. Causes of death will be categorized into ischemic stroke, intracerebral hemorrhage, 
cardiac causes, other vascular causes or non-vascular causes. If we cannot obtain information 
about the cause of death, the event will be classified as unspecified.
Secondary outcomes are seizures (classified according to the ILAE 9) and dementia (according 
to DSM-IV).
Whenever an outcome event is suspected with the aid of a standardized, structured 
questionnaire, information retrieved will be verified and adjudicated by physicians from 
the appropriate specialty. In case a patient has died, this information will be retrieved from 
their general practitioner or a relative. If there is no information available, the event will be 
classified as a possible event.
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Assessment of variables during follow-up
Demographics and life style
Standardized questionnaires on demographics, education (classified using 7 categories; 
‘1’ being less than primary school and ‘7’ reflecting an academic degree),10 marital status, 
living conditions, and life style habits (alcohol consumption, smoking, exercise) will 
be administered. Alcohol consumption will be defined as units per day and the age at 
which alcohol consumption had started (and ended if stopped) will be noted. Cigarette 
smoking behavior will be defined as never, former and current. Subsequently, former and 
current smoking behavior will be quantified as the number of pack-years, calculated as 
the number of packs of cigarettes smoked per day multiplied by the number of years a 
participant had smoked. Exercise will be expressed in the metabolic equivalent value 
(MET) according to accepted standards.11
Table 2. Schedule of assessments in the FUTURE study
Assessment Baseline Follow-up
Demographics
Ethnicity X
Education X
Marital status X
Social/living status X
Stroke Characteristics
Qualifying event X
Symptoms at onset X
Discharge date and destination X
TOAST X
NIHSS at admission and at discharge X
Modified Ranking Scale at discharge X
Medical History
History of any cardiovascular disease X  X*
Cardiovascular risk factors X  X*
Family history of cardiovascular disease X X
Medication use X  X*
Stroke related surgical procedures X  X*
Epilepsy X  X*
Neuropsychological examination
Global cognitive function
Mini Mental State Examination (MMSE) X X
Verbal memory function
Rey Auditory Verbal Learning Test X
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 26
Chapter 2
26
Table 2. Continued
Assessment Baseline Follow-up
Visuospatial memory
Rey’s Complex Figure Test X
Speed of information processing
Symbol-Digit Substitution Task X
Stroop test X
Working memory
Paper and Pencil Memory Scanning Tasks X
Executive functioning
Animal Fluency task X
Attention
Verbal series attention test X
Subjective cognitive failures
Cognitive failures questionnaire X
Depressive symptoms
Structured questionnaire depressive symptoms  X*
Mini International Neuropsychiatric Interview (MINI) X
Center of Epidemiological Studies Depression Scale 
(CES-D)
X
Hospital Anxiety and Depression Scale (HADS) X
Physical examination
Length and weight X X
Waist circumference X
Blood pressure X X
Heart rate X X
Neurological examination
Babinski sign X
Sensory system
Quantitative measurement by vibration tuning fork X
Muscle strength 
Medical Research Council Scale (MRC) X
Mobility and activities of daily living
TUG-test X
Exercise expressed in metabolic equivalent value X*
Tinetti test (body balance and gait) X
Modified Ranking Scale (MRS) X X
Barthel Index X
Instrumental activities of daily living questionnaire (IADL) X
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Table 2. Continued
Assessment Baseline Follow-up
Additional questionnaires
Fatigue
CIS20R X
Health related quality of life
Short Form 36 X
EQ-5D X
Stroke impact scale 3.0 X
Sleep disturbances X*
List of Threatening Experiences (LTE) X*
Work X*
Radiological examination
Confirmation of index event (CT or MRI) X
Angiography X
MRI
T1 magnetization-prepared rapid gradient echo X
FLAIR pulse sequences X
Transversal T2* weighted gradient echo sequence X
Diffusion Tensor imaging X
Resting state imaging X
Time-of-flight angiography X
Ancillary investigation
Electrocardiogram X X
Ultrasonography of the carotid arteries X X
* Variables were collected both for the period before and after the index event.
Medical history
Structured, standardized questionnaires will be used to assess participants history of 
hypertension, diabetes mellitus, atrial fibrillation, TIA, stroke, myocardial infarction, 
coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, 
carotid endarterectomy and other arterial revascularization procedures, 12-15 migraine 
with or without aura,16 pregnancy and malignancy. Whenever a primary or secondary 
outcome event is suspected with the aid of this standardized, structured questionnaire, 
information retrieved will be verified and adjudicated by physicians from the appropriate 
specialty (see outcome events). The presence of a family history of myocardial infarction, 
cerebrovascular disease and diabetes mellitus in next of kin will be recorded.
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Epilepsy
Each patient will be evaluated for a history of epilepsy by means of a standardized, 
structured questionnaire. Whenever epilepsy is suspected, information will be retrieved 
from the treating physician and verified and adjudicated by a neurologist (FEdL). Epilepsy 
will be classified according to the ILAE criteria.9 Post-stroke epilepsy will be subdivided 
into early (£7 days post-stroke) and late (>7 days) post-stroke epilepsy.
Current medication
Current medication use and the age at which medication use started will be noted 
and classified according to the Anatomical Therapeutic Chemical (ATC) classification 
system. (World Health Organization, WHO Collaborating Centre for drug statistics and 
methodology, http://www.whocc.no/atcddd/).
Neuropsychological assessment
We will administer an extensive neuropsychological test battery that encompasses items 
from other large-scale epidemiological studies covering the main cognitive domains.17, 18 Global 
cognitive function will be assessed using the Mini Mental State Examination (MMSE).19 
Verbal episodic memory function will be assessed by the 3-trial version of the Rey Auditory 
Verbal Learning Test (RAVLT) that also includes a delayed free-recall and recognition trial, a 
test used to evaluate the ability to acquire and retain new verbal information.20 Visuospatial 
episodic memory will be administered by the Rey Complex Figure Test (RCFT), that consists 
of 3 trials: a copy trial, an immediate recall trial after 3 minutes and a delayed-recall trial after 
30 minutes.21 To evaluate speed of information processing and executive function, 2 tests will 
be used; the abbreviated Stroop Color Word Test (3 subtasks, the interference trial measuring 
response inhibition)22 and the Symbol-Digit Substitution Task, which is a modified version of 
the Symbol Digit Modalities Test.23 A verbal fluency task in which as many animals as possible 
have to be named within 60 seconds will be used to test semantic memory and executive 
functioning (response generation). To assess working memory, the Paper and Pencil Memory 
Scanning Task (4 subtasks)24 will be used. To evaluate attention, the verbal series attention test 
(VSAT) will be used.25 To register subjective cognitive failures we will administer the modified 
Cognitive Failures Questionnaire (CFQ).26 The assessments will be carried out under standard 
circumstances in quiet rooms.
A standardized structured questionnaire used in previous large-scale epidemiological studies 
will be used to assess the history of depressive symptoms; normal reactions to stressful 
events or normal grief will carefully be excluded.27 In case of a depressive episode, age of 
onset, the medical advice and medication use will be registered. We defined ‘depression’ 
as those depressive episodes that have required attention of a general practitioner, 
psychologist, or psychiatrist. This definition includes minor depression, as well as more 
severe depression syndromes such as major depression and bipolar depression.27
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In addition, participants will be screened for current depressive symptoms by means of the 
Mini International Neuropsychiatric Interview (MINI), part A, which is a short diagnostic 
structured interview based on the DSM IV.28 Additionally, presence of actual depressive 
symptoms will be assessed by 2 self report questionnaires, the Centre of Epidemiologic 
Studies Depression Scale (CES-D)29 and the Hospital Anxiety and Depression Scale 
(HADS).30
Physical and Neurological Examination
Height and weight will be measured without shoes in light clothing. The body mass index 
(BMI) will be calculated as weight divided by height (in meters) squared. The maximal 
waist circumference will be measured without shirt, in standing position, between the 
lowest rib and the iliac crest, at the end of normal expiration.31 Blood pressure and pulse 
rate will be measured in triplicate in supine position after 5 minutes rest. Subsequently 
one measurement is performed after 1 minute in upright position.14
The strength of the biceps, hand grip, iliopsoas, quadriceps and foot extensor muscles on 
both sides will be scored according to the medical research council scale (MRC).
The sensory system will be assessed by a quantitative measurement by vibration tuning 
fork (Rydel-Seiffer®) on both first toes and both medial malleoli, also registering ankle 
edema and the ankle jerk reflex.
Gait and balance
We will use a widely used modified version of the original Tinetti test with 17 items: 
9 for body balance (score 0-16) and 8 for gait (score 0-12), with a maximum score of 
28.32 It grades balance while sitting, standing with eyes open and closed, nudging and 
turning, gait initiation, stride length and width and symmetry. Functional mobility will 
be classified by using the widely-used timed-up-and-go(TUG)-test which is a timed test 
during which the participant is asked to rise from a standard armchair, walk 3 m, turn, 
walk back and sit down again.33 Each participant will perform the test 3 times.
Functional performance
As a measure of disability the Barthel Index and modified Ranking Scale will be used.34 
The activities of daily living will be assessed by the instrumental activities of daily living 
questionnaire.35
Additional self-report questionnaires
Several primary sleep disorders are addressed using a number of screening questions. The 
presence of possible sleep disordered breathing is based on a history of snoring, witnessed 
sleep-related apneas and non-restorative sleep. Non-REM and REM parasomnias are 
addressed based on a history of sleepwalking, dream-enacting behavior. Excessive daytime 
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sleepiness will be assessed based on the presence of continuous feelings of sleepiness, 
sleep attacks or a combination of both. Finally, the presence of sleep-onset and/or sleep-
maintenance insomnia is recorded. 
For the assessment of fatigue we will use the Checklist on Individual Strength (CIS20R).36 
The overall health status (quality of life) will be assessed with the Short Form 36 (SF-36),37, 
38 the EQ-5D,39 and the Stroke Impact Scale 3 (SIS-3).40
Adverse life events will be assessed with the 12-item List of Threatening Events (LTE), 
6 months before the index event and subsequently the period after the index event.41
Patients will be asked for their employment status in the month before their index event, 
within the first year after their index event and at time of the follow-up visit. Each period 
includes a description of occupation, working hours a week, adjustments in tasks, use of 
supporting devices and reasons for not working.
Ancillary Investigations
MRI protocol
MRI scanning will be performed on a 1.5-Tesla Magnetom scanner (Siemens, Erlangen, 
Germany). The scanning protocol includes whole brain 3D T1 magnetization-prepared 
rapid gradient-echo (MPRAGE) sequence (TR/TE/TI 2730/2.95/1000ms; flip angle 7°; 
voxel size 1.0x1.0x1.0mm); FLAIR pulse sequences (TR/TE/TI 12220/85/2200 ms; voxel 
size 1.0x1.2x3.0mm; slice gap 0.6 mm); transversal T2-weighted turbo spin echo sequence 
(TR/TE 7440/96ms; voxel size 0.9x0.9x3.0 mm; slice gap 0.6 mm); Multi-slab 3D time of 
flight angiography sequence (TR/TE 24/7ms; voxel size 0.8x0.5x1.0mm) will be made 
of the carotid arteries and the circle of Willis. Gradient echo susceptibility weighted 
imaging sequence (TR/TE 49/40ms; voxel size 0.8x0.7x1.0mm); DTI (TR/TE 9100/98ms; 
voxel size 2.2x2.2x2.2mm; 7 unweighted scans, 61 diffusion weighted scans, with non 
co-linear orientation of the diffusion-weighting gradient, and b value 1000s/mm²) and 
resting state imaging using a gradient echo EPI (TR/TE 1870/35ms; voxel size 3.5x3.5x3.0 
mm; slice gap 0.5mm). During resting state, participants will be told not to concentrate 
on any particular subject, but just to relax with their eyes closed. The complete scanning 
protocol takes approximately 60 minutes.
Electrocardiogram 
An electrocardiogram (ECG) will be performed and evaluated by a standardized assessment 
by an experienced cardiologist, registering frequency, cardiac rhythm, cardiac ectopias, 
cardiac axis, conduction time over the PQ, QRS and QTC intervals, conduction disturbances, 
left ventricle hypertrophy, pathologic Qs, infarction, repolarisation disturbances and acute 
ischemia. A final diagnosis is defined as normal, abnormal without clinical significance, 
abnormal with clinical consequences or pathologic ECG with immediate consultation of 
a cardiologist when necessary.
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Carotid ultrasound
A carotid ultrasound assessment will be performed at which the intima media 
thickness (IMT) will be measured in the distal (near the bulbus) left and right 
common carotid artery. All measurements will be performed using a phased array 
real-time scanner (Philips i-u22, The Netherlands) with a 17-5 MHz broadband linear 
transducer. The IMT will be automatically measured by QLab® qualification software 
(V. 4.2.1.) according to previously described procedures.42 All ultrasound measurements 
will be performed by three experienced and specific trained clinical neurophysiology 
technicians.
Blood sampling
Fasting blood samples will be taken. Immediate analysis will include glucose, creatinine, 
lipid profile and complete blood count. Additional serum, plasma and DNA will be stored 
(-80°C) for future biochemical and genetic analyses.
Statistical analysis
Cumulative risk of primary and secondary outcomes will be estimated with Kaplan-Meier 
analysis. In the analysis of vascular events, patients who had died from other than the 
defined fatal endpoints will be censored at the time of death. Cox proportional hazard 
models will be used to calculate the risk of suffering from any of the primary or secondary 
outcomes in the follow-up period, with adjustments for the necessary covariates. The 
relative risk (hazards ratios) will be calculated with their corresponding 95% confidence 
intervals.
Cross-sectional analysis (for example in the comparison between patients and controls 
of data acquired during the follow-up) of continuous variables will be done with 
Student’s t-test or analysis of variance or in case of skewed distributions which cannot 
be normalized corresponding nonparametric tests will be used. Chi-squared test will be 
used for cross-sectional analysis of categorical variables.
Discussion
Detailed information on risk factors and the long-term prognosis in young stroke patients, 
and more specific the risk of mortality and recurrent vascular events, remains scarce. 
These data are often derived from selected patients (often with the exclusion of TIA and 
intracerebral hemorrhage patients) in small sized studies with short follow-up without 
in person assessment of risk factors and outcomes. We therefore performed the FUTURE 
study, designed to investigate risk factors and to prospectively assess prognosis in a large 
cohort of young stroke patients.
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Strong elements of our study are the inclusion of both TIA and hemorrhagic and ischemic 
stroke patients, the very long follow-up (up to 30 years), its sample size of over 1 000 
potential participants and the availability of baseline data of all consecutive patients in a 
single university medical centre. In addition, the extensive investigation during a follow-
up visit, including advanced neuroimaging has the potential of major contributions to 
the field. Our study differs from many other young stroke studies due to the inclusion of 
controls that enable us to compare the frequency of some presumed, but also unknown, 
risk factors between patients and controls. Detailed risk factor analysis can be done, not 
only for commonly documented risk factors but also for those that are rarely documented 
in medical records, like physical inactivity and sleep disturbances. Moreover, the inclusion 
of healthy controls provides the opportunity to distinguish consequences of a young 
stroke from other factors like aging effects.
We feel that completion of our study may contribute to a better understanding of the 
etiology of young stroke and may provide better information for treating physicians and 
patients with respect to the prognosis of young stroke.
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Abstract
Background: Incidence of ischemic stroke and transient ischemic attack (TIA) in 
young adults. However, etiology remains unknown in 30-40% of these patients when 
current classification systems designed for the elderly are used. 
Objective: Our aim was to identify risk factors according to a pediatric approach, 
which might lead to better identification of risk factors and provides a stepping 
stone for the understanding of disease mechanism, particularly in patients currently 
classified as “unknown etiology”.
Methods and results: Risk factors of 656 young stroke patients (aged 18-50) of the 
FUTURE study were categorized according to the “International Pediatric Stroke 
Study” (IPSS). Categorization of risk factors into ≥1 IPSS category was possible in 94% 
of young stroke patients. Chronic systemic conditions were more present in patients 
aged <35 compared to ≥35 years (32.6% versus 15.6%. p<0.05). Among 225 patients 
classified as “stroke of unknown etiology” using TOAST, we found risk factors in 198 
patients (88%) with the IPSS approach.
Conclusion: We identified multiple risk factors linked to other mechanisms of young 
stroke than in the elderly. This can provide a valuable starting point to develop an 
etiologic classification system specifically designed for young stroke patients.
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Introduction
The incidence of ischemic stroke among young adults (18-50 years) is rising and is 
currently estimated to constitute up to 15-18% of all ischemic strokes.1, 2 These young 
individuals, who are often in a period of life during which important decisions on starting 
a family or a career are being made, remain at high risk for recurrent stroke.3 As these 
patients generally still have a life expectancy of decades ahead, knowledge of risk factors 
and causes of stroke is essential to inform them on the cause of the disease and to possibly 
prevent future vascular disease. Despite the ever increasing number of young stroke 
patients, the risk factors and causes of stroke remain unknown in about one third of 
all patients,4 partly because of the tendency to classify them according to classification 
systems developed for elderly stroke patients, for example the TOAST classification.5 
This classification does not take into account other potential mechanisms of stroke that 
particularly occur in the young, including (reversible) vasoconstriction, migraine and non-
atherosclerotic (for example inflammatory) arteriopathies, as these are seldom causing 
stroke in elderly patients.6 At best, young patients with these causes end up as being 
classified with a stroke due to an “other determined” cause.
Another potential disadvantage of using a classification system developed for elderly 
patients is that treatment options based on this approach usually result in an “one size fits 
all” strategy, usually directed towards the prevention of recurrent thrombus formation, 
whereas this mechanism might only apply to a part of the young stroke patients. 
Conversely, stroke at the other end of the age spectrum, namely between 1-18 years, so 
called pediatric stroke is clearly recognized to be different from stroke in older patients, 
and risk factors are identified accordingly.7, 8 Applying this approach to a large group of 
young stroke patients may lead to an improved identification of risk factors and causes for 
stroke in young adults, leaving a smaller residual category of patients with an unknown 
cause of stroke. 
Therefore, the aim of this study was to investigate the prevalence of all potential risk 
factors in patients with a first-ever ischemic stroke or TIA aged 18-50 years, and categorize 
them according to the approach of the International Pediatric Stroke Study (IPSS).7 The 
second aim was to evaluate the effect of this approach on the residual proportion of 
patients that were classified as having an “unknown etiology” according to TOAST- 
criteria. Finally, we aimed to assess whether risk factor categorization according to IPSS 
may result in identifying more patients with a risk factor or cause of the disease in specific 
subgroups, such as age or sex.
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Materials and methods
Study population
This study is part of the FUTURE – study (Follow-Up of Transient ischemic attack and 
stroke patients and Unelucidated Risk factor Evaluation) a prospective cohort study on 
patients with a stroke at young age. Extensive details of the study have been described 
previously.9 The Medical Review Ethics Committee region Arnhem-Nijmegen approved 
the study. All patients signed informed consent. In short, all consecutive patients aged 18-
50 years admitted to our University hospital between 1980-2010 with either an ischemic or 
hemorrhagic stroke or TIA were included. For the present study we only included patients 
with a first-ever ischemic stroke or TIA. Exclusion criteria were cerebral venous sinus 
thrombosis and retinal infarction. TIA was defined as a rapidly evolving focal neurological 
deficit, without positive phenomena such as twitches, jerks, or myoclonus, with vascular 
cause only and persisting for a period of less than 24 hours.10, 11 Stroke was defined as a focal 
neurologic deficit persisting for more than 24 hours. Distinction between ischemic and 
hemorrhagic stroke was made based on radiological findings. From all patients, baseline 
characteristics were collected. Furthermore, severity of stroke (NIHSS; National Institutes 
of Health Stroke Scale)12 was assessed by a previously validated approach.13, 14 
Risk factor categorization following IPSS definitions 7
Information with respect to risk factors (following IPSS definitions), concurrent diseases 
as well as classical cardiovascular risk factors were extracted from medical charts in a 
structured, standardized way. Risk factors (either present in patients’ medical history 
or diagnosed when admitted for stroke) were divided into nine categories, based on 
IPSS definitions for pediatric stroke: arteriopathy, cardiac disorders, chronic systemic 
conditions, prothrombotic states, acute systemic conditions, chronic head and neck 
disorders, acute head and neck disorders, infection and risk factors for atherosclerosis in 
adulthood (which we changed in “risk factors for early atherosclerosis”). We additionally 
added one category called “pregnancy”, as pregnancy and the post partum period (< 6 
weeks) are one of the most prevalent risk factors in female young stroke patients.6, 15 
Definitions of all categories are found in table 1. Patients with more than one risk factor 
or cause were not mutually exclusive to one category.
Classification following TOAST criteria
Assessment of etiology was based on the modified Trial of Org 10172 in Acute Stroke 
Treatment classification as described earlier.16, 17 The modified TOAST classification has 
an additional category: “likely large-artery atherosclerosis.”
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Table 1. Definitions according to the risk factor categorization of the International 
Pediatric Stroke Study (IPSS)
Risk factor category Definition
1. Arteriopathy Arteriopathy: Any arterial abnormality on vascular imaging 
besides isolated vessel occlusion. Arterial dissection had to be 
confirmed by angiography (MRA/CTA/conventional).
2. Cardiac disorders Either a history of chronic cardiac disorder or when detected on 
ECG or echocardiography during analysis of stroke.
3. Chronic Systemic conditions A condition or disease with known changes in coagulation or 
vascular structure, such as connective tissue disease, genetic 
disorder, hematological, inflammatory or immune system 
disorder, oncological disease, use of oral contraceptives.
4.  Prothrombotic states A known disease in coagulation or found on laboratory testing, 
such as Factor V Leiden, antiphospholipid syndrome, protein C/S 
deficiency.
5.  Acute systemic disorders Any acute condition that leads to systemic disturbances, e.g. 
sepsis, hypotension, shock, <72 hrs after surgery.
6.  Chronic Head and neck 
disorders
A disease localized in the area of the head or neck, e.g. migraine, 
tumor, aneurysm or AVM.
7.  Acute head and neck disorders An acute disease, surgery or trauma localized in the head or neck 
region
8.  Pregnancy related a Stroke or TIA during pregnancy or the postpartum period 
(defined as within 6 weeks after delivery)
9.  ≥1 risk factors for early 
atherosclerosis b
Either a history of a risk factor (mentioned in medical history or 
the use of medication) or detected during admission or analysis 
of the stroke in the outpatient clinic.
-Diabetes mellitus as a random blood glucose level greater than 
200 mg/dL (11.1 mmol/L) or 2 consecutive fasting venous plasma 
glucose levels of 126.1 mg/dL (7.0 mmol/L) or greater.
-Hypertension as systolic blood pressure 135 mm Hg or greater, 
diastolic blood pressure 85 mm Hg or greater, or both, measured 
after the first week of the index event.
-Smoking as at least 1 cigarette per day in the year prior to the 
event.
- Excess alcohol consumption as consuming more than 200 g of 
pure alcohol per week. 
- Dyslipidemia as a cholesterol level of ≥5.0 mmol/l, LDL of ≥2.5 
mmol/l and/or triglycerides of ≥2.0 mmol/l.
a Category not present in original IPSS criteria, added for young adults6, 15, b Based on definitions of classical risk 
factors described earlier37
Abbreviations: MRA: Magnetic resonance angiography; CTA : Computed tomography angiography; AVM: 
arteriovenous malformation
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 44
Chapter 3
44
Statistical analysis
Prevalence of risk factors according to the IPSS score was determined. The distribution 
among the nine categories of the IPSS score was subsequently stratified by age (from 18 
to 35 years and from 35 to 50 years), stroke subtype (TIA or ischemic stroke) and sex. In 
addition, stroke etiology was also categorized by TOAST-classification and stratified by 
age groups (aged above or under 35 years). Finally, for patients with an unknown cause of 
stroke according to the TOAST-classification we determined the number of risk factors 
according to the IPSS categories. Numbers were presented as means or as medians for 
data with a normal or non-normal distribution respectively. For comparison of categorical 
variables between groups Chi-square or Fisher’s exact test were used when appropriate. 
Analyses were performed using IBM SPSS Statistics for Windows version 22.0 (IBM Corp., 
Armonk, NY). All p-values <0.05 were considered significant.
Figure 1. Flowchart of Study Population
Baseline population
n=1005 
Intracerebral 
hemorrhage n=98
Lost to follow-up, n= 73
 TIA/Stroke in medical 
history n=39
Refused to participate 
in follow-up
n=139
Eligible patients for present study
N=656
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Results
Baseline characteristics
Of 1005 patients enrolled in the FUTURE study, 656 cases with an ischemic stroke or 
TIA were eligible for assessment (figure 1). Participants and non-participants did not 
significantly differ except participants were slightly older than non-participants (40.7 yrs 
(SD 7.7) versus 39.1 yrs (SD 8.2) respectively). Baseline characteristics are shown in table 2. 
Categorization of risk factors according to IPSS criteria
Table 3 and Figure 2 show the risk factors present in 656 young stroke patients, categorized 
by stroke subtype according to IPSS criteria. We were able to classify 619 patients (94%) 
into at least one IPSS category, 315 patients (48.0%) were classified in two or more IPSS 
categories. None of the young patients was categorized into the IPSS category “infection” 
(one patient with a tonsillar abscess was listed as “acute head and neck disorder”).
Chronic systemic conditions (19.2%), chronic head and neck disorders (14.6%), cardiac 
disorders (13.9%) and arteriopathy (12.2%) were the most reported risk factor categories 
among patients with a young stroke, besides ≥1 risk factors for early atherosclerosis 
(95.3%). 
When stratified according to age (table 4), we found that chronic systemic conditions were 
significantly more present in stroke patients <35 years old compared with those ≥35 years 
old (32.6% versus 15.6%, p <0.05). On the other hand, risk factors for early atherosclerosis 
were more present in stroke patients aged 35 years or older versus patients younger 
than 35 years (96.9% and 89.0% respectively, p <0.05). When stratified by sex (table 4), 
women were more likely to have a chronic head and neck disorder and a chronic systemic 
condition than men (20.2% versus 8.4%, p<0.0001; 74.7% versus 25.3%, p<0.05).
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Table 2. Baseline characteristics
No. (%)
Total
656 (100)
TIA
209 (31.9)
Ischemic stroke
447 (68.1)
Mean age at stroke, yrs. [SD] 40.7 [7.7] 40.6 [8.0] 40.8 [7.6]
Age distribution, n (%)
 < 35 yrs. 
 ≥ 35 yrs.
138 (21.0)
518 ( 79.0)
52 (24.9)
157 ( 75.1)
86 (19.2)
361 (80.8)
Men, n (%) 309 (47.1) 94 (45.0) 215 (48.1)
Median NIHSS at admission (IQR)* 3 (1-7) 0 (0-1) 5 (2-10)
mRS ≥ 2 at discharge, n (%) 140 (21.3) 5 (2.4) 135 (30.2)
Etiology based on TOAST, n (%)
 Large artery disease
 Likely large artery disease
 Cardio-embolic stroke
 Small vessel disease
 Other defined
 Multiple causes
 Unknown cause
64 (9.8)
102 (15.5)
87 (13.3)
65 (13.1)
96 (14.6)
17 (2.6)
226 (34.5)
12 (5.7)
35 (16.7)
27 (12.9)
11 (5.3)
23 (11.0)
2 (1.0)
99 (47.4)
52 (11.6)
67 (15.0)
60 (13.4)
54 (12.1)
73 (16.3)
15 (3.4)
127 (28.4)
Period of inclusion, n (%)
 1980-1989
 1990-1999
 2000-2010
143 (21.8)
171 (26.1)
342 (52.1)
39 (18.7)
34 (16.3)
136 (65.1)
104 (23.3)
137 (30.6)
206 (46.1)
* NIHSS was missing in 3 cases. 
Abbreviations: TIA: transient ischemic attack, NIHSS: national institutes of health stroke scale, IQR: interquartile 
range, mRS: modified ranking scale, TOAST: Trial of Org 10172 in Acute Stroke Treatment.
Classification according to TOAST criteria
The distribution of patients across the various TOAST categories was age-dependent 
(table 5). Patients aged ≥35 years were more likely to be classified as having “large artery 
disease” than patients aged <35 years (11.6% versus 2.9% p<0.05) or as “likely large artery 
disease” (18.3% versus 5.1% p <0.05). On the other hand, stroke was more likely to be 
classified as “other defined etiology” in patients younger than 35 years (23.2% versus ≥35 
years 12.4% p<0.05). Stroke of cardio-embolic origin was equally found across both age 
groups (<35 years: 12.3% versus ≥35 years: 13.5%). In 225 patients (34.3%) a cause of stroke 
was not found according to TOAST criteria and was accordingly classified as “unknown 
etiology” (table 6); this was the most reported category in patients younger than 35 years 
(48.6% versus ≥35 years 30.5%, p<0.05). 
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 47
Risk factors and mechanisms of stroke in young adults
47
3
Figure 2. Comparison of IPSS versus TOAST classification
IPSS classification in children (a) and adults aged 18-50 years (b) 
TOAST classification in children (c), adults aged 18-50 years (d) and the elderly (e) 
(b)
Arteriopathy
Cardiac disorders
Chronic Systemic conditions
Prothrombotic states
Chronic Head and neck disorders
Acute head and neck disorders
Pregnancy related
≥1 RF for early atherosclerosis
Other
(a)
(c) (d) (e)
Large artery disease
Likely large artery disease
Cardio-embolic origin
Small vessel disease
Other defined
Multiple causes
Unknown etiology
Distribution of IPSS risk factors in children < 18 years (a) and in young adults aged 18-50 years; data from the 
FUTURE cohort6 (b). Estimation of causes in stroke in children <18 years (c), in young adults aged 18-50 years (the 
FUTURE cohort)6 (d) and in adults >50 years38 (e) when classified according to the TOAST classification
According to IPSS categorization, we found additional risk factors in 198 out of these 225 
patients (88.0%). We identified 13 patients (5.8%) with a prothrombotic disorder, 11 patients 
(4.9%) with hyperhomocysteinemia, one patient (0.4%) with antiphospholipid syndrome 
and one patient (0.4%) with Factor V Leiden. Migraine was reported in 38 patients 
(16.9%). Ten cases (8.1%) were pregnancy related, with nine women suffering stroke during 
pregnancy and one woman within 6 weeks post-partum. We found 44 patients (19.6%) 
with a chronic systemic condition; three patients (1.3%) with an autoimmune disorder, 
one patient (0.4%) with a hematological disease, one patient with an active oncological 
disease and one patient with a genetic disorder. Oral contraceptives were used by 37 of 
123 women (30.1%), Also, 188 patients (90.0%) out of these 225 with unknown etiology had 
at least one risk factors for early atherosclerosis. No arteriopathies or cardiac disorders 
were found.
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Table 3. Prevalence of risk factors categorized based on IPSS methods
IPSS Risk factor category
No. (%)
Total
656 (100)
TIA
209 (31.9)
Ischemic stroke
447 (68.1)
Arteriopathy a (n=368), n (%)
 Arterial dissection
 CADASIL
 Moyamoya
 Vasculitis
 Vasospasm
 Unspecified arteriopathy
 Other
45 (12.2)
29
1
5
5
3
1
1
12 (11.0)
4
0
2
4
2
0
0
33 (12.7)
25
1
3
1
1
1
1
Cardiac disorders, n (%)
 Acquired heart disease
 Congenital heart disease
 Atrial fibrillation
 Myocardial inflammation
 Prosthetic valve
 Myocardial disease
 Valve disease
 PFO
 PFO+ b
 <72 hrs after cardiac surgery
 Intracardiac thrombus
 Other
91 (13.9)
4
9
13
8
9
14
16
14
6
4
5
5
26 (12.4)
2
4
3
2
2
4
2
4
1
3
1
2
65 (14.5)
2
5
3
5
6
10
13
10
5
1
4
3
Chronic Systemic conditions, n (%)
 Connective tissue disease
 Genetic disorder
 Hematological disorder
 Immune system disorder c
 Inflammatory disease
 Oncological disease
 Oral contraceptive pill
 Other
126 (19.2)
3
3
4
21
2
4
97
1
30 (14.4)
1
0
1
4
0
1
23
1
96 (21.5)*
2
3
3
17
2
3
74
0
Acute systemic disorders, n (%)
 <72hrs after surgery
 Hypotension
3 (0.5)
2
1
0 (0.0)
0
0
3 (0.7)
2
1
Chronic Head and neck disorders, n (%)
 Aneurysm
 Brain tumor
 Intracranial AVM
 MELAS
 Migraine
 Other cranial tumor
96 (14.6)
1
3
1
3
87
1
37 (17.7)
1
1
0
0
35
0
59 (13.2)
0
2
1
3
52
1
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Table 3. Continued
IPSS Risk factor category
No. (%)
Total
656 (100)
TIA
209 (31.9)
Ischemic stroke
447 (68.1)
Acute head and neck disorders, n (%)
 Head or neck surgery
 Head or neck trauma
 Tonsillar abscess
8 (1.2)
5
2
1
3 (1.4)
2
1
0
5 (1.1)
3
1
1
Pregnancy related (n=347), n (%)
 Post-partum
 During pregnancy
20 (5.8)
4
16
11 (9.6)*
0
11
9 (3.9)
4
5
≥1 RF for early atherosclerosis d (n=615), n (%)
 ≥ 2
 ≥ 3
 ≥ 4
586 (95.3)
 346 (59.5)
 119 (19.3)
 21 (3.2)
185 (94.4) 
101 
 35
 5
401 (95.7)
 245 
 84
 16
Patients were not exclusive to one category. Some patients carried more than one risk factor in a category. a Vascular 
imaging (MRA/CTA/conventional angiography) not performed in n=288 (excluding duplex of carotid arteries). b 
PFO+: Patent foramen ovale in combination with a thrombus, septum aneurysm or left-right shunting. c Sjogren’s 
disease (n=1) Wegener’s disease (n=1), systemic lupus erythematosus (SLE, n=13) and immune thrombocytopenic 
purpura (ITP, n=5). d Complete information was unknown in n=41. 
Abbreviations: TIA: Transient ischemic attack, CADASIL: cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy, PFO: Patent foramen ovale, MELAS: Mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes, RF: risk factor. 
* p<0.05: TIA compared to Ischemic stroke patients. 
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Table 4. Prevalence of IPSS risk factor categories stratified by age and sex respectively
IPSS Risk factor category
No. (%)
<35 years
138 (21.1)
≥35 years
518 (78.9)
Men
309 (47.1)
Women
347 (52.9)
Arteriopathy a (n=368), n (%) 10 (13.7) 35 (11.9) 17 (5.5) 28 (8.1)
Cardiac disorders, n (%) 18 (13.0) 73 (14.1) 35 (11.3) 56 (16.1)
Chronic Systemic conditions, n (%) 45 (32.6)* 81 (15.6) 12 (3.9) 114 (32.9)*
Prothrombotic states, n (%) 15 (10.9) 36 (6.9) 18 (5.8) 33 (9.5)
Chronic Head and neck disorders, n (%) 23 (16.7) 73 (14.1) 26 (8.4) 70 (20.2)*
Acute head and neck disorders, n (%) 4 (2.9) 4 (0.8) 5 (1.6) 3 (0.9)
Pregnancy related (n=347), n (%) 15 (16.0)* 5 (2.0) N/A 20 (5.8)
≥1 risk factor for early atherosclerosis b 
(n=615), n (%)
113 (89.0) 473 (96.9)* 277 (96.2) 309 (94.5)
The category “acute systemic disorders” was not incorporated because of small numbers (n=3). a Vascular imaging 
(MRA/CTA/conventional angiography) not performed in n=288 (excluding duplex of carotid arteries).b Complete 
information was unknown in n=41. 
* p<0.05: comparison based on age (<35 years versus ≥35 years) or sex respectively. 
Table 5. Classification of young stroke based on TOAST criteria, stratified by age
TOAST category
No. (%)
<35 years
138 (21.1)
≥35 years
518 (78.9)
Large artery disease, n (%) 4 (2.9) 60 (11.6)*
Likely large artery disease, n (%) 7 (5.1) 95 (18.3)*
Cardio-embolic origin, n (%) 17 (12.3) 70 (13.5)
Small vessel disease, n (%) 8 (5.8) 57 (11.0)
Other defined, n (%) 32 (23.2)* 64 (12.4)
Multiple causes, n (%) 3 (2.2) 14 (2.7)
Unknown etiology, n (%) 67 (48.6)* 158 (30.5)
Abbreviation: TOAST: Trial of Org 10172 in Acute Stroke Treatment.
*p<0.05: patients <35 years compared to ≥35 years.
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Table 6. Prevalence of IPSS risk factor categories within TOAST category “stroke of 
unknown etiology”
IPSS Risk factor category
No. (%)
Stroke of unknown etiology (TOAST)
225 (34.3)
Arteriopathy, n (%) 0(0.0)
Cardiac disorders, n (%) 0 (0.0)
Chronic Systemic conditions, n (%) 44 (19.6)
Prothrombotic states, n (%) 13 (5.8)
Acute systemic disorders, n (%) 0 (0.0)
Chronic Head and neck disorders, n (%) 38 (16.9)
Acute head and neck disorders, n (%) 1 (0.4)
Pregnancy related (n=123), n (%) 10 (8.2)
≥1 risk factor for early atherosclerosis (n=209), n (%) 193 (90.0)
Abbreviation: TOAST: Trial of Org 10172 in Acute Stroke Treatment.
Discussion
We have shown that classifying risk factors according to the IPSS in patients with a stroke 
at young age may lead to a more appropriate categorization of risk factors. By doing so, 
we were able to find at least one risk factor in 94% of 656 patients. In addition, in almost 
90% of patients that would have been categorized as “unknown etiology” according 
to the TOAST classification we were able to identify risk factors. This calls upon an 
appropriate stroke classification system specifically tailored for younger stroke patients. 
To our knowledge, we are the first to apply a pediatric stroke risk factor categorization to 
a large young stroke population leading to a unique opportunity to characterize stroke 
or TIA in young adults more accurately.
However, also some limitations need to be addressed. Due to the long inclusion period, 
diagnostic measures and strategies may have changed over time leading to variable 
approaches of risk factor identification as well as new etiologic insights might have 
emerged. This is supported by the fact that we found patients more likely to be classified 
into a specific category (e.g. arteriopathy, prothrombotic disorders and chronic systemic 
conditions) when they suffered a stroke more recently (inclusion period 2000-2010 
compared with those included between 1980 and 1990). Second, initially our data were 
not collected according to the study protocols of the IPSS, thus some specific (pediatric) 
risk factors were only identified when mentioned in the history of the patient or when 
a specific situation warranted further diagnostic evaluation (such as genetic disorders). 
This might potentially have caused some misclassification. Also, in case of short-term 
survivors (3.4% first month, 5.9% first year) the diagnostic process might not have been 
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performed to full extent. However, we feel that our approach, if any, would only have led 
to an underestimation of presence of risk factors, although we were able to find a least 1 
risk factor in 94% of patients. 
Furthermore, our data cannot directly be used as a mutually exclusive classification 
system because identification of risk factors is not limited to only one IPSS risk factor 
category. Also, amongst all reported risk factors, some are qualified as a necessary causal 
factor for stroke whilst other factors can be considered sufficient causes.18 However, this 
appears almost to be inevitable with classification systems of causes of stroke as virtually 
no one witnesses the true origin of the embolus that causes the stroke. In addition, it is 
important to recognize that IPSS identifies risk factors that are not necessary causes of 
stroke. However, this in-depth phenotyping of patients may be a stepping stone for future 
research in the identification of novel mechanisms and causes of stroke in young adults.
If we compare our data to the results of the IPSS Registry 7, among the most frequent 
reported categories in pediatric stroke were arteriopathy (53%) and cardiac disorders (31%). 
These percentages point towards the same direction as we found in our young stroke 
patients, albeit that the percentages were higher in the IPSS registry because of the 
large proportion of focal cerebral arteriopathies and congenital heart disease in children, 
respectively. Chronic systemic conditions were equally present in young adults and the 
pediatric stroke patients described in IPSS cohort (19%). 
A large difference though was found for the presence of one or more risk factors for 
early atherosclerosis in only 2% of children versus more than 90% of young stroke 
patients. Especially patients aged 35 years and older at time of stroke were more 
likely to have risk factors for early atherosclerosis and therefore were more likely 
to be classified as “(likely) large artery disease” according to TOAST criteria. This is 
consistent with the current findings that risk factors for atherosclerosis increase with 
age.1 On the other hand, patients younger than 35 years at stroke onset are more likely 
to be classified as a stroke of “unknown origin”, this was the case in almost 50% of our 
patients. Overall, more than one-third (34.5%) of our cohort was left unclassified with 
the aid of the TOAST criteria, which is comparable with the current literature of 30-
40%.19, 20 Criticism has been raised on this large proportion of unknown etiology and 
also on the applicability of TOAST classification on a (young) stroke population.21, 22 
Using IPSS, we were able to identify additional risk factors in 88% of patients otherwise 
classified as “unknown”. These factors are considered to be risk factors in pediatric 
stroke patients, but to date have not been implemented in a stroke classification 
such as TOAST. An important explanation for the large proportion of unclassified 
stroke in the young is that several other mechanisms of stroke not related to known 
mechanisms such as atherosclerosis or cardio embolic disorders were not considered 
as a separate category/entity in TOAST; including non-atherosclerotic arteriopathy, 
changes in the haemostatic balance and migraine.23 In our cohort we found that at least 
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12% of patients had a non-atherosclerotic arteriopathy, emphasizing the importance 
to recognize this category as a separate entity in young stroke patients. Dissection, 
both traumatic and non-traumatic, was the most prevalent arteriopathy in our cohort, 
but other non-atherosclerotic diseases such as vasculitis (due to multiple causes) or 
moyamoya disease were also found. These diseases are thought to cause ischemia by a 
thrombotic occlusion rather than by emboli derived from atherosclerotic plaques.24 In 
antiphospholipid syndrome, various mechanisms of stroke have been described. First, 
antibodies binding to antiphospholipids on the endothelial surface are thought to 
cause a hypercoagulable state.25 In addition, cardiac valve vegetations may develop (so 
called Libman-Sacks endocarditis) that ultimately can cause cardio-embolic stroke. 26 
Also vasospasm, e.g. due to exposure to vasoactive substances or pregnancy, can lead 
to ischemia through direct insufficient perfusion.27 Another mechanism underlying 
stroke is a coagulation disorder. In our cohort at least 8% of all patients carried one or 
more factors altering the haemostatic balance. This is in line with a recent paper in 
which it was suggested that hypercoagulability should be taken into account in the 
diagnostic process after young ischemic stroke.4 We did not find patients with genetic 
coagulation disorders that are known to be overrepresented in certain ethnic groups 
such as sickle cell anemia or specific arteriopathies (such as moyamoya disease) that 
more frequently occurs in the Japanese population.28
There is still discussion about the mechanism of stroke within the context of migraine. 
A recent study shows that migraine (especially with aura) should be considered as a 
risk factor for ischemic stroke and TIA.29 For migraine with aura, it is hypothesized 
that the cortical spreading depression is responsible for hypoperfusion and/or a local 
inflammatory response.30 In addition, genome-wide association studies showed that there 
is a shared genetic basis between ischemic stroke and migraine.31 There is also increasing 
evidence for a role of a preceding infection and stroke. Both inflammatory responses 
causing platelet activation and endothelial dysfunction, as well as hypercoagulability 
due to immobilization and dehydration when having an infection have been proposed 
as possible pathophysiological theories. The inflammatory response causes increased 
concentrations of plasma fibrinogen, C-reactive protein (CRP), and interleukin-6 (IL-
6), ultimately resulting in a hypercoagulable state. The role of inflammation as a cause 
of arterial plaque instability is currently being investigated.32, 33 Pregnancy and the 
postpartum period are well-known conditions with an increased risk of stroke. There 
are several explanations for these observations. First, pregnancy-related disorders such 
as preeclampsia, gestational hypertension, gestational diabetes and on the furthest end 
of the range, HELLP-syndrome (Hemolysis, Elevated Liver enzymes Low Platelet count) 
increase the risk of stroke. Furthermore, pregnancy itself comes with a hypercoagulable 
state with higher levels of coagulation factors (II, VII, VIII, IX, X, XII en XIII), most 
pronounced in the third trimester, which is thought to be a protective mechanism of 
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the women’s body to prevent high volumes of blood loss during the delivery.34, 35 At last, 
complications during delivery such as traumatic dissection, amniotic fluid emboli and 
postpartum angiopathy may also cause stroke.34, 36
To date, current treatment options in young stroke patients are generally focused on the 
removal of an acute thrombus or prevention of thrombus formation, that perhaps does 
not even play a role in the etiology of some young stroke patients. Considering all these 
other mechanisms for stroke from the view of a young adult, a “one-size-fits-all” therapy is 
not effective. In pediatric stroke this is supported by the fact that to date, a favorable effect 
of intravenous thrombolysis could not be demonstrated and that secondary preventive 
medication is generally not indicated because only a small proportion of all children 
(in IPSS 2%) carried risk factors for atherosclerosis.7, 24 The effectiveness of a treatment 
can be assessed more accurately when clinical trials as well as clinicians could rely on a 
classification system that takes into account all possible mechanisms of young stroke.
In summary, several other than the “classic” cardiovascular risk factors or cardiac diseases 
can be found in young stroke patients. We propose that etiology of stroke in young adults 
should preferably not be classified according to a classification system designed for elderly 
stroke patients, such as TOAST classification, specifically in patients aged below 35 years 
of age. Using a risk factor categorization according to IPSS, we were able to identify at least 
one risk factor in 94% of all young stroke patients. Thereby we were able to find additional 
risk factors in 88% of patients otherwise classified as “unknown etiology” according to 
TOAST classification. Therefore, our modified risk factor inventory based on pediatric 
findings provides a valuable starting point for the development of a young stroke specific 
classification system. Future studies are warranted that confirm the causality of these 
risk factors and to develop and validate an etiologic classification approach specifically 
for young stroke patients. This ultimately can lead to better treatment strategies focused 
on the specific mechanism underlying young stroke.
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Abstract
Background: Patients who suffer a stroke at young age, remain at substantial risk of 
developing recurrent vascular events and information on very long-term prognosis 
and its risk factors is indispensable. Our aim is to investigate this very long-term risk 
and associated risk factors up to 35 years after young stroke.
Methods: Prospective cohort study among 656 patients with a first-ever ischemic 
stroke or transient ischemic attack (TIA), aged 18-50, who visited our hospital 
(1980–2010). Outcomes assessed at follow-up (2014-2015) included TIA or ischemic 
stroke and other arterial events, whichever occurred first. Kaplan-Meier analysis 
quantified cumulative risks. A prediction model was constructed to assess risk factors 
independently associated with any ischemic event using Cox proportional hazard 
analyses followed by bootstrap validation procedure to avoid overestimation.
Results: Mean follow-up was 12.4 (SD 8.2) years (8105 person-years). Twenty-five years 
cumulative risk was 45.4% (95%CI: 39.4–51.5) for any ischemic event, 30.1% (95%CI: 
24.8–35.4) for cerebral ischemia and 27.0% (95%CI: 21.1–33.0) for other arterial events. 
Risk factors retained in the prediction model were smoking (HR 1.35, 95%CI: 1.04–1.74), 
poor kidney function (HR 2.10, 95%CI: 1.32–3.35), history of peripheral arterial disease 
(HR 2.10, 95%CI: 1.08–3.76) and cardiac disease (HR 1.84, 95%CI: 1.06–3.18) (C-statistic 
0.59 (95%CI: 0.55–0.64)).
Conclusions: Young stroke patients remain at a substantial risk for recurrent events; 
almost 1 of 2 develops a recurrent ischemic event and 1 of 3 develops a recurrent 
stroke or TIA during 25 years of follow-up. Risk factors independently associated with 
recurrent events were poor kidney function, smoking, history of peripheral arterial 
disease and cardiac disease.
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Introduction
Long-term prognosis after a stroke at young age is significantly affected by the occurrence 
of incident vascular events. It is already known that this risk is not only high in the first 
months or years after stroke, but patients remain at a substantial risk even 10 years after 
their initial stroke.1
Reliable information thereafter is largely lacking, though important to know as after 
10 years these patients are still young and can expect to live for many more decades. 
Providing young adults with reliable information on the course of their disease including 
the risk factors associated with this prognosis, also after the first 10 years is therefore of 
utmost importance.
Only a few large studies have tried to identify which particular risk factors were associated 
with recurrent vascular events. However, in those studies mean follow up did not exceed 
5 years, 2, 3 or only the association between the etiologic subgroups based on TOAST 
classification and recurrent events was taken into account rather than subgroups based 
on (potentially modifiable) risk factors.4 Also, prognosis has only been examined for the 
overall stroke population. Though this is important information from the health care 
perspective, this does not always answer the question of individual patients who have 
a particular interest in their own, personalized prognosis. So far, there are no prediction 
models for recurrent vascular events with a good predictive performance. One study 
did develop a score for individual risk estimation of recurrent thrombotic events, with 
a moderate predictive value and follow-up duration of more than 3 years.2 Especially for 
these younger patients, an individualized long-term risk assessment, also after the first 
years after stroke is of great importance. 
Therefore, aims of this study were to investigate the very long-term risk of recurrent 
vascular events up to 35 years after a stroke at young age. In addition, we aimed to identify 
risk factors independently associated with the risk of recurrent vascular events on the 
long-term. Subsequently, predictive performance of the resulting model was assessed.
Methods
Study population
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE-study), a prospective cohort study 
on causes and consequences of a stroke in young adults.5 Detailed methods have been 
described previously.1 The Medical Review Ethics Committee region Arnhem-Nijmegen 
approved the study. All patients signed informed consent.
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 62
Chapter 4
62
In the present study, we included all consecutive patients with a first-ever transient 
ischemic attack (TIA) or ischemic stroke, aged 18–50 years, admitted to the Radboud 
University Nijmegen Medical Centre from 1980 till 2010. The World Health Organization 
definition for TIA and stroke was used.6
Patients were identified through a prospective registry with standardized collection of 
baseline characteristics. Cardiovascular risk factors were defined as either a history of a 
risk factor or detected during analysis of the initial event: hypertension as mean systolic 
blood pressure ≥135 mmHg or a diastolic blood pressure of ≥85 mmHg, measured after 
the first week of the index event 7 or the use of antihypertensive medication; diabetes 
mellitus as random blood glucose level > 200 mg/dL (11.1 mmol/L) or two consecutive 
fasting venous plasma glucose levels ≥ 6.1 mg/dL (7.0 mmol/L)8 or the use of ant diabetics 
(oral or insulin); dyslipidemia as total cholesterol ≥5.0 mmol/L or LDL ≥2.5 mmol/L or 
triglycerides ≥2.0 mmol/L1 or the use of statins; smoking as smoking at least 1 cigarette 
per day in the year prior to the event; atrial fibrillation when identified on either an 
electrocardiogram or during continuous electrocardiographic recording; excess alcohol 
consumption as consuming more than 200g of pure alcohol per week. Kidney function 
was divided in estimated glomerular filtration rate (eGFR)<60, eGFR 60–120 and eGFR>120 
mL/min/1.73m2.9 In addition, a history of cardiovascular disease (myocardial infarction, 
cardiac intervention procedures and peripheral artery revascularization procedures) was 
collected.
The assessment of stroke etiology (Trial of Org 10172 in Acute Stroke Treatment 
(TOAST))10 and severity (National Institutes of Health Stroke Scale11) was done for all 
cases retrospectively by a validated approach.12
Follow-up
Follow-up assessment took place from 2009 to 2012 and subsequently from August 2014 
to January 2015. In case information from this last follow-up assessment was missing, 
follow-up data from the previous follow-up (2009-2012) were used (n¼28, 4.3%). Patients 
underwent structured questionnaires on the occurrence of recurrent events. In case a 
patient had died, information was retrieved by the general practitioner. All confirmed 
events were verified by a neurologist or cardiologist. TIA and ischemic stroke were defined 
similar to the index event, myocardial infarction was defined according to the universal 
definition of myocardial infarction.13 
Outcome
Primary outcome was the risk of any recurrent ischemic event, defined as the composite of 
cerebral ischemia (ischemic stroke or TIA), and other arterial events or revascularization 
procedures (myocardial infarction, coronary artery bypass grafting, percutaneous coronary 
intervention, carotid endarterectomy or peripheral artery revascularization procedures). 
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Secondary outcomes were the risk of recurrent cerebral ischemia or the risk of any other 
arterial event. 
Statistical analysis
Kaplan-Meier analysis was used to estimate cumulative risks of any recurrent ischemic 
event, cerebral ischemia and any other arterial event, whichever occurred first. Person-
years at risk were calculated for each patient from date of the index stroke until recurrent 
event, death or end of follow-up. Patients who died and/or did not reach an endpoint 
were censored. Survival plots were curtailed at 25 years to ensure that the provided 
survival plots were reliable for all subgroups,14 all events were retained in subsequent 
analyses. Analyses were stratified by stroke subtype, age categories (18-29, 30-39 and 40-
50 years) and TOAST-subtype with undetermined cause as reference. Annual risks were 
calculated from survival estimates obtained by Kaplan-Meier analysis. Mean annual 
risks were subsequently calculated for the periods 2-5 years, 6-10 years, 11-15 years, 16-
20 years and 21-25 years. Missing data were handled using multiple imputation by the 
method of chained equations (eGFR 29.9% and dyslipidemia 20%),15 under the assumption 
that missing data were missing at random. Thirty imputed datasets were created using 
predictive mean matching for eGFR and logistic regression for dyslipidemia. All variables 
considered in the subsequent regression analyses were included in the imputation model. 
Regression analyses were performed on each of the imputed datasets individually and 
subsequently the coefficients were pooled using Rubin’s rules.16 Restricting the analyses 
to only complete patients, yielded similar point estimates as obtained in the imputed 
datasets. Cox proportional hazard analysis was used to calculate hazard ratios with their 
95% confidence intervals (CI’s) for baseline characteristics, adjusted for age and sex for 
the risk of any ischemic event, cerebral ischemia and other arterial events. A composite 
variable with number of traditional risk factors was used (any of the following: diabetes 
mellitus, hypertension, smoking, dyslipidemia or atrial fibrillation). 
Finally, we constructed a multivariable Cox regression model to predict recurrent ischemic 
events. All predictors were considered for entrance in the models irrespective of their 
univariable association with the outcome. Subsequently, the model was simplified using 
a backward selection procedure (exclusion if p<0.20). A bootstrap validation procedure 
(b=100) was performed to avoid overestimation in regression coefficients.17 A shrinkage 
factor was derived from this procedure and subsequently applied to the regression 
coefficients. Discriminative performance of the model was assessed by calculating the 
concordance (c) statics. Also, the C-statistic was corrected for over optimism by applying 
the bootstrap validation procedure. All p-values of less than 0.05 were considered as 
significant. IBM SPSS 20.0 and R version 3.2.1 software package (packages MICE version 
2.25 and RMS version 4.4-0) were used.
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Results
Study population
Six hundred fifty-six entered present study, 209 (31.9%) patients with TIA and 447 
(61.7%) patients with ischemic stroke. Mean follow-up was 12.4 (SD8.6) years and 21.3% 
had a follow-up of more than 20 years. At the end of follow-up, 167 (25.5%) patients were 
deceased. Baseline characteristics are shown in table 1.
There were no differences in baseline characteristics between participants and non-
participants (lost to follow-up n=73 and refusers n=139) except for age (39.1 years (SD8.2) 
versus 40.7 years (SD7.7) respectively).
Cumulative risk of ischemic events
During 8105 person-years of follow up, 197 (30%) patients had at least one ischemic event 
of whom 67 (34.0%) had more than one event. 
Twenty-five years cumulative risk of any ischemic event was 45.4% (95%CI: 39.4–51.5), 
30.1% (95%CI: 24.8–35.4) for cerebral ischemia and 27.0% (95% CI: 21.1–33.0) for other arterial 
events (Figure 1(a) to (c)). There was no sex difference. Annual risks are shown in Figure 2.
There were no differences between patients with a TIA or ischemic stroke at young age 
with regards to their 25-years cumulative risk of any ischemic event (TIA 40.7% (95%CI 29.7-
46.4) and ischemic stroke 47.1% (95%CI 40.0%-50.8%), cerebral ischemia (TIA 27.8% (95%CI 
23.0%-37.0%) and ischemic stroke 30.8% (95%CI 27.6%-37.2%), or other arterial events (TIA 
23.7% (95%CI 18.3%-34.2%) and ischemic stroke 28.5% (95%CI 24.9%-35.8%).
There were no differences in 25-years cumulative risk of any ischemic event or cerebral 
ischemia by age category. Patients aged 40-50 years at the time of their qualifying stroke 
at young age had a higher 25-years cumulative risk of other arterial events (38.2%, 95%CI 
28.9%-47.6%) compared to patients aged 30-39 years (15.5%, 95%CI 7.2%-23.7%) (log rank 
p=0.004) and patients aged 18-29 years (7.8%, 95%CI 0.3%-15.4%) (log rank p=0.002).
Figure 3 shows the cumulative risk of any ischemic event stratified by TOAST-subtype. 
For cerebral ischemia, patients with a cardio-embolic stroke (50.8%, 95%CI 25.8%-75.7%) 
or small vessel disease (37.5%, 95%CI 22.7%-52.4%) had a higher 25-years cumulative risk 
than patients with undetermined cause (22.9%, 95% 15.2%-30.6%) (Log rank p=0.02 and 
p=0.02 respectively). For other arterial events, patients with a large artery stroke (48.5, 
95%CI 37.8-59.2) or cardio-embolic stroke (60.9, 95%CI 6.0-115.8) had a higher 25-years 
cumulative risk than those with undetermined cause (17.3, 95%CI 8.6-26.1) (log rank p<0.001 
and p=0.05 respectively). 
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Table 1. Baseline characteristics
Total
656
TIA
209 
Ischemic stroke
447 
Mean age at time of event, years [SD] 40.7 (7.7) 40.6 (8.0) 40.8 (7.6)
Men, n (%) 309 (47.1) 94 (45.0) 215 (48.1)
Mean follow-up time, years [SD] 12.4 (8.6) 11.9 (8.1) 12.6 (8.8)
>15 years 217 (33.1) 56 (26.8) 171 (38.3)
>20 years 140 (21.3) 41 (19.6) 99 (22.1)
>25 years 73 (11.1) 26 (12.4) 47 (10.5)
Median NIHSS at admission (IQR)a 3 (1-7) 0 (0-1) 5 (2-10)
TOAST, n. (%)
Large artery disease 166 (25.3) 47 (22.5) 119 (26.6)
Cardio-embolic stroke 86 (13.1) 27 (12.9) 59 (13.2) 
Small vessel disease 65 (13.1) 11 (5.3) 54 (12.1)
Other defined 96 (14.6) 23 (11.0) 73 (16.3)
Multiple causes 17 (2.6) 2 (1.0) 15 (3.4)
Unknown cause 226 (34.5) 99 (47.4) 127 (28.4)
History of vascular risk factors, n (%)
Hypertension 231 (35.2) 71 (34.0) 160 (35.8)
Diabetes 54 (8.2) 13 (6.2) 41 (9.2)
Dyslipidemiaa 424 (80.8) 147(83.5) 277 (79.4)
Atrial fibrillation 15 (2.3) 5 (2.4) 10 (2.2)
Smokinga 324 (51.8) 83 (40.7) 241 (57.2)
Excess drinking 48 (7.3) 15 (7.2) 33 (7.4)
Number of traditional risk factorsb
0 72 (11.0) 26 (12.4) 46 (10.3)
1 243 (37.0) 82 (39.2) 161 (36.0)
2 238 (36.3) 71 (34.0) 167 (37.4)
≥3 103 (15.7) 30 (14.4) 73 (16.3)
History of cardiovascular disease, n (%)c 38 (5.8) 11 (5.3) 27 (6.0)
History of cardiac disease 29 (4.4) 9 (4.3) 20 (4.5)
History of PAD 21 (3.2) 7 (3.3) 14 (3.1)
Baseline kidney function, n(%)
eGFR 60-120 392 (85.2) 122 (88.4) 270 (83.9)
eGFR <60 29 (6.3) 7 (5.1) 22 (6.8)
eGFR >120 39 (8.5) 9 (6.5) 30 (9.3)
a Missing data: NIHSS 0.5%, dyslipidemia 20%, smoking 4.7%, eGFR in 29.9%.
b Risk factors included diabetes mellitus, hypertension, dyslipidemia, atrial fibrillation and smoking.
c Some patients both had a history of both PAD and cardiac disease.
Abbreviations: TIA: transient ischemic attack; SD: standard deviation; NIHSS: national institutes of health stroke 
scale; IQR: interquartile range; TOAST: Trial of Org 10172 in Acute Stroke Treatment; PAD: peripheral arterial 
disease; eGFR: estimated glomerular filtration rate.
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Figure 1. Cumulative risks of ischemic events
0 
10 
20 
30 
40 
50 
60 
0 5 10 15 20 25 
C
u
m
u
la
ti
ve
 r
is
k 
(%
) 
Time to vascular event (years) 
Cumulative risk 
95% CI 
Number at risk 
                      656                432                       259                     161                            94                       53        
                       
0 
10 
20 
30 
40 
50 
60 
0 5 10 15 20 25 
C
u
m
u
la
ti
ve
 r
is
k 
(%
) 
Time to vascular event (years) 
Cumulative risk 
95% CI 
Number at risk 
                      656                454                       281                     186                            112                       62        
                       
0 
10 
20 
30 
40 
50 
60 
0 5 10 15 20 25 
C
u
m
u
la
ti
ve
 is
k 
(%
) 
Time to vascular event (years) 
Cumulative risk 
95% CI 
Number at risk 
                      656                496                       297                     189                            114                       61        
                       
Cumulative risks of ischemic events: (A) any ischemic event; (B) cerebral ischemia; (C) other arterial events.
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Figure 2. Annual risk of ischemic events
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Annual risk of ischemic events. Data points represent mean annual risks for the periods 2 to 5 years, 6 to 10 years, 
11 to 15 years, 16 to 20 years and 21 to 25 years.
Figure 3. Cumulative risk of any ischemic event stratified by TOAST-subtype
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Cumulative risk of any ischemic event stratified by TOAST subtype. Patients with large artery (61.4%, 95%CI 
51.1%-71.8%) or cardio-embolic stroke (62.7%, 95%CI 38.6%-86.7%) had a higher cumulative risk of any ischemic 
event compared to undetermined cause (33.8%, 95%CI 24.3%-43.2%) (log rank p<0.001 and p=0.001 respectively).
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Risk factors
In age- and sex-adjusted univariable analyses, age (HR 1.03 per year increase, 95%CI 1.01-
1.05), diabetes mellitus (HR 1.62, 95%CI 1.03-2.57), hypertension (HR 1.36, 95%CI 1.02-1.82), 
eGFR <60 (2.51, 95%CI 1.47-4.26, history of peripheral arterial disease (HR 3.44, 95%CI 21.95-
6.08) and history of cardiac disease (HR 3.33, 95%CI 2.01-5.52) were associated with any 
ischemic event. In addition, the number of traditional risk factors was associated with 
any vascular event (Table 2).
Kidney function (eGFR < 60) was associated with recurrent cerebral ischemia (HR 3.18, 
95%CI 1.74-5.80). Factors associated with any other arterial event were age (HR 1.08 per 
year increase, 95%CI 1.04-1.11), diabetes mellitus (HR 2.54, 95%CI 1.42-4.52), hypertension 
(HR 1.61, 95%CI 1.06-2.43), smoking (HR 2.12, 95%CI 1.32-3.42), history of peripheral arterial 
disease (HR 6.87, 95%CI 3.60-13.12) and history of cardiac disease (HR 4.99, 95%CI 2.70-9.21).
Table 3 shows the multivariable Cox proportional hazard model. Smoking (HR 1.35, 95%CI 
1.04-1.74, p=0.02), eGFR<60 (HR 2.10, 95%CI 1.32-3.35), history of peripheral arterial disease 
(HR 2.01, 95%CI 1.08-3.76) and history of cardiac disease (HR 1.84, 95%CI 1.06-3.18) were 
independently associated with any ischemic event. Reported hazard ratios have been 
shrunk by applying a shrinkage factor of 0.82 derived from the bootstrap validation 
procedure. C-statistic of the model was 0.59 (95%CI: 0.55–0.64) after correction for over 
optimism.
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Table 3. Predictors of any ischemic event
HR (95%CI) p-value
Age 1.02 (1.00-1.04) 0.06
Diabetes mellitus 1.39 (0.93-2.07) 0.11
Alcohol 0.73 (0.47-1.15) 0.18
Smoking 1.35 (1.04-1.74) 0.02
Baseline kidney function
eGFR 60-120            1
eGFR <60 2.10 (1.32-3.35) 0.002
eGFR >120 0.80 (0.42-1.52) 0.50
History of peripheral artery disease 2.01 (1.08-3.76) 0.03
History of cardiac disease 1.84 (1.06-3.18) 0.03
Predictors of any ischemic event selected by backward LR (exclusion if p <0.200). C-statistic 0.59 (95%CI 0.55-0.64). 
The regression coefficients were corrected for overfitting with a shrinkage factor of 0.82.
Abbreviations: HR: hazard ratio; eGFR: estimated glomerular filtration rate.
Discussion
We showed that patients who have suffered a stroke at a young age remain at a high 
risk of developing recurrent ischemic events, even decades after their stroke. Traditional 
vascular risk factors are common in these patients and are associated with this life-long 
risk. 
A unique and essential strength of our study is the large study population in combination 
with a very long-term follow-up duration up to 35 years. For patients who suffer a stroke 
at young age, a long-term risk assessment is crucial, as patients are still young after only 
a few years of follow-up. Moreover, the single centre, prospective design, made it possible 
to uniformly collect data, making information bias less likely. 
However, some possible limitations need to be addressed. First, selection bias might have 
occurred as patients who did not participate in the study might have been the ones with 
a more severe outcome. The number of patients who refused to participate and those lost 
to follow-up is rather high, which is probably due to the long follow-up duration, however 
there were no differences in baseline characteristics, making selection bias less likely.
Second, since our study features a long inclusion period, recall bias may have influenced 
our findings, especially in patients who experienced their event a long time ago or 
died. However, this would only have resulted in an underestimation of the cumulative 
incidence. In addition, we have tried to overcome this by collecting information in an 
identical way in patients who died and those still alive.
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Along the course of the long inclusion period, specific young stroke investigations and 
secondary prevention strategies changed over time, which might have influenced the 
risk of recurrent vascular events. However, these are unavoidable features of a long-term 
follow-up study.
We have previously shown that patients who suffer a stroke at young age remain at a 
high risk of developing recurrent vascular events.1 Due to the extension of our follow up 
we were now able to show that even up to 25 years after stroke at a young age the risk of 
recurrent vascular events remains high. Moreover, we found an even higher risk compared 
to other large cohorts,2-4, 18-20 most likely due to the far longer follow-up duration and the 
inclusion of TIA as an outcome event in our cohort. In addition, most other studies were 
small and/or retrospective. 3, 18-20
To determine secondary prevention strategies and provide information on the course 
of the disease for individual patients, it is necessary to assess risk of recurrent events at 
an individual level and treatment decisions should ideally be based on clinical trials. As 
younger patients were usually underrepresented in trials on secondary prevention,21 it 
remains uncertain how to treat patients with a stroke at young age and information should 
be obtained from large cohorts.22 We therefore aimed to identify risk factors associated 
with recurrent vascular events. Poor kidney function, smoking and a history of peripheral 
arterial disease and cardiac disease were independently associated with recurrent 
ischemic events. However, the prediction model only had a moderate discriminative 
ability. Possible reasons for this finding might include residual confounding which 
might have arisen from inevitable differences in measurement of risk factors during an 
inclusion period spanning almost 30 years. Furthermore, due to the long inclusion period 
in our cohort, secondary prevention strategies changed, which may have influenced the 
prediction model as well. 
Two previous studies also tried to identify risk factors associated with recurrent vascular 
events. One study found age, heart failure, previous TIA and diabetes mellitus to be 
important predictors3 while the other prospective study found especially discontinuation 
of medication, antiphospholipid antibodies, family history, migraine with aura and any 
increase in traditional vascular risk factors to be associated with recurrent events.2 
However, follow-up in those studies was shorter and they had a smaller number of events 
to include in the analyses. Differences in study design and inclusion criteria between 
the studies could have contributed to the variation in associated risk factors. Patients in 
our study and the Finnish study were older (41.5 years) than in the Italian stroke project 
(36.8 years), which may have resulted in a higher incidence of traditional risk factors. In 
addition, it may be possible that due to the longer follow-up duration, traditional vascular 
risk factors become more important as patients are longer exposed to the risk factors. In 
addition, the Italian study developed a score for individual risk estimation, with a better 
predictive value than the prediction model in our study (C-statistic 0.66). Unfortunately, 
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none of the models had a good discriminative ability, which may also indicate that there 
is considerable potential to be gained. Other unknown factors may contribute to the risk 
of recurrent events. For example, increasing evidence suggests that stroke at a young age 
has a stronger genetic basis than stroke occurring at older ages.23, 24 Genetic factors might 
also interact with vascular risk factors, possible making patients with a stroke at young 
age more vulnerable to traditional vascular risk factors.
Furthermore, we found that patients with a cardio-embolic stroke or large artery disease 
as cause of their stroke had a higher risk of any ischemic event or other arterial event. 
Another large study on the association between etiologic subgroups and recurrent events, 
also found large artery atherosclerosis and cardio embolism to be important predictors 
of recurrent events.4 Moreover, in our study patients with small vessel disease or large 
artery disease had a higher risk of recurrent ischemia. This is probably explained by the 
fact that patients with these etiologies of their stroke are more likely to have traditional 
vascular risk factors than patients with an undetermined cause.
Surprisingly, age was not associated with a higher risk of recurrent events, which indicates 
that even very young patients remain at a substantial risk of developing recurrent vascular 
events. 
Our findings may indicate that risk factors for vascular diseases and a history of vascular 
diseases such as peripheral artery or cardiac disease should create awareness among the 
treating physician for risk of future recurrent events. Especially smoking is an important 
modifiable risk factor, which can be addressed more straightforward than pre-existing 
atherosclerosis in daily practice. Although prediction models are not perfect, traditional 
vascular (partly) modifiable risk factors do seem to play an important role in developing 
recurrent events. This might suggest that strict long-term secondary prevention strategies 
should be encouraged, even in very young patients, however it should be noted that the 
use and adherence of medication was not considered in this study.
Therefore, future research should especially aim at secondary prevention strategies in 
this specific age group.
In conclusion, we have shown that patients with a stroke at young age remain at 
substantial risk for developing recurrent vascular events, even decades after their initial 
event. Particularly young patients, with vascular risk factors that are usually prevalent 
at higher ages should raise the level of suspicion of their treating physicians as they are 
at the highest risk for future vascular events.
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Abstract 
Purpose of review: Ischemic stroke during pregnancy or the puerperium is a 
devastating disease during a crucial period in life and warrants a specific approach. 
To date, current practice is mainly based on expert opinion because of a lack of 
randomized controlled trials and high-quality observational studies. This review 
is intended as a practical guide to (acute) management of ischemic stroke during 
pregnancy and puerperium.
Recent findings: Recent findings showed that the incidence of stroke during 
pregnancy is rising. In 2014 the first guideline for the prevention of stroke in women 
was released, however on many (pregnancy) related topics the evidence was too scarce 
to make clear evidence-based recommendations.
Summary: The risk of ischemic stroke is elevated especially from the third trimester 
until 6 weeks postpartum. MRI is the most accurate and well tolerated diagnostic 
option but low-dose CT-head is a valid alternative. Reperfusion therapies should not 
be withheld from a pregnant woman with moderate-to-severe stroke when benefits 
outweigh the risk. Aspirin up to 150mg daily is considered well tolerated during 
pregnancy and lactation period. Multidisciplinary care is essential when counseling 
these women in the acute and later stages.
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Introduction
Stroke during pregnancy or the puerperium (defined as the period starting from delivery 
up to the subsequent 12 weeks)1 is relatively rare but is associated with significant 
mortality and high morbidity during a crucial and vulnerable period in life. In 16-18% of 
Western women and in 11% of Asian women under the age of 35 years, pregnancy with its 
associated risk factors including (pre)eclampsia, HELLP-syndrome and hypercoagulability 
is related to the cause of stroke.2-4 However, our understanding of the complex processes 
underlying pregnancy-related stroke remains limited, as illustrated by the fact that in 
about one fourth of these patients the exact cause remains unknown. Management of an 
(acute) ischemic stroke during pregnancy and the puerperium therefore poses a challenge 
in daily practice, also because it necessitates a different diagnostic and therapeutic 
approach as the clinician must take care of the health and safety of both the mother 
and the unborn child. This management is not supported by data from clinical trials and 
therefore mainly relies on expert opinion.5 This shortcoming also applies to adequate 
counseling of women who would like more children after pregnancy-related stroke. 
In this review, we will provide a practical guide to management of stroke of presumed 
arterial origin during pregnancy and puerperium. We will start with an overview on the 
epidemiology and provide practical recommendations, regarding diagnostic and treatment 
options, including for lactating women. We will end with some recommendations with 
respect to counseling of women with stroke, who would like to have more children.
Epidemiology 
Between 1.5 – 67.1 per 100.000 deliveries are complicated by an ischemic stroke6-9 and 
the incidence is rising.10, 11 In Asian countries a comparable incidence is reported (10.2 
– 46.2 per 100.00 deliveries).12-14 Pregnant (and especially postpartum) women have an 
estimated 3 to 9-fold increased risk of all stroke subtypes compared to non-pregnant 
women.7, 15 Interracial differences have been observed; Afro-American women more often 
had pregnancy related stroke (52.5 per 100.000 deliveries) compared with Caucasian 
(31.7/100.000) and Hispanic (26.1/100.000).7 Higher age is a risk factor7, while others have 
found that age under 35 years increased the risk of stroke.15, 16 About half of all strokes 
during pregnancy are of the ischemic subtype in Western countries (48%-62%),6, 17, 18 and 
this fraction may be slightly lower in Asian countries (25%-57%).12-14 The risk of ischemic 
stroke is increased until 12 weeks postpartum, but the highest risk was found in the 
period starting from the third trimester1, 6, 15 until the first 6 weeks postpartum.1, 6, 15, 17 It is 
important to note that the wide variation in reported incidence and age-dependent risk 
of stroke might also be related to study design; population or (tertiary) hospital-based 
study, heterogeneity with respect to inclusion of stroke subtypes, and operationalization 
of the postpartum period.
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Cause of pregnancy-related ischemic stroke 
According to the TOAST (Trial of ORG 10172 in Acute Stroke Treatment)19 classification 
system, the causes of stroke during pregnancy can be classified as large artery atherosclerosis 
(9-10%, mainly in Asian studies),13, 20 cardioembolism (19%, but up to 56% in Asian studies),12, 13, 
20 and other determined causes (31-65%), such as hypercoagulability (7-18%), arterial dissection 
(5-7%) and preeclampsia (24-47%).6, 17, 18 In a quarter to a third of Western women and in 
one fifth of Asian women the cause remains cryptogenic.12, 17, 18, 20 A selection of pregnancy-
related causes will be highlighted below (for further reading, see table 1).
Cardioembolism
During pregnancy, the body has to accommodate profound hemodynamic changes such 
as increase in blood volume (30-40%), cardiac output (45%) and a cardiac remodeling 
resulting in a physiological (left) ventricular hypertrophy. It has been suggested that an 
inability to adapt to these changes can put pregnant women with known cardiac disease 
at greater risk of cardiovascular complications, but also can reveal a (previously unknown) 
underlying cardiac disease.21, 22
Peripartum cardiomyopathy (PPCM)
PPCM is a specific pregnancy-related dilated cardiomyopathy of unknown etiology typically 
occurring during the third trimester until up to 6 months after delivery.23 Rheumatic valvular 
heart disease is now a rare disease in Western countries but frequent in developing countries,24 
and still reported as a major cause of pregnancy related stroke in Taiwanese patients.12 
Other determined causes
Hypercoagulability 
Especially in the third trimester (in preparation for delivery) and shortly postpartum a 
physiological hypercoagulable condition develops (table 2), with an attendant increased 
risk of ischemic stroke.25 In the presence of a hypercoagulable state (such as the 
antiphospholipid syndrome) this risk is even higher.26 
Hypertensive disorders of pregnancy (HDP)
HDP is an umbrella term for a group of potentially life threatening pregnancy-specific 
disorders that are highly associated with ischemic stroke,27 namely gestational hypertension 
(defined as a blood pressure of >140mmHg systolic and/or 90mmHg diastolic typically 
resolving within 12 weeks after delivery), preeclampsia (progression to a combination of 
gestational hypertension and proteinuria >300mg/24h), eclampsia (occurrence of seizures 
in preeclamptic women)28 and HELLP-syndrome (hemolysis, elevated liver enzymes 
and low platelets). These pregnancy complications are pathophysiological not yet fully 
understood, but are thought to be the result of a dysfunction of the placenta or placental 
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development leading to systemic endothelial damage.29 Also, during the second trimester 
the blood pressure is supposed to decrease due to a decreased vascular resistance, but 
when these mechanisms fail this results in gestational hypertension. 
Postpartum cerebral angiopathy (PPA)
PPA is also referred as (a form of) Reversible Cerebral Vasoconstriction Syndrome (RCVS), 
marked by a postpartum temporarily vasoconstriction of the cerebral arteries resulting 
in focal neurological deficits, usually after an uncomplicated pregnancy with imaging 
features, such as ischemic stroke and subarachnoid hemorrhage.30
Amniotic fluid embolism
Cerebral embolism due to amniotic fluid entering the maternal circulation (during 
(traumatic) delivery or disruption at the site of placental insertion) is considered a very 
rare but specific cause of stroke.31 
Choriocarcinoma
Choriocarcinoma is a rare malignant neoplasm arising from placental trophoblastic tissue 
with a high tendency to metastasize to the brain. Ischemic stroke is possibly caused by 
trophoblastic embolism or direct vascular damage due to cerebral metastases.32
Diagnostic approach 
Clinicians need to carefully consider the diagnostic options and should limit the risk 
of radiation and contrast exposure to the fetus as much as possible. No diagnostic 
imaging should be withheld when indicated, but the benefit should outweigh the risk.33 
Uncertainty of modality choice might cause unnecessary delay in the diagnostic process. 
Here, we provide guidance on diagnostic approach. 
Magnetic Resonance Imaging (MRI)
MRI is the first choice of imaging modality with a high diagnostic yield without 
radioactive radiation, which can also be used to rule out other diagnoses. MR-angiography 
(i.e. time-of-flight (TOF) sequence without contrast agent) can be used for vessel imaging 
and diffusion weighted imaging (DWI) to detect acute ischemia.33, 34
Computed tomography (CT)
When MRI is not readily available or in case of contraindications (e.g. pacemaker), CT-
scan is a valid option, preferably with a low radiation technique. Fetal radiation exposure 
due to a regular CT head/neck is approximately 1.0 – 10 mGy while an expected threshold 
dose for negative effects on the fetus is considered to be above 50 mGy.33 This (indirect) 
radiation exposure is therefore rarely of concern.
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Table 1. Risk factors and causes of ischemic stroke during pregnancy and puerperiuma, 
categorized following TOAST-classification
Risk factor or cause Specific high-risk period (when applicable)
Cardioembolism
Peripartum cardiomyopathy Third trimester, puerperium (up to 6 months 
after delivery)
Cardiomyopathy, congestive heart failure During pregnancy, delivery
Rheumatic valvular heart disease During pregnancy, delivery
Mechanical heart valves First trimester, Third trimester, delivery, 
puerperium 
(possibly due to suboptimal anticoagulant 
therapy)
Other determined causes
Arterial (cervical/intracranial) dissection Delivery
Postpartum angiopathy Puerperium
Coagulation disorders
• Systemic lupus erythematosus (SLE)
• Antiphospholipid Syndrome (APS)
• Factor V Leiden (FVL)
• Sickle cell anemia
• Protein C/S deficiency
Third trimester, delivery, puerperium
Air embolism Delivery, puerperium
Amniotic fluid embolism Delivery, puerperium
Caesarean sectionb Delivery
Blood transfusion During or directly after delivery
Gestational hypertension From second trimester
(Pre)eclampsia/HELLP syndrome From second trimester, Puerperium
Migraine During pregnancy
Choriocarcinoma No specific high-risk period
(Postpartum) infection Puerperium
a Puerperium is defined as the period between delivery and 12 weeks after delivery. b May in part be attributed to an 
increased likelihood of caesarean delivery in already high risk patients.66 
Abbreviations: TOAST: Trial of ORG 10172 in Acute Stroke Treatment; HELLP: Hemolysis Elevated Liver enzymes 
and Low Platelets.
Source: Frontera et al 2014,30 James et al 2005,7 Lanska et al 2000,66 Leffert et al 2015,11 Miller et al 2017,67 Wabnitz 
et al 2015.68
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Table 2. Physiological alterations in coagulation and fibrinolytic factors during pregnancy
Haemostatic changes during pregnancy 
Procoagulants
Factor I (fibrinogen) ↑
Factor II =?
Factor V = /mild ↑?
Factors VII, VIII, IX, X, XII, XIII ↑
Factor XI (Mild) ↓
Von Willebrand factor ↑
D-dimer ↑
Plasminogen activator inhibitor 1 and 2 (PAI-1/PAI-2) ↑
Anticoagulants
Protein S activity ↓
Antithrombin III =/ mild ↓?
Protein C activity =
↑: increase, ↓: decrease, =: unchanged, ?: contrasting or insufficient data.
Source: Bremme 2003,25 Brenner et al 2004 69 and Cerneca et al 1997.70
Intravenous contrast agents
Administration of contrast during pregnancy should be done with caution. Gadolinium 
and iodinated contrast pass the placenta and are found to be potentially harmful to 
the fetus in animal models,31, 35 although there are also reports of safe administration in 
pregnant women.36 In a lactating woman intravenous contrast can be safely administered 
and breastfeeding can be continued.33, 34, 37
Ultrasonography (US)
Duplex US of the carotids is frequently performed for the detection of carotid dissection 
or (atherosclerotic) carotid stenosis. Concerns of tissue temperature elevation produced 
by the sound waves reaching the fetus are of no concern when US is performed outside 
the pelvic area.33 
Treatment of acute ischemic stroke 
Recombinant tissue plasminogen inhibitor (rTPA)
Pregnancy and the postpartum period are formal contra-indications of treatment with 
rTPA, because all randomized controlled studies on safety and efficacy of acute stroke 
treatment have excluded pregnant patients. However, in animal models no teratogenicity 
was found, which was in line with pharmacological studies that reported that rTPA does 
not cross the placenta.38 This is in line with studies that reported that rTPA was safely 
administered during pregnancy and had a comparable effect and risk of complications in 
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pregnant women compared to non-pregnant women.39, 40 Note that these statements rely 
on case reports 41, 42 and retrospective analyses 43 with the risk of confounding by indication 
or publication bias. To overcome the lack of reliable information, the Safe Implementation 
of Treatments in Stroke-Fertile Women Stroke Thrombolysis Study (SITS-FW) was 
initiated and especially addresses the safety of thrombolysis in pregnancy.44 Until these 
results become available, the current expert opinion is to consider treatment with rTPA 
in moderate-to-severe ischemic stroke in pregnancy and to balance the risks against the 
potential benefits.41, 45, 46
Intra-arterial procedures
Mechanical thrombectomy is proven to be effective in acute ischemic stroke patients 
with an occlusion of one of the proximal intracranial vessels of the anterior circulation,47 
but pregnant women were excluded from this trial. The procedure appears as well 
tolerated as in non-pregnant women, but evidence on this treatment modality is based 
on case reports with the risk of publication bias.37, 48 In case of an occlusion of a proximal 
intracranial artery in a pregnant woman primary mechanical thrombectomy may be 
considered without prior administration of rTPA.49 Treating clinicians should be aware 
of the intraprocedural radiation that is used during angiography and should limit the 
exposure of scattered radiation on the fetus using low-dose or pulsed fluoroscopy and 
protection with radiation shields.37 
Secondary prevention during pregnancy and lactation 
Secondary prevention treatment after ischemic stroke in pregnant women is generally 
indicated but the choice depends on the etiology, risk of recurrence, gestational age and/
or whether a woman is lactating. This will result in an individualized treatment strategy, 
based on shared decision making. 
We strongly advise to use a drug database (such as Toxnet,50 Lactmed,51 and Reprotox® 
52) prior to actual prescribing any medication during pregnancy and/or lactation but in 
general the following recommendations can serve as a guidance (table 3): 
Antiplatelet therapy
There is extensive experience with the use of aspirin, which crosses the placenta without 
teratogenic effects and thus can be used in low daily doses (50- 150mg/d) during the 
second and third trimester, and during the lactation period.53-55 Data on safety in the 
first trimester are limited; there are some but inconsistent reports of birth defects such 
as gastroschisis.55 The effects of other antiplatelet agents (e.g. dipyridamole, ticagrelor, 
clopidogrel) on the fetus or breastfed newborn are unknown because of limited data and 
should not be prescribed.56, 57 
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Anticoagulant therapy
Vitamin K antagonists cross the placenta and are found to be teratogenic (especially 
before 12 weeks of gestation) and thus contraindicated during pregnancy, but are well 
tolerated when a woman is lactating.58 The new direct-acting oral anticoagulants 
(DOAC) such as dabigatran, rivaroxaban and apixaban are found to cross the placenta 
in animal models, but to date there are insufficient data on toxicity during both 
pregnancy and lactation period and DOAC should therefore be avoided.59 Alternatively, 
low-molecular weight heparins (LMWH; preferred) and unfractionated heparin (UFH) 
are recommended as they do not cross the placenta and are not secreted in breast 
milk.60 
Antihypertensive treatment
Almost all classes of antihypertensive drugs cross the placenta. For the treatment of 
hypertension during pregnancy labetalol, nifedipine and methyldopa are considered 
the most safe and effective options. Atenolol, angiotensin receptor blockers, and 
direct renin inhibitors are contraindicated in pregnancy.5
Cholesterol lowering therapy
For the treatment of hypercholesterolemia, there is a lack of knowledge on the 
consequences of statin use. As there is no direct maternal risk when these medications 
are temporarily interrupted, they should best be avoided during pregnancy and 
breastfeeding.61
Peripartum management 
There are no specific data on the most optimal management of (type of) delivery 
in a woman with a history of pregnancy-related ischemic stroke. In general, these 
women will be admitted to a hospital to monitor labor. There are no studies that 
investigated whether vaginal or caesarean section is safer in case of ischemic stroke 
during pregnancy, and this decision will generally be made based on an obstetric 
indication. When stroke is the consequence of (pre)eclampsia or HELLP-syndrome, 
the best treatment for both the mother and the unborn child is to induce labor as 
early as possible.28 It is advised to temporarily interrupt aspirin at the 36th week or 
1 week prior to a scheduled delivery and anticoagulant medication (UFH/LMWH) 
preferably 24 hours prior to labor to prevent bleeding complications. After labor, 
heparins can be restarted after 12-24 hours. Vitamin K antagonists can be initiated 
after 1-3 days (table 3).62, 63 
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Table 3. Ischemic stroke treatment: Recommendations during pregnancy, delivery and 
lactation period
Medication Period
Pregnancy Delivery Lactation
Recombinant 
tissue 
plasminogen 
activator (rt-PA)
Relative contra-
indication, however 
individual decision, 
benefit should outweigh 
risk (Level of evidence C)
Limited evidence: within 
48 hours after delivery 
considerable risk of fetal 
and maternal bleeding 
(Level of evidence C)
Limited evidence: 
temporarily 
discontinuation advised 
(Level of evidence C)
Aspirin Safe up to 150mg 
in second and third 
trimester, in first 
trimester no consensusa 
(Level of evidence B)
Discontinue at 36th 
week or 1 week prior to a 
scheduled delivery (Level 
of evidence C)
Safe up to 150 mg (Level 
of evidence C)
Other antiplatelet 
agents
(dipyridamole, 
ticagrelor, 
clopidogrel)
Limited evidence, do not 
use (Level of evidence C)
Limited evidence, do not 
use (Level of evidence C)
Limited evidence, do not 
use (Level of evidence C)
Heparin (LMWH, 
UFH)
Safe, LMWH preferred 
over UFH (Level of 
evidence B)
Discontinue 24h 
prior to delivery, or 
as soon as possible in 
case of contractions/
spontaneous rupture 
of membranes. Restart 
within 12-24 hours after 
delivery (Level of evidence 
B)
Safe, not secreted in 
breast milk (Level of 
evidence UFH: A , level of 
evidence LMWH: B)
Vitamin K 
antagonists
 (warfarin, 
acenocoumarol)
Teratogenic, convert 
to LMWH/UFH 
especially in first and 
third trimester (Level of 
evidence B)
In case of high 
cardioembolic risk
(mechanical heart 
valves): Adjusted-dose 
UFH/bid LMWH or 
UFH/LMWH until 13th 
week, then vitamin K 
antagonists until close 
to term, then resume 
UFH/LMWH.60, 71 (Level of 
evidence A)
Discontinue close to 
delivery (in case of high 
cardioembolic risk), 
restart 1-3 days after 
delivery (Level of evidence 
C)
Safe (Level of evidence A )
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Table 3. Continued
Medication Period
Pregnancy Delivery Lactation
Direct Oral 
Anticoagulants 
(DOAC)
(apixaban, 
rivaroxaban, 
dabigatran)
Limited evidence, do not 
use (Level of evidence C)
Limited evidence, do not 
use (Level of evidence C)
Evidence of secretion in 
breast milk, do not use 
(Level of evidence C)
Statins Discontinue. Limited evidence, therapy not essential 
during pregnancy (Level of evidence C)
Limited evidence, do not 
use (Level of evidence C)
Antihypertensive 
treatment
(intravenous) Labetalol, nifedipine and methyldopa 
well tolerated and effective (Level of evidence A)
Avoid Atenolol, angiotensin receptor blockers and 
direct renin inhibitors (Level of evidence C)
Widely used and 
compatible with 
breastfeeding (consult 
Lactmedb for complete 
summary):
Beta blockers: 
propranolol, labetalol, 
metoprolol; Calcium 
channel blockers: 
nifedipine, nicardipine; 
Methyldopa; 
ACE-inhibitors: 
captopril, enalapril, 
quinapril
Avoid diuretics: can 
inhibit milk production 
(Level of evidence C)
a Data on safety in first trimester are limited, aspirin crosses the placenta, inconsistent reports of birth defects but 
potential benefits may warrant use of the drug in pregnant women despite potential risks.55 Abbreviations: LMWH: 
low-molecular weight heparins; UFH: unfractionated heparin. ACE: Angiotensin Converting Enzyme.
Source: Bates et al., 60 Caso et al.,63 Demaerschalk et al.,45 Kernan et al.,55 bLactmed,51 Nishimura et al.,71 Reprotox®,72 
and Toxnet .50
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Risk of recurrent ischemic stroke during subsequent pregnancies 
The absolute risk of a recurrent ischemic stroke during a subsequent pregnancy was found 
to be low (0% - 1.8%),17, 64, 65 but to date there are no large studies available. In general, the 
postpartum period is associated with a higher recurrence risk than during pregnancy in 
women with a history of an ischemic stroke (risk ratio 9.7 versus 2.2 respectively).64 This 
risk depends on the underlying disease or cause of stroke. Especially among women with 
stroke due to the antiphospholipid syndrome, the risk of recurrence was found to be 
high (15%) in a small study with only three events in 20 patients.26 Based on the (limited) 
findings on the actual risk of stroke recurrence in pregnancy, future pregnancies do not 
need to be discouraged in women after stroke, but adequate counseling is advised. 
Counseling of women who are still at a reproductive age after pregnancy-related stroke
When a woman with a history of stroke has a desire to have children, they are generally 
referred to a gynecologist for preconception consultation, although this is solely based on 
expert opinion. There is no consensus on whether or not to start/continue antithrombotic 
prophylactic therapy in a pregnant woman with a history of stroke, especially during the 
embryonic phase (first trimester). Despite the presumed low risk of recurrent stroke during 
a subsequent pregnancy, the general opinion based on a survey among 230 neurologists 
was to prescribe antithrombotic prophylaxis during the first trimester of pregnancy in 
women after a pregnancy related stroke (88% of participants favored the prescription 
of some form of antithrombotic therapy).56 Recent AHA guidelines recommend that for 
pregnant women “In the presence of a low-risk situation in which antiplatelet therapy 
would be the treatment recommendation outside of pregnancy, UFH/LMWH or no 
treatment may be considered during the first trimester of pregnancy depending on the 
clinical situation (Class IIb; Level of Evidence C)”, followed by aspirin 50-150mg/d for the 
remainder of the pregnancy (Class IIa; level of Evidence B) [page 2209].55 For women at 
high risk of embolism, continuation of anticoagulant therapy is preferred and in such 
cases it is generally recommended to administer LWMH twice daily or adjusted dose 
UFH.55
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Conclusion
Pregnancy-related ischemic stroke warrants a specific management for both mother 
and the unborn child. Pregnancy specific risk factors are the hypertensive disorders of 
pregnancy and hypercoagulability. Diagnostic imaging with MRI is preferred, but low-
dose CT is also a valid option. Therapeutic management should be based on risk-benefit 
analysis, but intravenous rTPA and mechanical thrombectomy should not be withheld 
from a pregnant woman with moderate-to-severe acute ischemic stroke when indicated. 
Aspirin (50-150mg/daily) is well tolerated during pregnancy and the lactation period. The 
risk of recurrent stroke during subsequent pregnancies is considered low but continuation 
of antithrombotic or anticoagulant therapy is preferred. Multidisciplinary care with a 
team consisting a neurologist, an obstetrician and a radiologist/interventionalist is 
essential.
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Abstract
Background and purpose: The study goal was to investigate the prevalence of 
pregnancy complications and pregnancy loss in women before, during and after young 
ischemic stroke/transient ischemic attack (TIA).
Methods: In the FUTURE-study (Follow-Up of Transient Ischemic Attack and 
Stroke Patients and Unelucidated Risk Factor Evaluation), a prospective young 
stroke study, we assessed the occurrence of pregnancy, miscarriages and pregnancy 
complications in 223 women aged 18 to 50 years with a first-ever ischemic stroke/
TIA. Pregnancy complications (gestational hypertension, diabetes, preeclampsia and 
HELLP-syndrome) were assessed before, during and after stroke using standardized 
questionnaires. Primary outcome was occurrence of pregnancy complications and the 
rate of pregnancy loss compared to the Dutch population. Secondary outcome was the 
risk of recurrent vascular events after stroke, stratified by a history of hypertensive 
disorders of pregnancy.
Results: Data were available of 213 patients. Mean age at event was 39.6 years[SD 
7.8] and mean follow-up 9.5 years[SD 8.5]. Miscarriages occurred in 35.2% and fetal 
death in 6.2% versus 13.5% and 0.9% in the Dutch population respectively (p<0.05). 
In nulliparous women after stroke (n=22), in comparison with Dutch population, 
there was a high prevalence of hypertensive disorders of pregnancy (33.3 versus 12.2%, 
p<0.05), HELLP-syndrome (9.5 versus 0.5%, p<0.05) and early preterm delivery <32 
weeks (9.0 versus 1.4%, p<0.05). In primi/multiparous women (n=141) after stroke, 29 
events occurred (20-years cumulative risk 35.2%; 95% confidence interval, 21.3-49.0), 
none during subsequent pregnancies, and a history of a hypertensive disorder in 
pregnancy did not modify this risk (log-rank p=0.62).
Conclusions: When compared to the general population, women with young 
stroke show higher rates of pregnancy loss throughout their lives. Also, after stroke, 
nulliparous women more frequently experienced serious pregnancy complications.
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Introduction
Each year, 16 to 59 per 100.000 women of childbearing age are affected by a stroke,1 which 
amounts to an estimated 180.000 women with an ischemic stroke per year in Europe. 
Apart from the acute disabling stroke symptoms, all of a sudden, these young women are 
confronted with lifelong consequences2 and limitations occurring in a period of life during 
which plans about starting a family are being made. Difficulties in taking these decisions 
are fuelled by a lack of knowledge on the risks of future pregnancy complications after 
stroke in women. It is known that pregnancy and the
puerperium itself are associated with an increased risk of cerebrovascular disease caused 
by pregnancy-related disorders such as gestational hypertension and preeclampsia.3, 4 
Because of a clear relationship between hypertensive disease during pregnancy and 
the increased risk of maternal cardiovascular disease (CVD) later in life,4-6 it has been 
speculated that a common cause such as endothelial dysfunction may play a role.7, 8
It is, therefore, our hypothesis that women with stroke have an increased risk of future 
pregnancy complications. We investigated the frequency of pregnancy complications, 
miscarriages and fetal death before, during and after a first-ever transient ischemic 
attack (TIA) or stroke at young age and compared this with the general Dutch 
population. As a secondary outcome, we investigated whether a history of serious 
pregnancy complications increases the risk of a recurrent vascular event after a first-
ever ischemic stroke/TIA. 
Methods
Study design
This study is part of the FUTURE study (Follow-Up of Transient Ischemic attack 
and stroke patients and Unelucidated Risk factor Evaluation study), a single-centre 
prospective cohort study on risk factors and prognosis of young patients with transient 
Ischemic attack (TIA), ischemic stroke and intracranial hemorrhage. We used the same 
methodology as employed in our previous published study.9 In short, the FUTURE study 
comprises all consecutive patients with a TIA, ischemic stroke or intracranial hemorrhage, 
aged 18-50 years, admitted to the Radboud University Medical Centre from January 1st, 
1980 until November 1st, 2010. For present study we only included women with first-ever 
TIA or ischemic stroke who reported they had been pregnant at least once. Exclusion 
criteria were cerebral venous sinus thrombosis and retinal infarction. TIA was defined as 
rapidly evolving focal neurological deficit, without positive phenomena such as twitches, 
jerks, or myoclonus, with vascular cause only and persisting for less than 24 hours. Stroke 
was defined as focal neurologic deficit persisting for more than 24 hours. 
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The Medical Ethics Committee region Arnhem-Nijmegen, the Netherlands, approved the 
study. All participants gave written informed consent. The data that support the findings 
of this study are available from the corresponding author upon reasonable request.
Baseline assessment 
Information on demographics, NIHSS (National Institutes of Health Stroke Scale) and 
cardiovascular risk factors was collected in a structured manner. A history of cardiovascular 
risk factors was determined by information on medical history or diagnosis at the time 
of index event; definitions of risk factors have been described earlier.2 
Assessment of pregnancy complications and outcome
During follow-up in November 2015, all eligible patients were contacted by telephone by a 
trained investigator. Structured questionnaires were used to assess the number of children, 
date of birth and the occurrence of pregnancy complications e.g. gestational hypertension, 
preeclampsia, HELLP-syndrome (Hemolysis, Elevated Liver enzymes, Low Platelet count), 
gestational diabetes, preterm delivery, miscarriages and fetal death. Patients who could not 
be contacted by telephone were sent a questionnaire by mail or via general practitioner. 
Primary outcome was the occurrence of any pregnancy complication, these were defined 
as follows:
1.  Gestational hypertension as an elevated blood pressure after 20 weeks of gestation 
(systolic ≥140mmHg and diastolic ≥90mmHg), measured at two different times in a 
woman with a normal blood pressure before pregnancy.10
2.  Preeclampsia as the combination of gestational hypertension with proteinuria ( ≥ 
300mg/24h).10 
3.  HELLP-syndrome as the combination of hemolysis, elevated liver enzymes and 
thrombocytopenia. 
4.  Preterm delivery as delivery before 37 weeks of gestation11 and divided in iatrogenic 
(induction of labor or cesarean delivery for medical reasons, due to fetal or maternal 
disease such as HELLP, preeclampsia or growth restriction) and spontaneous (without 
an apparent cause).12
5.  Gestational diabetes as hyperglycemia diagnosed during pregnancy.13 
6.  Miscarriage as spontaneous embryonic or fetal death <16 weeks of pregnancy, fetal 
death as spontaneous fetal death ≥16 weeks of pregnancy or death within 24 hours 
after delivery.14 Induced abortions were not taken into account. 
Other variables at follow-up
Secondary outcome was the risk of any vascular event after stroke, stratified by the 
occurrence of pregnancy complications. During the telephonic assessment we identified 
the occurrence of recurrent vascular events (stroke or “other arterial event”, e.g. myocardial 
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infarction or cardiovascular procedure). In case of a reported vascular event, medical 
records were retrieved from their treating physicians and verified by a neurologist or a 
cardiologist.
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics for Windows version 22.0 
(IBM Corp., Armonk, NY). Baseline characteristics were presented as means or medians 
for data with a normal or non-normal distribution respectively. Based on the date of 
stroke/TIA and date of birth of the children, patients were divided into 3 groups: patients 
who experienced stroke/TIA before their first pregnancy of a live born child (group 1, 
‘nulliparous’); after one or more pregnancies (group 2, ‘primi/multiparous’); or during 
pregnancy or postpartum, defined as within 6 weeks after delivery (group 3, ‘gravidas’).15
For population-based characteristics of pregnancy (such as mean age at first gravidity, 
number of children per woman) we consulted the Central Bureau of Statistics of the 
Netherlands (CBS).16 Prevalence of pregnancy complications within the Dutch reference 
population was assessed with the aid of Perined; a registry annually describing the 
overall outcome, morbidity and mortality of pregnancy between 1999-2012 in 2.517.916 
women and 2.564.530 live and stillborn children.17 For early miscarriages (which occur 
more often subclinical) and for HELLP syndrome Perined has insufficient data, to allow 
for comparison of our data with population data we used the most reliable epidemiologic 
data from other, in part Dutch large cohorts.18-21 A Fisher-exact test was used to compare 
the incidence of pregnancy complications in nulliparous women to the Dutch population.
As a secondary outcome, we assessed the cumulative risk of recurrent vascular events in 
women with a history of hypertensive disorders in pregnancy (preeclampsia, hypertension) 
and/or HELLP-syndrome versus those with uncomplicated pregnancies using Kaplan 
Meier survival analyses. Using the same analyses, we calculated the cumulative risks of 
any vascular event in 3 subgroups based on the severity of the complication: those with a 
history of a more severe pregnancy complication (preeclampsia, HELLP) versus those with 
gestational hypertension only, versus women with uncomplicated pregnancies. P-values 
<0.05 were considered significant. 
Results
Two hundred and thirteen female patients completed follow-up assessment on vascular 
events and pregnancy complications (figure 1). Baseline characteristics are shown in 
Table 1. 
Of 210 women, 569 pregnancies resulted in 425 live births (in 3 women the number of 
pregnancies was unknown). Maternal age at birth of a first child did not significantly differ 
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between groups of primi/multiparous (n=163), nulliparous (n=22) or gravidas (n=20) (Table 
2). All pregnancy complications were equally reported in all groups. Overall, ≈40% of the 
women suffered at least from one pregnancy complication (Table 3). Miscarriage was the 
most frequent complication (total n=75, 35.2% versus 13.5% in population19, p<0.05); 6.1% Of 
women with a stroke (either before or after pregnancy) experienced a fetal death in their 
life, while this proportion was 0.9% in the Dutch population from 1999-2012 implicating 
a 6-fold higher incidence (p<0.05).17, 22 5.5% Of women experienced ≥3 miscarriages, which 
is a 5-fold higher incidence compared to the estimated 1% among the general population 
(p-value could not be calculated, only percentages are available).17, 21 
Figure 1. Flowchart of Study Population 
Women with first-ever TIA or 
Ischemic stroke
N=466
Lost to follow-up 
n = 40
Patients included in present 
study n = 213
BA
SE
LI
N
E
FO
LL
O
W
-U
P
Eligible follow-up study 
population n = 426
Women without any reported 
pregnancy n=58
Deceased 
n=71
Refused to participate 
n=79
Participated in FUTURE-study, 
but could not be contacted n=5
Follow-up survivors n=276
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Table 1. Baseline Characteristics of women with young stroke
Total Primi/
Multiparous*
Gravidas† Nulliparous‡
N (%) 213§ 163 (76.5) 20 (9.4) 22 (10.3)
Mean age at time of event, yrs. [SD] 39.6 [ 7.8] 42.2 [5.6] 33.1 [2.9] 24.8 [4.4]
Median NIHSS at admission [IQR]‖ 2 [0-5] 2 [0-5] 1 [0-8] 2 [0-3]
Mean follow-up time, yrs. [SD] 12.7 [8.7] 11.8 [8.3] 14.8 [10.0] 17.9 [9.4]
mRS-score at discharge, n(%)
mRS 0-2
mRS 3-5
184 (86.4)
29 (13.6)
142 (87.1)
21 (12.9)
16 (80.0)
4 (20.0)
20 (90.9)
2 (9.1)
Stroke subtype, n(%)
 TIA
 Ischemic Stroke
81 (38.0)
132 (62.0)
61 (37.4)
102 (62.6)
11 (55.0)
9 (45.0)
7 (31.8)
15 (68.2)
Decade of event, n(%)
 1980-1989
 1990-1999
 2000-2010
36 (16.9)
42 (19.7)
135 (63.4)
23 (14.1)
28 (17.2)
112 (68.7)
5 (25.0)
6 (30.0)
9 (45.0)
7 (31.8)
6 (27.3)
9 (40.9)
TOAST, n(%)
 Atherothrombotic stroke
 Likely atherothrombotic stroke
 Cardioembolic stroke
 Lacunar stroke
 Other defined
 Multiple causes
 Unknown cause
16 (7.5)
33 (15.5)
25 (11.7)
17 (8.0)
37 (17.4)
3 (1.4)
82 (38.5)
13 (8.0)
31 (19.0)
21 (12.9)
13 (8.0)
25 (15.3)
2 (1.2)
58 (35.6)
0 (0)
0 (0)
2 (10.0)
1 (5.0)
6 (30.0)
1 (5.0)
10 (50.0)
2(9.1)
1 (4.5)
2 (9.1)
2 (9.1)
5 (22.7)
0 (0)
10 (45.5)
History of (cardiovascular) risk factors, n(%)
 Hypertension
 Diabetes
 Dyslipidemia¶
 Smoking
 Factor V Leiden
 Systemic Lupus Erythematosus
 Antiphospholipid Syndrome (APS) 
66 (31.0)
9 (4.2)
143 (67.1)
98 (46.7)
6 (2.8)
6 (2.8)
5 (2.3)
54 (33.1)
8 (4.9)
118 (81.4)
72 (44.4)
0 (0)
1 (5.0)
2 (10.0)
7 (35.0)
1 (5.0)
8 (66.7)
6 (31.6)
0 (0)
2 (9.1)
2 (9.1)
4 (18.2)
0 (0)
10 (62.5)
13 (59.1)
6 (3.7)
3 (1.8)
1 (0.6)
*Patients suffering TIA/stroke after pregnancy. † patients with stroke during pregnancy or <6 weeks postpartum. 
‡Patients suffering TIA/stroke before pregnancy of a liveborn child. § 8 patients (3.8%) never had a live birth and 
could not be placed in a group; ‖Range of scores between 0 – 21; in 1 patient NIHSS was missing. ¶In 33 patients 
information on hyperlipidemia was missing.
Abbreviations: NIHSS: National Institute of Health Stroke Scale; IQR: Interquartile Range; MRS: Modified Rankin 
Scale; TOAST: Trial of Org 10172 in Acute Stroke Treatment.
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Pregnancy complications after stroke in nulliparous women
30% Of nulliparous women suffered at least one complication during subsequent 
pregnancies after stroke (Table 3); 33.3% suffered from hypertensive disorders in pregnancy 
as opposed to 12.2% in the general Dutch population implicating a 3-fold higher incidence 
(p<0.05). Prevalence of HELLP was 20-fold higher (9.5% vs 0.5%, p<0.05) when compared to 
the general Dutch population.20,10 Early preterm delivery <32 weeks occurred in 9.0% of all 
pregnancies as compared to 1.4% in the general Dutch population (p<0.05)17, with HELLP 
or preeclampsia being the cause in 50% of cases. 
Recurrent Vascular Events
In primi/multiparous women after stroke, 29 recurrent vascular events occurred; 12 
events (six ischemic strokes and six “other arterial event”) in 46 women (26.0%), with 
hypertensive disorder/HELLP in pregnancy versus 17 events (11 ischemic strokes, one 
intracranial hemorrhage, six “other arterial event”) in 95 women (17.9%) with uncomplicated 
pregnancies.
The cumulative risk of recurrent cardiovascular events after stroke was 35.2% [95% CI 21.3-
49.0] after 20 years and a history of a hypertensive disorder/HELLP in pregnancy did not 
modify this risk (log-rank p=0.62). Those with a history of preeclampsia or HELLP (e.g. a 
more severe pregnancy complication) had a higher, though not significant, cumulative 
risk of a recurrent event (74.4%, n=13) after 20 years of follow-up when compared to 
women with a history of gestational hypertension only (33.7%, n=33) or no complications 
during pregnancy (27.2%, n=95) (p=0.086). 
Of those who suffered stroke/TIA during pregnancy or the post-partum period (n=20), 
three women had a recurrent ischemic stroke (20yrs cumulative risk: 15.6%). Of women 
who were nulliparous at time of stroke (n=22), 4 women experienced a recurrent vascular 
event (20yrs cumulative risk: 19.6%). None of abovementioned vascular events occurred 
during subsequent pregnancies.
Discussion 
We found that obstetric prognosis after stroke is less favorable compared with the 
general population, as we found a higher prevalence of serious pregnancy related 
complications such as (severe) hypertensive disorders in pregnancy and HELLP syndrome 
with consequently a high rate of early preterm delivery. Also, women who experienced 
a stroke/TIA at a fertile age showed very high rates of (recurrent) miscarriages or fetal 
death throughout their lives, compared to the general population.
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This is the first study that addressed risk of pregnancy complications in a large group 
of women after their stroke. Main strengths are an exceptional long-term follow-up 
and a high response rate with consequently very detailed information on the course of 
pregnancy in these patients. However, there are some methodological considerations. 
First, due to the retrospective and patient-reported collection of pregnancy data, recall 
bias may have played a role. However, pregnancy and its complications such as birth (or 
loss) of a child are important life events which are generally remembered remarkably well. 
Also, it was previously demonstrated that using self report versus professional reported 
outcome in pregnancy did not influence the outcome of the analyses performed.23 Second, 
retrospective collected data on pregnancy loss prevented us from collecting specific dates 
of miscarriages, which resulted in a life-time prevalence. Third, as a consequence of the 
very long-term follow-up, diagnostic guidelines and medication protocols may have 
changed over time. It is already known that secondary prevention lowers the risk of 
developing preeclampsia with 15%,10 and because most patients likely received secondary 
prevention after stroke this may have led to an underestimation of preeclampsia after 
experiencing stroke in comparison with the Dutch (untreated) population. Fourth, some 
of the population-based data we used from Perined should be interpreted with caution 
as Perined makes note of possible underreporting of especially gestational diabetes 
(1.8%) and preeclampsia (0.5%). Current population-based Dutch cohorts suggest the 
incidence of these conditions is estimated at 1.4−3.5% for preeclampsia24, 25 and 3.0−4.9% 
for gestational diabetes13, 26, which is in accordance with our data. Finally, although our 
study is the largest of its kind, the absolute numbers of patients eligible to answer our 
outcome measures was small and therefore the power is limited. This possibly results 
in an underestimation of the prevalence of pregnancy complications. Especially for our 
secondary outcome our findings suggest there may be a higher risk of recurrent vascular 
events after stroke for those who suffered preeclampsia or HELLP, but we were unable 
to reach significance (p= 0.086).
We found that 1 out of 3 women experience a serious pregnancy complication after 
stroke. Although there are no comparable studies focusing on prognosis of pregnancies 
after stroke in women, there is growing evidence that pregnancy complications such as 
gestational hypertension or preeclampsia are significantly associated with a doubled risk 
of cardiovascular disease such as stroke.6, 27 Conversely, we now build upon this notion 
by showing that a stroke preceding pregnancy is also related to higher frequency of 
pregnancy complications.
There are several explanations for this; one explanation is that the stroke and pregnancy 
complications share common risk factors, such as the “classical” cardiovascular risk 
factors such as dyslipidemia and hypertension.7 In our cohort 18% of nulliparous women 
was diagnosed with hypertension and 62.5% with dyslipidemia at time of stroke. The 
antiphospholipid syndrome (APS) is also considered as a shared risk factor, this is 
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supported by one other study that found an increased risk of pregnancy complications 
after stroke in patients with APS.28 They also found a high risk of pregnancy complications 
(8.7% fetal deaths, 34.8% preeclampsia, 42.9% preterm delivery) after stroke and a non-
significant higher risk of recurrent events in women with APS and preeclampsia. 
Another explanation linking these conditions might be a unelucidated shared 
pathophysiology. Although the pathological processes involved in both pregnancy 
complications and CVD are still largely unknown, most studies focus on endothelial 
damage as a common denominator; in preeclampsia for example, the inadequate 
maternal uterine spiral artery remodeling leads to inadequate uteroplacental circulation 
with oxidative stress, with not only local, but also systemic inflammatory response and 
endothelial dysfunction as a result.7, 29 It has been suggested that this leads to early-in-life 
(irreversible) endothelial damage to the systemic vascular system which persists after 
pregnancy. This in turn might ultimately contribute to an increased risk of maternal 
CVD such as ischemic stroke later in life.4, 5 Vice versa, we found that women who suffer 
stroke also have an increased risk of future pregnancy complications, which might be 
because of the same proposed endothelial dysfunction as common denominator, although 
more studies are needed to confirm this hypothesis. Not all pregnancy complications 
related to CVD are hypertensive disorders per se, other complications such as preterm 
delivery and fetal loss also have been associated with a higher risk of CVD. A recent 
study showed that preterm delivery increased the risk of CVD by a 2-fold, even when the 
pre-term delivery was not preceded by hypertensive pregnancy complications.30 Thereby, 
multiple miscarriages are also found closely linked to placental endothelial dysfunction31 
and multiple pregnancy loss or fetal death doubles the risk of ischemic stroke.32, 33 Our 
cohort shows high rates of miscarriages (35.2%), multiple miscarriages (5.5%) and extreme 
high rates of fetal death (6.1%). Besides involvement of endothelial damage also shared 
risk factors play a role: late miscarriages >12 weeks are mostly due to maternal (usually 
vascular) risk factors18 and thereby in our cohort 17 women suffered from APS, Factor V 
Leiden or systemic lupus erythematosus which are also risk factors for suffering (multiple) 
miscarriages.34, 35
Our study provides insight in the frequency of pregnancy complications in women who 
suffer a stroke at young age. Our data can be used to inform women with stroke who are 
seeking personalized advice on future pregnancies. We hereby addressed a very important 
but underexposed topic of a higher frequency of serious pregnancy complications after 
a stroke at a young age. This may imply that women with a history of stroke should be 
put under intensive control of a gynecologist during pregnancy to prevent serious and 
possibly life-threatening pregnancy complications. 
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Abstract
Background and purpose: Patients with a stroke at a young age are at an increased 
risk of small vessel disease(SVD), but the reasons for this are largely unknown. 
Hypertensive disorders of pregnancy(HDP) are associated with SVD in the general 
population. We investigated whether patients with young ischemic stroke or transient 
ischemic attack and a history of HDP have higher risk of SVD, compared to controls 
and patients without HDP.
Methods: This study was part of the FUTURE-study, a prospective cohort study (1980-
2010). We investigated 132 women with a first-ever young ischemic stroke or transient 
ischemic attack (aged 18 to 50 years) and 28 controls with at least one pregnancy. 36 
patients suffered from HDP and 96 did not. All underwent MRI and assessment of 
HDP (preeclampsia, gestational hypertension, HELLP-syndrome) at follow-up 2009-
2012. Lacunes, microbleeds and white matter hyperintensity (WMH)-volumes were 
assessed according to STRIVE-criteria. Logistic and linear regression were used to 
compare SVD-markers between groups, adjusted for known risk factors for SVD (age, 
hypertension, smoking).
Results: Mean age at MRI was 50.1yrs(SD 9.3); mean follow-up 9.9yrs(SD 8.2). Both 
patients with and without HDP had higher median WMH-volumes than controls 
(median 1.70ml [IQR 0.54-3.93] and 1.30ml [IQR 0.47-2.82] versus 0.61ml [IQR 0.01-2.50] 
respectively, p<0.001). There was no difference for lacunes and microbleeds. There 
were no significant differences on SVD markers between patients with or without 
HDP.
Conclusions: Women with a young ischemic stroke or transient ischemic attack have 
a higher WMH-volume compared to controls, but a history of HDP does not modify 
this observation. As we adjusted for known risk factors for SVD within the young 
stroke patients, the young stroke itself, or alternative (unknown) risk factors might 
be the main risk factors for SVD in these patients. 
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Introduction
Apart from the increased risk of recurrent stroke after a stroke at a young age (18-50 years)1, 
2 there is also an increased risk of cerebral small vessel disease (SVD), including lacunes, 
microbleeds and white matter hyperintensities (WMH), even when the cause of stroke 
was not due to small vessel disease.3 This increased risk of SVD therefore remains largely 
unexplained. Even more so because well known classical cardiovascular risk factors for 
SVD, such as hypertension4, are often not present in these young individuals or not for a 
long period of time. It is important to gain more insight in the etiology of SVD already 
early in life as this may provide a window of (preventive) treatment opportunity. This is 
highly relevant as SVD is considered the most important vascular contributor to cognitive 
decline5, 6 and especially these young patients have to rely on their cognitive functioning 
in their everyday post-stroke life to run a family, work and manage a demanding social life. 
As the burden of SVD is more prominent in (elderly) women compared to men,7, 8 and 
the incidence of young stroke is higher among women especially <35 years,9, 10 a possible 
risk factor could include a female specific risk factor such as a history of “hypertensive 
disorders of pregnancy”(HDP). HDP includes gestational hypertension, (pre)eclampsia 
and HELLP syndrome and these pregnancy complications are now recognized as 
important risk factors for late-life cardiovascular disease.11, 12 Also, recent studies in the 
general population showed that women with a history of HDP, especially (pre)eclampsia, 
show a higher burden of SVD than controls.13-15 However, whether a history of HDP is also 
a risk factor for SVD among women with a young stroke is unknown. We hypothesized 
that a history of HDP is a risk factor for SVD later in life in patients with a previous young 
stroke. Therefore, we investigated the risk of SVD in women with a previous young stroke, 
with or without HDP, compared with controls.
Materials and methods
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE-study), a prospective cohort study that 
investigates causes and consequences of a young stroke.16 The FUTURE-study comprises all 
consecutive patients (n=1005) with an ischemic stroke, intracranial hemorrhage or transient 
ischemic attack (TIA), aged 18 - 50 years, admitted to the Radboud University Nijmegen 
Medical Centre from 1980 till 2010. For the present study, we included women with a first-
ever TIA or ischemic stroke and at least one reported pregnancy (Figure 1). 
TIA was defined as an acute focal neurological deficit, with no other than a vascular 
cause lasting less than 24 hours.17, 18 Stroke was defined similarly, but lasting longer than 
24 hours. Exclusion criteria were retinal infarction and cerebral venous sinus thrombosis. 
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Eligible patients were prospectively identified with a standardized collection of baseline 
characteristics (demographics, stroke subtype and risk factors). All patients underwent 
neurological examination and brain imaging at the time of their stroke. The stroke 
etiology (Trial of Org 10172 in acute stroke treatment (TOAST)19, 20) and severity (National 
Institutes of Health Stroke Scale (NIHSS) 21) were retrospectively evaluated in a validated 
manner.22 The Medical Review Ethics Committee region Arnhem-Nijmegen approved the 
study and written informed consent was obtained from every participant. 
Follow-up
All patients were approached by telephone for a follow-up assessment between 2009 and 
2012. Patients were invited to our research centre for an extensive physical, psychological 
and neurological examination, laboratory testing and extensive MRI protocol.16 At the 
time of follow-up, blood pressure was measured three times in both arms in supine 
position. The cardiovascular risk factors were defined as follows: Hypertension as a 
systolic blood pressure of ≥135mmHg or a diastolic blood pressure of ≥85mmHg, or the 
use of antihypertensive medication. Current smoking as smoking ≥1 cigarette a day the 
year prior to follow-up, dyslipidemia as a total cholesterol ≥5.0mmol/L or LDL ≥2.5mmol/L 
or triglycerides ≥2.0mmol/L or the use of statins, diabetes as a random blood glucose level 
of >11.1 mmol/L or fasting glucose >7.0mmol/L or the use of antidiabetics. 
Pregnancy and its complications
During the extensive follow-up from 2009-2012, women were asked whether they had been 
pregnant and whether one or more pregnancies were complicated by HDP. During follow-
up in November 2015, all women who reported at least one pregnancy were contacted 
by telephone by a trained investigator. Structured questionnaires were used to assess the 
number of children, date of birth and the occurrence of pregnancy complications.23 These 
complications include gestational hypertension, preeclampsia and HELLP-syndrome 
(Hemolysis, Elevated Liver enzymes, Low Platelet count). Patients who could not be 
contacted by telephone were sent a questionnaire by mail or via the general practitioner. 
Pregnancy complications were defined according to the guidelines of the Dutch Society 
of Obstetrics and Gynecology (NVOG) (http://www.nvog.nl): gestational hypertension 
was defined as an elevated blood pressure after 20 weeks of gestation (systolic ≥ 140 
mmHg and diastolic ≥ 90 mmHg), measured at two different times in a woman with a 
normal blood pressure before pregnancy. Preeclampsia was defined as the combination 
of gestational hypertension with proteinuria ( ≥ 300mg/24h), and HELLP-syndrome as 
the combination of hemolysis, elevated liver enzymes and thrombocytopenia. The term 
HDP includes gestational hypertension, HELLP syndrome and/or preeclampsia.23
When participants could not be reached during the follow-up in 2015, the available data 
of 2012 were used (patients n=7, controls n=9) . 
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Neuroimaging data acquisition
Detailed information on neuroimaging, data acquisition and processing has been 
described elsewhere.3, 24 Patients and controls underwent a 1.5 Tesla MRI on the Magnetom 
Avanto (Siemens, Erlangen, Germany). The scanning protocol included whole brain 3D 
T1 magnetization-prepared -rapid gradient-echo sequence (TR/TE/Tl 2730/2.95/1000ms; 
flip angel 7º; voxel size 1.0x1.0x1.0mm); Fluid-attenuated inversion recovery (FLAIR) pulse 
sequences (TR/TE/Tl 12220/85/2200ms; voxel size 1.0x1.2x3.0; slice gap 0.6mm); transversal 
T2-weigted turbo spin echo sequence (TR/TE 7440/96ms; voxel size 0.9/0.9x3.0 mm; slice 
gap 0.6 mm) and gradient echo susceptibility weighted imaging (SWI) sequence (TR/
TE 49/40ms; voxel size 0.8x0.7x1.0mm). All patients underwent scanning conform this 
protocol.16
MRI markers of SVD
Lacunes, microbleeds and WMH of presumed vascular origin were defined based on the 
STRIVE-criteria25; lacunes of presumed vascular origin were defined as 3 mm - 15 mm 
round or ovoid, subcortical, fluid-filled cavities, consistent with a previous acute small 
deep brain infarct in the territory of one perforating arteriole; microbleeds were defined as 
areas less than 10 mm in diameter of signal void with associated blooming seen on SWI. 
Signal voids in areas of territorial infarcts were not considered to be microbleeds. Lacunes 
and microbleeds were localized and counted for each subject. WMH of presumed vascular 
origin were defined as white matter hyperintense signal abnormalities on FLAIR images, 
without cavitation. Hyperintensities in the subcortical grey matter or brainstem were 
included in the analysis. Gliosis around lacunar and territorial infarcts was not considered 
as WMH. We used an in-house developed semi-automatic programme to define WMH.26 
All scans were checked visually. WMH volume was calculated and normalized for total 
intracranial volume (ICV).27 The assessment of SVD markers was done by an experienced 
investigator who rated all the MRI scans, and who was blinded for baseline characteristics 
and outcome. In a random sample of 10%, the interrater and intrarater reliability for 
lacunes yielded a kappa of 0.76 and 0.80, and for microbleeds 1.0 and 0.92 respectively.
Diffusion tensor imaging (DTI) processing 
To assess the white matter integrity, we calculated the mean fractional anisotropy (FA) 
and mean diffusivity (MD) of the white matter for each participant.24 DTI data were first 
denoised using a local PCA filter after which in-house developed iteratively reweighted-
least-square PATCH-algorithm was employed to correct for the cardiac and motion 
artefacts and eddy currents.28 EPI distortions in the diffusion weighted images were 
unwarped along the phase-encode direction by mapping the mean unweighted image 
onto the T1 reference image. After the brain extraction using BET within FSL, the diffusion 
scalar parameters were calculated using DTI-fit within FSL.24 To calculate the mean FA 
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and MD of the white matter, we first segmented the native T1-image into grey matter, 
white matter and cerebrospinal fluid using SPM8. We then registered the masks linearly 
using the transformation matrix from T1-image to B0-image. Registrations were manually 
checked; in two patients the registrations were not successful (and unrecoverable) and 
thus these registrations were excluded from further analyses.
Controls
Stroke-free controls (women aged 18 or older) were recruited among patients’ family or 
social environment and matched for age and level of education. They underwent the 
same follow-up examination as patients and were excluded from this sub-study when 
they experienced HDP (n=3).
Statistical analysis
First, baseline characteristics and the prevalence of SVD between patients with or without 
a history of HDP and controls were compared with chi-square, Mann-Whitney-U or a 
student t-test when appropriate. Because of skewed distribution, MD and WMH volumes 
were log-transformed with addition of a constant number of 0.001 to the WMH data 
because they contained zeros. We used the square root for FA. For the analyses between 
the three groups we used Analysis of variance (ANOVA) for continuous outcome variables 
(WMH-volume, FA and MD) with adjustments for potential confounders (age at MRI, 
current hypertension, current smoking; including infarct volume for FA/MD). Second, the 
relation between HDP and microbleeds or lacunes was analyzed with binominal logistic 
regression, with age at MRI, current hypertension and current smoking as confounders. 
Dyslipidemia was not included in any of the analyses as it was not related to the outcome 
in univariate analyses. All p-values of <0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY).
Results
Study population
Of 466 women with a first-ever ischemic stroke or TIA in the FUTURE-study, 132 patients 
were eligible to participate in this study (history of HDP n=36, no history of HDP n=96; 
flowchart: figure 1). 28 Controls fulfilled inclusion criteria. Baseline characteristics are 
shown in table 1. Mean age of patients with or without a history of HDP was 40.5yrs (SD 
7.3) and 39.2yrs (SD 7.7) respectively. There were no significant differences in type of event, 
age of stroke, NIHSS at admission and cause of their initial stroke at young age between 
participants and non-participants (n=334), but participants less often smoked (43.1% and 
54.3% respectively, p<0.05). Patients with a history of HDP had the highest prevalence of 
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current hypertension (66.7%), followed by those without HDP (49.0%) and controls (39.3%) 
(p=0.08). 9 out of 36 (25%) patients with a history of HDP experienced (pre)eclampsia or 
HELLP syndrome, 75% suffered from gestational hypertension (n=27).
Figure 1. Flowchart of Study Population
Women with first-ever TIA 
or Ischemic stroke
N=466
Lost to follow-up 
n = 40
Patients included in 
present study n = 132
BA
SE
LI
N
E
FO
LL
O
W
-U
P
Women without any reported pregnancy (n=58) 
or only early miscarriages (n=6)
Deceased 
n=71
Refused to participate 
n=79
Status of HDP unknown (n=5)
Follow-up survivors n=276
No MRI (n= 72) or MRI data incomplete (n=3) 
 
Hypertensive disorders of pregnancy and SVD markers 
There were no significant differences in total brain volume between patients with HDP 
(1100.5ml SD(85.6)), without HDP (1068.1ml SD(113.1)) and controls (1095.9ml SD(104.5)). 
Patients (not stratified by a history of HDP) compared to controls had significantly more 
lacunes (13.6% and 0%, p=0.04) and a higher WMH-volume (median 1.44ml IQR[0.50-3.30] 
and 0.61ml IQR[0.02 - 2.20], p=0.02) (Table 2). After adjustment for confounders, patients 
with a history of HDP and patients without a history of HDP had significantly higher 
WMH volume compared to controls (median 1.70ml IQR[0.54-3.93] and 1.30 IQR[0.47-2.82] 
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versus 0.61ml IQR[0.02 - 2.20], p<0.001) (figure 2). There were no significant differences 
for lacunes or microbleeds between groups. We found no significant differences for the 
severity nor prevalence of these SVD markers between patients with and without HDP. 
FA and MD of the white matter did not significantly differ between patients with and 
without HDP, nor between patients and controls (Table 2). 
Table 1. Participant characteristics
No. (%)
All 
patients
n=132
Patients 
without 
HDP
n=96
Patients 
with HDP
n= 36
Controls
n=28
p-value
Mean age at time of event, yrs. (SD]) 39.6 (7.6) 39.2 (7.7) 40.5 (7.3) N/A 0.40
Median NIHSS at admission [IQR]* 2 [0-5] 2 [0-6] 1 [0-4] N/A 0.03
Mean age at first child, yrs. (SD) 27.5 (4.7) 27.6 (4.6) 27.3 (5.0) 27.7 (5.2) 0.92
Number of Kids, median [min-max] 2 [1-5] 2 [1-5] 2 [1- 3] 2 [1-6] 0.73
Stroke subtype, No. (%)
 TIA
 Ischemic Stroke
45 (34.1)
87 (65.9)
27 (28.1)
69 (71.9)
18 (50.0)
18 (50.0)
N/A 0.02
TOAST, No. (%)
 Large artery disease
 Cardioembolism
 Small vessel disease
 Other determined cause
 Multiple causes
 Undetermined cause
30 (22.7)
15 (11.4)
9 (6.8)
24 (18.2)
1 (0.8)
53 (40.2)
21 (21.9)
10 (10.4)
5 (5.2)
19 (19.8)
0 
41 (42.7)
9 (25.0)
5 (13.9)
4 (11.1)
5 (13.9)
1 (2.8)
12 (33.3)
N/A 0.37
Cardiovascular risk factors, No. (%)
 Hypertension
 Diabetes
 Dyslipidemia
 Smoking ever
 Smoking current
71 (53.8)
12 (9.1)
122 (92.4)
94 (71.2)
38 (28.8)
47 (49.0)
8 (8.3)
87 (90.6)
67 (69.8)
27 (28.1)
24 (66.7)
4 (11.1)
35 (97.2)
27 (75.0)
11 (30.6)
11 (39.3)
1 (3.6)
22 (78.6)
17 (60.7)
7 (25.0)
0.08
0.60
0.05
0.48
0.89
Mean time from pregnancy to MRI, 
yrs. (SD)†
20.4 (10.8) 20.2 (10.0) 21.0 (12.9) 24.1 (13.1) 0.26
Mean follow-up time (from index-
event), yrs. (SD)
9.9 (8.2) 10.1 (8.4) 9.3 (7.9) N/A 0.70
Mean age at follow-up, yrs. (SD) 49.4 (8.8) 49.3 (8.1) 49.8 (10.8) 53.1 (10.6) 0.15
* NIHSS missing in 1 patient (without HDP), † It was unknown during which pregnancy the HDP was diagnosed, 
therefore the time from pregnancy to MRI was calculated separately for every pregnancy and subsequently the 
mean of these times for every individual. Abbreviations: HDP=Hypertensive disorders of pregnancy, SD=standard 
deviation, NIHSS=National Institutes of Health Stroke Scale , IQR=interquartile range, TIA=transient ischemic 
attack, TOAST=Trial of Org 10172 in Acute Stroke Treatment.
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Figure 2. Boxplot of normalized total WMH volume of groups 
Controls without HDPPatients with HDPPatients without HDP
W
M
H 
vo
lu
m
e 
(m
l)
11,0
10,0
9,0
8,0
7,0
6,0
5,0
4,0
3,0
2,0
1,0
0
p < 0.001
p < 0.001
Significant p-values after adjustment for age at time of MRI, current hypertension and smoking
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Discussion
In this study, we investigated whether a history of HDP is a risk factor for SVD in patients 
with a young stroke. We demonstrated that approximately 10 years after stroke, patients 
with a young stoke have a significantly higher burden of WMH than controls, but a 
history of HDP did not further modify this observation. 
Major strengths of this study are the uniformly collected data from a single centre and 
the long-term follow-up. This study also included extensive MRI-data with the possibility 
to analyze the microstructure of the brain using DTI, and thus we were able to determine 
a broad spectrum of SVD markers as well as the microstructural integrity of the white 
matter.
There are also some methodological limitations. We focused on a very specific patient 
group in a rather small sample size with a potentially limited statistical power to detect 
significant differences between groups. Also, because of the cross-sectional design we 
could only investigate the prevalence rather than the development of SVD over time, 
thus no causal inferences can be made. Last, recall bias could have played a role in the 
history of HDP as this was collected retrospectively. As the specificity of self reported 
pregnancy complications is generally moderate to good and the sensitivity is high (>90%), 
this probably could have led to an underestimation of the prevalence of HDP.29
Previous studies showed that HDP increases the risk of SVD in the general population.13-15 
We were not able to replicate this observation in our study among young stroke patients. 
There are several explanations for this. Our findings may suggest that the additional 
impact of HDP on the risk of development of SVD is limited compared to the impact 
of the previous stroke. It could thus be that a history of a previous stroke poses these 
patients already at such high risk of developing SVD,3 without the opportunity to 
disentangle the contribution of HDP to this known increased risk . Another explanation 
might be that only the more severe determinants of HDP (preeclampsia, eclampsia, 
HELLP-syndrome) play a role as risk factor for SVD. This was supported by studies from 
the general population that concluded that the increased risk of SVD was especially 
found in patients with preeclampsia or eclampsia.14, 15, 30 Unfortunately our power was 
limited to confirm this relation in our young stroke cohort. However, although our group 
of 9 patients with (pre)eclampsia or HELLP syndrome is too small to execute statistical 
analyses, we did not find any visual differences on SVD markers between patients with 
(pre)eclampsia/HELLP syndrome or gestational hypertension only (results not shown). 
Another explanation is possibly that not the HDP itself, but the increased risk of chronic 
hypertension thereafter drives the risk of SVD in young stroke patients. Other studies 
found that HDP is an important risk factor for chronic hypertension31-33 and it is a known 
fact that particularly hypertension is an important contributor to the development of 
SVD.4 Because we corrected for hypertension in our analyses, there is a possibility that we 
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corrected for a part of the causal chain between HDP and SVD. However, repeating the 
analysis without adjustment for hypertension did not change SVD differences between 
patients with or without HDP. 
Other studies investigating the risk of SVD in women with HDP excluded patients with a 
history of a stroke, making comparisons based on the same study population not possible. 
Two other studies among stroke-free women with or without prior preeclampsia also did 
not find any significant difference in total WMH volume between these groups, which 
is in line with our results.30, 34
However, with HDP not being a risk factor for SVD in young stroke patients, other yet 
unknown risk factors may explain the higher WMH-volume in young stroke patients 
than in controls. This is consistent with another study that concluded that only 2% of the 
total variance in WMH is explained by traditional vascular risk factors,35 suggesting that 
causes are unknown for most markers of SVD. As the development of SVD takes many 
years and we already found pronounced SVD at a mean age of 49 years, this suggests that 
these young adults have been exposed to certain risk factors already early in life including 
genetic, lifestyle and environmental factors.36-39
In conclusion, a history of HDP does not increase the risk of SVD in patients with a 
previous stroke at a young age. The stroke itself, or its associated (partly unknown) 
risk factors are likely the main contributors to this increased risk of future SVD. Future 
prospective population-based studies should focus on (early in life) risk factors of SVD 
other than the classical cardiovascular risk factors, such as lifestyle, environmental factors 
and genetic predisposition.
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Abstract
Background: The proportion of strokes occurring in younger adults has been rising 
over the past decade. Due to the far longer life expectancy in the young, stroke in this 
group has an even larger socio-economic impact. However, information on etiology 
and prognosis remains scarce.
Methods/design: ODYSSEY is a multicentre prospective cohort study on the 
prognosis and risk factors of patients with a first-ever TIA, ischemic stroke or 
intracerebral hemorrhage aged 18 to 49 years. Our aim is to include 1500 patients. 
Primary outcome will be all cause mortality and risk of recurrent vascular events. 
Secondary outcome will be the risk of post-stroke epilepsy and cognitive impairment. 
Patients will complete structured questionnaires on outcome measures and risk 
factors. Both well-documented and less well-documented risk factors and potentially 
acute trigger factors will be investigated. Patients will be followed every 6 months 
for at least 3 years. In addition, an extensive neuropsychological assessment will be 
administered both at baseline and 1 year after the stroke/TIA. Furthermore, we will 
include 250 stroke-free controls, who will complete baseline assessment and one 
neuropsychological assessment.
Discussion: ODYSSEY is designed to prospectively determine prognosis after a young 
stroke and get more insight into etiology of patients with a TIA, ischemic stroke and 
intracerebral hemorrhage in patients aged 18 to 49 years old in a large sample size.
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Background
Recent studies have shown that the proportion of strokes occurring in adults younger 
than 50 years of age has increased from 13 to 19% over the past decade. 1, 2 Due to the longer 
life expectancy in the young compared with a general elderly stroke patient, stroke in this 
younger group has a large impact on number of years lost to ill-health, disability or early 
death.3 This impact will not only be determined by the direct mortality and residual post-
stroke deficit, but may also be influenced by future vascular events, cognitive impairment 
or post-stroke epilepsy that may occur throughout their post-stroke lives.4, 5 Especially 
for young patients reliable information on this prognosis is of great importance as their 
stroke occurs in the period of life in which they would like to form families, have an active 
social life and make decisive career moves. However, it is exactly the prognosis of this 
younger group that remains unclear.
Previous studies on stroke in the young were mainly retrospective and included patients 
who had their index events at times with a completely different secondary prevention 
strategy. Most studies only aimed at prognosis in terms of mortality and vascular events, 
which are very important outcome measures. However, other important post-stroke 
complications, such as cognitive deficits, post-stroke epilepsy and post-stroke functioning 
were not taken into account. Furthermore, previous studies have only included patients 
with an ischemic stroke, whereas studies in younger patients with a transient ischemic 
attack (TIA) or intracerebral hemorrhage are scarce. There is growing evidence that 
despite the fact that TIA patients suffer from (by definition) transient neurological 
deficits, their cognitive or social sequelae may last way longer.6-8 In addition, survival of 
patients with an intracerebral hemorrhage has improved substantially due to improved 
care resulting in longer post-stroke life expectancy. Information on prognosis after an 
intracerebral hemorrhage or TIA is consequently of great importance as well, both for 
patients and their health professionals when counseling their patients with information 
on the course of the disease.
Introduction
Apart from uncertainties about prognosis and the major socio-economic impact of a 
young stroke, the explanation for the increased incidence of young stroke remains unclear. 
It has been suggested that an increased prevalence in traditional vascular risk factors, 
such as diabetes mellitus and obesity due to unhealthy life style and poor education, 
results in (more) atherosclerosis already at younger ages which may lead to stroke. 9, 10 
Furthermore, a rising incidence of substance abuse which may be more pronounced in the 
young might play a role.11 However, despite the use of ever increasing additional clinical 
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investigations that take place in renowned specialized stroke centers, etiology remains 
unknown in more than 30% of the young stroke patients.12 An approach to get more 
insight into pathophysiological mechanisms of a young stroke, is to identify potentially 
acute trigger factors that precede a young stroke. In studies on subarachnoid hemorrhage 
and ischemic stroke in elderly, several acute trigger factors already have been identified 
(including for example vigorous physical exercise, emotions and coffee consumption).13, 14
The assessment of prognosis and etiology is a first step in informing young stroke 
patients in terms of prognosis. We therefore will perform the Observational Dutch Young 
Symptomatic StrokE studY (ODYSSEY); a large multicentre prospective cohort study on 
prognosis and both traditional and other risk factors of patients with a TIA, ischemic 
stroke or intracerebral hemorrhage aged 18 through 49 years.
Methods/Design
Study design
ODYSSEY is a multicentre prospective cohort study that investigates prognosis and 
risk factors of patients with a TIA, ischemic stroke or intracerebral hemorrhage aged 
18 through 49 years. Within this setting we will perform a case-crossover design on 
potential acute trigger factors. The Medical Review Ethics Committee region Arnhem-
Nijmegen approved the study (NL41531.091.12) and all participants will be requested to 
sign an informed consent form.
Objectives
The main objective of our study is to determine the risk of mortality and recurrent 
vascular events in patients with a first-ever young TIA, ischemic stroke or intracerebral 
hemorrhage.
Secondary objectives are to determine the risk of post-stroke epilepsy, cognitive impairment 
and (vascular) dementia after a young stroke. The influence of a young stroke on functional 
outcome, quality of life and depressive symptoms will also be investigated. We will investigate 
the prevalence of traditional vascular risk factors and the relation between potential acute 
trigger factors and the occurrence of a young stroke. In addition, we will identify baseline 
characteristics that are associated with our primary and secondary outcomes.
Study population
All consecutive patients with an acute first-ever young stroke or TIA admitted to the 
stroke unit or outpatient department of one of the participating centers will be asked to 
participate in the study. Participating study centers are the Departments of Neurology 
at the Haga Hospital Den Haag, St Franciscus Gasthuis Rotterdam, Tweesteden Hospital 
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and St. Elisabeth Hospital Tilburg, Catharina Hospital Eindhoven, Amphia Hospital Breda, 
Medisch Spectrum Twente Enschede, Canisius Wilhelmina Hospital Nijmegen, Rijnstate 
Hospital Arnhem and Radboud University Medical Centre Nijmegen.
Inclusion criteria
1. First-ever stroke (ischemic stroke or intracerebral hemorrhage) or TIA with corresponding 
lesion and/or evidence of acute arterial occlusion on CT(A)- or MRI/A-scan.
2. Age 18 through 49 years
3. Onset of symptoms within 14 days prior to inclusion.
TIA is defined as a rapidly evolving focal neurological deficit, without positive phenomena 
such as twitches, jerks or myoclonus, with no other than vascular cause lasting less than 
24 hours. Acute stroke is defined similar, but with symptoms persisting for more than 24 
hours. Based on neuro-imaging, stroke is further divided into intracerebral hemorrhage 
and ischemic stroke. Hemorrhagic transformation of an ischemic stroke will be classified 
as an ischemic stroke.
Exclusion criteria
1. History of TIA or stroke.
2. Traumatic intracerebral hemorrhage.
3. Any subarachnoid hemorrhage.
4. Intracerebral hemorrhage due to a known ruptured aneurysm.
5. Intracerebral hemorrhage in a known cerebral malignancy (either primary brain 
tumor or metastasis).
6. Transient monocular blindness or retinal infarction.
7. Cerebral venous sinus thrombosis.
8. Not permanently living in the Netherlands.
Controls
Controls will be recruited among patients’ spouses, relatives or social environment. 
Controls have to be aged 18 through 49 years and will be matched for mean age, sex and 
level of education. A history of TIA, ischemic stroke or intracerebral hemorrhage is an 
exclusion criterion, which will be confirmed by a validated questionnaire for verifying 
stroke-free status.15
Procedures
All eligible patients will be recruited during the evaluation of their TIA or stroke. 
Patient recruitment is planned over a 3 to 4-year period and we intend to include 1500 
patients. After informed consent and written approval of the participants patients will 
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 134
Chapter 8
134
formally enter the study. If the patient is unable to provide informed consent, consent 
is provided by the patient’s legally acceptable representative. During admission or visit 
to the outpatient department, patients will undergo a baseline assessment. In addition, 
patients will undergo an extensive baseline neuropsychological investigation 6–8 weeks 
after the index event. The same neuropsychological assessment will be administered 1 
year after the TIA or stroke. After baseline assessment, patients will be followed every 6 
months for at least 3 years by telephone interview. See Figure 1 for the flowchart of the 
study design. In addition, we intend to include 250 controls who will undergo a baseline 
assessment on demographics and a neuropsychological assessment.
Sample size and power calculation
Sample size is based on the least frequent endpoint after young stroke. According to 
previous literature cumulative incidence of post-stroke dementia is approximately 1% per 
year. To adjust for the most important confounders (age, sex, stroke severity, education 
and depression) in our cox proportional hazard analysis, at least 40 cases are needed. To 
detect a cumulative incidence of 1% per year and a follow-up of 3 years with a power of 
80%, results in a sample size of at least 1500 patients.
Control subjects are included to compare cognitive tasks between patients and healthy 
subjects. Our pilot studies showed that ‘attention’ is the cognitive task which differs the 
least between patients and healthy subjects (impaired in 14% versus 8% respectively). To 
identify this difference with a power of 80% and alpha 0.05 in previous mentioned 1500 
patients, 265 healthy control subjects need to be included.
Measures-baseline
Medical history
At baseline all participants (patients and controls) will undergo standardized structured 
questionnaires on demographics, level of education (scored using seven categories in 
accordance with the Dutch educational system: 1 = less than primary school; 7 = university 
degree),16 marital status and employment.
The presence of cardiovascular risk factors will be assessed by standardized, structured 
questionnaires and classified according to the current guidelines of the American 
Heart Association.17 Non-modifiable risk factors include age, sex and a family history of 
cardiovascular diseases in the next of kin. Well-documented and potentially modifiable 
risk factors will include cardiovascular diseases (valvular heart diseases, myocardial 
infarction, coronary artery bypass grafting (CABG), percutaneous transluminal coronary 
angioplasty (PTCA) and peripheral revascularisation procedures). Furthermore, well-
documented potential modifiable risk factors will include diabetes mellitus, hypertension, 
dyslipidemia, smoking and atrial fibrillation.
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Less-well documented, potentially modifiable risk factors included a history of migraine, 
acute infections, the use of oral contraceptives, alcohol consumption and the use of 
recreational drugs. Patients will be screened for migraine with the MISS questionnaire, 
a screening instrument regularly used in Dutch hospitals containing questions about 
migraine in terms of diagnosis, frequency, aura and concomitant symptoms. Definitions 
of both well-documented and less-well documented, potentially modifiable risk factors 
are shown in Additional file 1.
In addition to the assessment of risk factors, patients will be asked about a history of 
epilepsy, pregnancies and complications, pulmonary embolism, deep vein thrombosis and 
current medication use. Furthermore, functional performance prior to the index event 
will be assessed by modified Rankin scale.
Potential trigger factors
In addition to the questionnaires on cardiovascular risk factors, patients will be requested 
to fill out a standardized structured self-reported questionnaire on acute factors that 
might trigger stroke. For each trigger factor, patients will be asked to report their usual 
exposure during the past year and the exposure during a predefined period before the 
onset of stroke; the hazard period. Hazard periods are based on the estimated duration of 
the effect of each potential trigger factor as used in previous studies investigating trigger 
factors of cardiovascular events.13, 14, 18 In addition to exposure in the hazard period, patients 
will be asked about the last exposure before stroke. In this case-crossover design, each 
patient will serve as his or her own control.19
Potential trigger factors that will be investigated include smoking, consumption of 
alcohol, recreational drugs (cocaine, heroin, methadone, amphetamine, cannabis, XTC, 
anabolic steroids, hallucinogens and EPO), caffeine containing drinks (coffee and cola), 
Valsalva maneuver, fever, positive and negative emotions, physical exercise and sexual 
activity. Table 1 shows the hazard periods for the different potential trigger factors. To 
investigate the effect of Valsalva maneuver as stroke trigger, patients will be asked 
about sneezing, coughing, nose-blowing and heavy lifting. The exposure to positive and 
negative emotions will be measured using the PANAS scale, a 5 level scale which contains 
9 positive and 9 negative affects.20 Whenever patients report a mean score of ≥3.5 on the 
negative affects, they will be considered exposed to negative emotions.21 Anger will be 
measured using the anger scale, consisting of 7 levels of anger.22 Patients are considered 
exposed to anger if they report a peak level of anger ≥4 (very angry, furious or enraged). 
Physical exercise will be expressed in the metabolic equivalent value (MET) according 
to accepted standards.23 The exposure of vigorous to extreme exercise (MET ≥ 6) will be 
reported.18 Consumption of alcohol, recreational drugs, coffee, cola and smoking will be 
reported in units per day.
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Table 1. Hazard period for potential trigger factors
Hazard time 
Smoking 1 hour
Alcohol consumption 24 hours
Recreational drugs 4 hours
Consumption of coffee 1 hour
Consumption of cola 1 hour
Valsalva maneuver 1 hour
Fever 24 hours
Positive and negative emotions 1 hour
Anger 1 hour
Physical exercise 1 hour
Sexual activity 2 hours
Clinical evaluations
Physical examination and additional investigations
Baseline standard clinical evaluation will be performed during admission or visit to 
the outpatient departments. Clinical signs, symptoms and duration of stroke and 
TIA will be reported. Stroke severity will be assessed by the National Institutes of 
Health Stroke Scale (NIHSS)24 and modified Rankin scale (mRS),25 both measured at 
admission and at discharge.
Furthermore, standard clinical evaluation will include a physical examination and 
laboratory measures. Table 2 shows an overview of all investigations. Additional 
investigational DNA will be stored for future genetic analysis. Patients must consent 
for storage of the DNA and future analysis.
Classification of TIA or stroke: etiology and neuro-imaging
Etiology of ischemic stroke and TIA will be classified according to the TOAST 
criteria,26 Causative Classification System of ischemic stroke (CCS)27 and ASCO.28 
Etiology of intracerebral hemorrhage will be classified as hypertensive (deep or 
infratentorial hemorrhage in combination with hypertension), arteriovenous 
malformation, cavernous angioma, coagulopathy (iatrogenic or bleeding disorder), 
central nervous system infection, septic embolism, vasculitis, substance abuse or 
unknown (cryptogenic, multiple causes and incomplete evaluation).29 Etiology will 
be based on neuro-imaging, medical history and the use of medication.
All patients will undergo neuro-imaging and additionally CT-angiography, MR-
angiography or ultrasound will be performed according to standard clinical care. CT- 
and MRI-scans will be reviewed centrally in the Radboud University Medical Centre. 
TIA and ischemic strokes will be classified according to arterial territory and addition 
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will be classified as lacunar or territorial. Whenever hemorrhagic transformation of 
an ischemic stroke has occurred this will be documented.
Intracerebral hemorrhage will be classified as infratentorial (brainstem or cerebellar) 
or supratentorial hemorrhage (lobar, deep or ventricular) with or without ventricular 
involvement. Lobar hemorrhage will be further subdivided into frontal, temporal, parietal 
or occipital. In addition hematoma volume will be calculated according to the A*B*C/2 
method.30
Table 2. Overview of investigations
Standard
Physical examination Neurological examination 
NIHSS X
mRS X
Blood pressure X
Oxygen saturation X
Heart rate X
Body temperature x
Body Mass Index X
Additional investigations ECG X
Laboratory measures X
Fasting glucose X
Cholesterol levels X
Blood count X
Sedimentation rate X
DNA storage X
Other specific laboratory measures on indication 
(young stroke laboratory measures) 
Echocardiography on indication
Imaging Neuro-imaging* X
CT 
MRI
Vascular imaging† X 
Angio-CT
Angio-MRI
Ultrasound
* All patients will undergo neuro-imaging, either CT or MRI scanning.
† All patients will undergo either angio-CT, angio-MRI or ultrasound according to standard clinical care. 
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Course of the disease
Furthermore, the course of the disease during admission will be reported, including 
medication use, (intra-venous or arterial) thrombolysis or other treatments and 
complications. Whenever a patient develops a recurrent vascular event (ischemic stroke, 
intracerebral hemorrhage, TIA, myocardial infarction) or post-stroke epilepsy this will 
be reported. In addition, the course of stroke severity during admission will be assessed 
by mRS and NIHSS.
Measures - follow up
All patients will be followed every 6 months by telephone interview. Patients will undergo 
standardized structured questionnaires on the occurrence of post-stroke epilepsy and 
recurrent vascular events (TIA, ischemic stroke, intracerebral hemorrhage, myocardial 
infarction, CABG, PTCA and other revascularization procedures). In addition, they will 
be asked about well-documented potentially modifiable vascular risk factors (diabetes 
mellitus, hypertension, dyslipidemia and smoking), the use of medication and pregnancies. 
In case a patient has died, this information will be retrieved from the general practitioner.
As measure of functional outcome mRS and Barthel Index31 will be administered and 
patients will be asked about their occupation or education. Occupation will be categorized 
into 4 skills levels (ranging from first = primary education only to fourth = tertiary 
education with university degree or equivalent), according to the ISCO-88 (International 
Standard Classification of Occupations).32
Neuropsychological investigation
An extensive neuropsychological investigation will be administered in all patients six 
weeks and 1 year after the index event (using parallel versions for some tests that are 
susceptible to test-retest effects). Controls will be assessed only once at baseline.
The cognitive assessment includes tests used in other large-scale epidemiologic studies 
covering the main cognitive domains.33, 34 Table 3 shows an overview of all cognitive 
tests performed. Global cognitive functioning will be assessed by the Mini Mental State 
Examination.35 Episodic memory will be measured using the 3-trial version of the Rey 
Auditory Verbal Learning Test,36 which includes a delayed recall and a delayed recognition 
trial, assessing the acquisition and retention of new verbal information. To assess speed 
of information processing, Parts I and II of the Stroop Color Word test 37 and the Letter-
Digit Substitution Task (an adaptation of the Digit-Symbol Substitution Test)38 will be 
used. Visuoconstructive ability will be assessed by the copy trial of the Rey Complex 
Figure Test.39 With respect to executive functioning, verbal fluency (animal naming, 60 
sec) will be used to test response regeneration, the Brixton Spatial Addition Task 40 will 
be administered as a measure of concept shifting and rule detection, and the Stroop 
Interference Score 32 will be included as a measure of response inhibition. Furthermore 
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participants will complete the Star Cancellation of the Behavioral Inattention Test, a 
short screening battery to assess the presence of a visual neglect.41 Participants will be 
tested for language deficits by means of the short version of the Token Test, validated 
for the Dutch language.42 To evaluate attention and working memory we will assess the 
Digit Span subtest from the Wechsler Adult Intelligence Scale - Fourth Edition 43 and the 
Paper and Pencil Memory Scanning Task (4 subtasks).44 Subjective cognitive complaints 
will be assessed by the Cognitive Failure Questionnaire.45 The cognitive assessment will 
be performed in quiet rooms and administered by trained investigators.
In case cognitive impairment is suspected on the basis of the cognitive screening, relatives 
will be interviewed on the influence of cognitive performance on daily functioning by 
means of the IQCODE.46
In addition to the cognitive screening, questionnaires on mood and functional outcome 
will be administered. Participants will be screened for a history of depressive symptoms 
with a standardized questionnaire used in previous large-scale epidemiological studies,47 
in which normal reactions to stressful events or normal grief will be excluded. A history 
of depression is defined as those episodes that require attention of a medical caregiver, 
including both minor depression and major depressive syndromes as defined by the 
Research Diagnostic Criteria.48 Current anxiety and depression will be evaluated by 
means of the Mini International Neuropsychiatric Interview,49 which is a short diagnostic 
structured interview based on the DSM-IV. Functional outcome will be assessed by mRS, 
Barthel Index and Instrumental Activities of Daily Living.50
Furthermore participants will fill out validated self-report questionnaires on fatigue by 
means of the Checklist on Individual Strength (CIS20r)51 and quality of life by means of 
the EQ-5D.52 Health status will be assessed by means of the Stroke Impact Scale 53 and 
SF-12.54
Outcome
Primary outcome will be all cause mortality. Depending on date and location of death 
information on cause of death will be available either from the hospital (in-hospital 
mortality) or the general practitioner. Secondary measures of outcome will be the 
composite endpoint of any recurrent vascular event. Vascular events will include TIA, 
fatal or non-fatal stroke (ischemic or hemorrhagic), myocardial infarction, CABG, PTCA 
and other revascularization procedures, whichever occurs first. Stroke and TIA will be 
defined similar as the index event. Myocardial infarction will be defined by ischemic 
symptoms with electrocardiographic, cardiac biomarker, or pathological evidence of 
infarction according to the universal definition of myocardial infarction.55
In addition, the occurrence of post-stroke epilepsy and dementia will be noted 
as secondary outcome. Epilepsy will be classified and defined according to the 
International League Against Epilepsy, in which patients with a single seizure 
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associated with an enduring condition that could cause epilepsy, meet the criteria of 
epilepsy.56, 57 Dementia will be defined according to DSM-5. Finally, tertiary outcome 
measures will include functional outcome, quality of life and mood disorders.
Whenever an outcome event is suspected with the aid of standardized structured 
questionnaires, information from the treating physician will be retrieved. This 
information will be verified and adjudicated by two independent experienced 
neurologists or, in case of a myocardial infarction, by a cardiologist, who will be 
blinded for the index event.
Table 3. Neuropsychological assessment
Domain Test/Questionnaire
Cognitive assessment
Global cognitive functioning Mini Mental State Examination
Episodic memory Rey Auditory Verbal Learning Test
Speed of information processing Stroop Color Word Test
Letter-Digit Substitution Task
Visuoconstruction Rey Complex Figure Test - Copy
Executive functioning Animal Fluency test
Stroop Interference score
Brixton Spatial Anticipation Test
Neglect Star Cancellation
Language deficits Short Token Test
Attention and working memory Digit Span Test
Paper and Pencil Memory Scanning Task
Subjective cognitive complaints Cognitive failures questionnaire
Mood and functional outcome
History of depression
Anxiety and depression Mini International Neuropsychiatric Interview
Fatigue Checklist on Individual Strength (CIS20r)
Quality of life EQ-5D
Health Status Stroke Impact Scale
SF-12
Functional outcome Modified Rankin Score
Barthel Index
Instrumental Activities of Daily Living
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Analysis
Cumulative risk of mortality, vascular events and epilepsy will be estimated by Kaplan-
Meier survival analysis. In the analysis for epilepsy and vascular events, patients who 
have died will be censored. Cox proportional hazard analysis will be used to calculate 
hazard ratios for previous mentioned primary and secondary outcome measures adjusted 
for the necessary covariates. For the outcome measures vascular events and epilepsy, 
additional competing risk analysis will be performed in which death will be considered 
as a competing risk as suggested by Fine and Gray.58, 59
For the analysis containing cognition, raw test scores of each test will be calculated and 
converted to Z-scores using the mean and standard deviation of the controls. Z-scores of 
tests assigned to the same cognitive domain will be averaged and used in all subsequent 
analyses as composite Z-score, or domain score. ANCOVA models will be used to compare 
means of different variables on each cognitive domain adjusted for the necessary 
covariates. Linear regression will be used to explore the effect of different variables on 
each cognitive domain and results will be reported as beta coefficients.
For the analysis including acute trigger factors, a case-crossover design as previous 
described will be used in which each patient will serve as his or her own control.19 The 
ratio of the observed exposure frequency in the hazard period to the expected frequency 
based on the control period will be used to estimate relative risks.
Hazards ratios, beta coefficients and relative risks will be calculated with their 
corresponding 95% confidence intervals. Comparisons of continuous variables will be 
done by Student’s t test or analysis of variance or, in case of skewed distributions which 
cannot be normalized, corresponding nonparametric tests will be used. Chi-squared test 
will be used for comparison of categorical variables.
Discussion
ODYSSEY aims to investigate the prognosis after a first-ever young TIA, ischemic stroke 
or intracerebral hemorrhage in terms of mortality, recurrent vascular events, post-stroke 
epilepsy and cognitive impairment. Furthermore, we intend to determine the prevalence 
of vascular risk factors in young stroke patients and to relate potential acute trigger 
factors to the occurrence of a young stroke.
Strong elements of the study are the multicentre prospective design with multiple 
follow-up assessments. Due to the multicentre approach we will be able to include a 
large sample size, covering a vast part of the Netherlands including both academic and 
regional hospitals. The prospective design allows us to obtain an accurate evaluation 
of the prognosis of young stroke patients, unlike previous small retrospective studies. 
Furthermore, most previous studies only included patients with an ischemic stroke while 
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we will include patients with a TIA and intracerebral hemorrhage as well. This allows us 
to study a large part of the spectrum of stroke in young adults. Since patients will only be 
eligible for inclusion in our study when they have positive brain imaging corresponding 
with their neurological deficits, ODYSSEY will have a clearly defined population without 
misclassification. In retrospective studies, a clinical diagnosis was often used for defining 
stroke, leading to a more heterogeneous study population.
Only few small studies among young stroke patients investigated cognitive performance 
after a young stroke. To our knowledge we are the first to investigate cognitive performance 
both at baseline as well as 1 year after follow-up. This enables us to describe the course of 
cognitive performance and potential further decline after an initial assessment. On top of 
this we will include healthy matched control subjects which will allow for a comparison 
of cognitive performance with a healthy group.
In addition, this study is the first investigating potential acute trigger factors preceding 
a stroke or TIA in a non-selected young population. In studies on subarachnoid 
hemorrhage and ischemic stroke in the elderly, several acute trigger factors already have 
been identified.13, 14 Due to the case-crossover design we hope to identify possible acute 
trigger factors, which may give us more insight in the underlying pathophysiological 
mechanisms of a young stroke. As some of those trigger factors are potentially modifiable, 
the assessment of acute trigger factors might lead to new prevention strategies in high 
risk patients.
The estimation of etiology and prognosis is a first step in informing young stroke patients 
in terms of prognosis. The estimates of recurrent vascular events risks may be used to 
design future intervention studies on start and withdrawal of secondary prevention in 
these young patients, as the current prescription of these drugs is based on extrapolated 
findings from stroke trials in which young patients have been underrepresented or 
excluded.
In conclusion, ODYSSEY is designed to prospectively determine prognosis after a young 
stroke and get more insight in etiology of patients with a TIA, ischemic stroke and 
intracerebral hemorrhage in patients aged 18 through 49 years old in a large sample size.
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Additional file 1.
Definition of well-documented and less-well documented modifiable risk factors
Well-documented potentially modifiable risk factors: Smoking will be defined as at least 1 
cigarette in the 6 months prior to the event. Overweight will be defined as Body Mass 
Index=25-29 and obesity as Body Mass Index≥30.60 On the basis of laboratory findings 
diabetes mellitus will be defined as a random blood glucose level ≥ 200 mg/dL (11.1mmol/L) 
or 2 consecutive fasting venous plasma glucose levels of ≥ 126 mg/dL (7.0 mmol/L)61, 62 
or the use of antidiabetics. Dyslipidemia will be defined by either total cholesterol level 
≥5.0 mmol/L or low-density lipoprotein level ≥2.5 mmol/L or high-density lipoprotein 
level <1.0 mmol/L or the use of lipid-lowering drugs. Hypertension will be defined as a 
systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 (measured at least 24 
hours after stroke, with 2 independent measures)63, 64 or the use of antihypertensive drugs. 
Less-well documented potentially modifiable risk factors: Excess alcohol consumption will be 
defined as consuming more than 200 g of alcohol per week. Furthermore migraine will 
be defined according to the international classification of headache disorders.65
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Summary
Ischemic stroke is the second leading cause of mortality worldwide and is also one of 
the most pronounced causes of disability. Despite the fact that a stroke mainly occurs 
in the elderly, approximately 15% of all strokes affects a young person aged 18 to 50 years 
and the incidence is increasing. Currently, 13 million people worldwide suffer an ischemic 
stroke each year, thus resulting in nearly 2 million young patients aged 18 to 50 years. 
Patients who are affected by a stroke at a young age are in the middle of a working 
and social life and therefore have a great need for information about the cause of their 
stroke and their prognosis. Because of their age, young patients usually have different 
questions about their future after stroke than older patients, for example on the risks 
of a subsequent pregnancy. Also, because the life expectancy of patients with a stroke 
at a young age is much longer than of elderly patients, they are interested in their very 
long-term prognosis. However, studies on the very long-term consequences of a stroke 
at a young age are unfortunately very scarce.
For that reason, the FUTURE study was initiated, a prospective cohort study on the causes 
and consequences of stroke at a young age. In part I, chapter 2, the design of the FUTURE-
study is described. The FUTURE-study included 1005 patients aged 18-50 years with an 
ischemic or hemorrhagic stroke or TIA who were admitted to the Radboud University 
Medical Center Nijmegen, The Netherlands between January 1, 1980 and November 1, 2010. 
Patients received follow-up examination from 2009 to 2012 and from 2014 to 2015, with 
a follow-up duration of up to 30 years.
The studies from this thesis describe the results of the FUTURE study, focusing on the 
risk factors and the long-term prognosis of ischemic stroke or TIA, with special attention 
to pregnancy and pregnancy-related complications.
Risk factors and long-term consequences of young stroke
In part II, chapter 3, the risk factors and the associated mechanisms of young stroke 
are described. The cause of stroke in young adults remains undetermined in of 30-40% 
when classification systems designed for the elderly (TOAST-classification) are used. 
Therefore, our aim was to identify potential risk factors of young stroke according to an 
inventory that is also used in children (IPSS), and to evaluate whether this leads to better 
identification of risk factors and possible mechanisms. We were able to classify 94% of 
all 656 patients into one or more IPSS-categories. These risk factors often pointed to 
specific mechanisms such as non-atherosclerotic arteriopathies, prothrombotic disorders 
and migraine. In 88% of the patients for whom the cause of stroke was classified as 
“undetermined” according to the TOAST classification, additional risk factors were found 
using IPSS. These observations can be used as a stepping stone for creating a classification 
system specifically for young stroke. 
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The very long-term consequences after stroke at a young age are addressed in part II, 
chapter 4, in which the risk of recurrent vascular events and its most important predictors 
were investigated. After 25 years of follow-up, the cumulative risk of any vascular event 
was 45.4% (1 in 2 patients) and 30.1% for a recurrent stroke (1 in 3 patients). If the cause 
of the primary stroke was “large vessel disease” or “cardiac embolism”, that risk was even 
higher (25 years cumulative risk of 60%). The most important predictors of a recurrent 
vascular event were smoking, poor kidney function and a history of peripheral vascular 
disease or myocardial infarction. The predictive value of the prediction model was 
moderate, implying that besides the traditional cardiovascular risk factors, also other 
(yet unknown) risk factors might play a role.
Pregnancy and stroke in young adults
Part III, chapter 5 describes a practical overview of the management of an (acute) 
ischemic stroke during pregnancy and the secondary prevention. The risk of an ischemic 
stroke during pregnancy is increased, particularly from the third trimester up to 6 weeks 
postpartum. For the diagnosis of ischemic stroke during pregnancy an MRI is advised, but 
a (low-dose) CT of the brain is a valid alternative. Acute ischemic stroke treatments, such 
as intravenous thrombolysis or intra-arterial thrombectomy, have not been evaluated 
in pregnant women, but should be considered in pregnant patients with a moderate to 
severe acute ischemic stroke when benefits outweigh the risk. Focusing on secondary 
prevention; aspirin is safe in pregnant or lactating women, but clopidogrel should not 
be prescribed because of limited (safety) data. A multidisciplinary approach, involving at 
least a neurologist, gynecologist and (intervention) radiologist is indispensable.
Part III, chapter 6 describes the occurrence of pregnancy complications in 223 women 
with stroke at a young age. When compared to data available from the general Dutch 
population, these women more frequently suffered from (multiple) miscarriages (35.2% 
versus 13.5%) and intrauterine fetal death (6.1% versus 0.9%). Furthermore, several serious 
pregnancy complications more frequently occurred in women who were pregnant after 
stroke compared to the general population, such as hypertensive disorders in pregnancy 
(33.3% versus 12.2%), HELLP syndrome (9.5% versus 0.5%) and premature birth (9.0% versus 
1.4%). In chapter 6 was also investigated whether hypertensive disorders in pregnancy 
are a risk factor for recurrent vascular events after stroke at a young age; the 20-year 
cumulative risk of a recurrent vascular event was 35.2%, but a history of hypertensive 
pregnancy during pregnancy did not influence this risk. Also, none of the recurrent 
vascular events occurred during a subsequent pregnancy after stroke, even if the index 
stroke occurred during pregnancy. 
In part III, chapter 7 was investigated whether these hypertensive disorders in pregnancy 
are a risk factor for developing small vessel disease (SVD) after a stroke at a young age. We 
showed that both patients with or without a history of hypertensive disorders of pregnancy 
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have a higher white matter hyperintensity (WMH) volume than controls (1.70 ml and 
1.44ml versus 0.61 ml), also when corrected for (cardiovascular) risk factors such as age, 
hypertension and smoking. However, SVD markers did not significantly differ between 
patients with or without hypertensive disorders of pregnancy. 
Future perspectives
Part IV, Chapter 8 of this thesis describes the study rationale and protocol of a new young 
stroke study: the ODYSSEY study (Observational Dutch Young Symptomatic StrokE 
study). This is a nationwide multicenter prospective cohort with the aim of investigating 
the prognosis and etiology of a TIA, ischemic or hemorrhagic stroke in patients aged 18 to 
50 years. Follow-up takes place every six months. The primary outcome is mortality and 
the risk of recurrent vascular events. Also, during follow-up, medication changes and the 
use of secondary prevention will be assessed. Secondary outcome measures also include 
pregnancy complications and cognitive functioning. The occurrence of acute trigger 
factors, “traditional” and less traditional risk factors will be assessed. Also, a proportion 
of patients will receive an MRI with vessel wall imaging. Blood samples will be collected 
from each patient for future genetic purposes.
Conclusion
The studies in this thesis show that patients who are affected by a stroke at a young age 
have a high risk of developing vascular events thereafter and that women also suffer more 
frequently from pregnancy complications. The traditional cardiovascular risk factors play 
an important role in the risk of vascular events and development of small vessel disease, 
but hypertensive disorders of pregnancy do not appear to further increase this already 
increased risk.
For future studies it is important to focus on all possible mechanisms of stroke at a young 
age, as this may ultimately increase the possibility of more targeted treatment based on 
the underlying cause and its associated prognosis.
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General discussion 
Especially for young patients who are affected by a stroke in the middle of their lives, it 
is of utmost importance to adequately inform them about their prognosis and etiology 
of stroke. The heterogeneity of risk factors, etiology and prognosis of stroke among the 
young often poses a challenge to reliably provide them with this information. Because 
of their young age, several issues are different than in elderly patients: the clinician must 
inform patients on the risk of recurrent vascular events on the very long term because 
of their long life-expectancy. A group that warrants special attention and care include 
women who are pregnant or still at a reproductive age; they want to be counseled on the 
risk of complications during pregnancy. In addition, they also need to be informed on 
the risk of developing small vessel disease (SVD), which is associated with later in life 
cognitive impairment, depressive symptoms and unemployment. 
The overall aim of this thesis was to investigate risk factors and long-term prognosis of 
stroke at a young age, with special interest in pregnancy and pregnancy-related disorders. 
This chapter will focus on the methodological considerations and main findings of the 
studies discussed in this thesis. Potential implications for current clinical practice will 
then be highlighted and recommendations for future research will be given. 
Methodological considerations
Study design
The main and unique strength of the FUTURE-study is the very long-term follow-up 
in a large group of patients with a previous young stroke. The study is designed as a 
longitudinal cohort, which allows for the assessment of risk factors and recurrent events 
over time. However, the study on risk of SVD in relation to hypertensive diseases in 
pregnancy (chapter 7) has a cross-sectional design: MRI was performed at time of follow-
up, because during the inclusion period (at the time of the qualifying event) an MRI 
was not readily available and not regularly used in the diagnosis of stroke. Therefore, we 
could only determine the prevalence of SVD at one time point and we were not able to 
investigate the development of SVD over time. 
Though FUTURE is a prospective study, some of the studies in this thesis are based 
on retrospective data. For example, data on pregnancy were collected after inclusion, 
based on the questionnaires administered during the first follow-up period in 2009-2012 
(chapter 6 and 7). However, all data were uniformly collected in a structured manner, 
independent of the outcome, thereby limiting the risk of misclassification. 
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Internal validity
Internal validity is the extent to which a study can properly demonstrate a causal relation 
between two variables. Due to random or systematic errors, the internal validity of the 
study can be compromised. These systematic errors are subdivided in different categories: 
Selection bias (sampling), information bias (validity of measurements) and confounding 
(interference of confounding variables). The precision of the study is determined by random 
errors.1
Selection bias
Selection bias occurs when participation depends on either the determinant or the 
outcome.1 Our inclusion was not based on outcome, but on the diagnosis of stroke or 
TIA at admission, thus making this risk of selection bias less likely. The FUTURE-study 
was designed as a single center study and executed in an academic hospital, which makes 
referral bias possible, but because it is a referral center for a large region we do not feel 
that it would have resulted in a major selection bias. 
Due to the longitudinal design of the FUTURE study, there is an unavoidable risk that 
eligible participants will be lost to follow-up or deceased. This possibility especially 
applies to the chapters that included follow-up data: e.g. risk of recurrent vascular events 
(chapter 4), pregnancy complications (chapter 6 and 7) and SVD (chapter 7). The loss 
of patients who did not participate because they died before the follow-up assessment 
in 2009-2012, could have resulted in a selection of patients with an underestimation 
of poor outcome. Those who refused, or patients lost-to follow-up are probably either 
very seriously affected and are physically unable to participate, or healthy and do not 
feel the importance of participation. In our studies though, there were no significant 
differences in baseline characteristics between participants and non-participants making 
selective survival bias unlikely. In the studies regarding mechanisms of stroke (chapter 3) 
and recurrent vascular events (chapter 4), participants were only slightly older than 
non-participants (mean 40.7 years (SD 7.7) and 39.1 years (SD 8.2) respectively), thus it 
is unlikely that this small difference would have had a major influence on our results.
Information bias
Information bias occurs when there is a measurement error regarding the determinant or 
outcome, leading to misclassification.1 Information bias also occurs when the definitions 
of the outcomes are not or not unequivocally defined.
In the FUTURE-study, all variables were clearly defined according to current guidelines 
and/or in concordance with other published papers. However, diagnostic measures, 
imaging techniques and secondary preventive treatment strategies changed over time, 
resulting in a risk of misclassification. Therefore, TIA and stroke were diagnosed based 
on clinical symptoms rather than on radiological findings at the time of admission. To 
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reduce misclassification of stroke or TIA, all events were verified by two independent 
neurologists who were blinded for the outcome. Misclassification of cardiovascular risk 
factors could also have occurred because these definitions at present are more stringent 
than decades ago, potentially resulting in an underestimation of risk factors especially 
in the earlier decades. Furthermore, we defined the risk factors as present when either 
in the patients’ medical history or when identified during admission based on the exact 
measurements. Considering the possibility that certain risk factors were not present 
at admission but were developed in the years thereafter, all participants underwent 
laboratory testing (glucose, lipid-spectrum etcetera) and blood pressure measurements 
again at time of follow-up to define current cardiovascular risk factors. 
Misclassification could also have occurred in our study described in chapter 3 
(mechanisms and risk factor evaluation according to the International Pediatric Stroke 
Study (IPSS)), because the risk factors in our cohort were not primarily collected according 
to the definitions of risk factors in IPSS, and in some cases the diagnostic process was 
incomplete. However, this could only have resulted in underestimation of the presence 
of risk factors. 
Regarding the occurrence of pregnancy complications there is a potential risk of 
information bias: gestational diabetes and HELLP-syndrome were first accepted as 
diseases around 1950-1960 and in 1982 respectively.2, 3 Especially for women who were 
included in our study around 1980, this could have resulted in an underestimation of the 
incidence of these pregnancy complications. Therefore, we compared our results on the 
occurrence of pregnancy complications with historical data from a large reference group; 
the Dutch population. A limitation is that the Dutch obstetrical population data were 
not structurally collected before 1999 4 and as our inclusion started in 1980, these periods 
do not completely overlap. Excluding women with children born before 1999 would have 
resulted in loss of valuable information on the course of these pregnancies. We consider 
the risk of misclassification low as we found no significant differences between the 
occurrence of pregnancy-related complications before and after 1999 in our data, except 
for HELLP syndrome that was less frequently reported before 1999 (which can be related 
to the fact that it was a relatively ‘new’ diagnosis at the time). 
For the assessment of SVD, two investigators independently rated the MRI scans 
for markers of SVD. They could not be blinded for a stroke on MRI, thus making 
misclassification possible because there is a chance that the interpretation of SVD 
markers is modified by the presence (or absence) of a cerebral infarction on MRI. However, 
the SVD were clearly predefined according to STRIVE-criteria5 and the investigators were 
blinded for demographical data and outcome. Also, the inter- and intrarater reliability for 
the segmentations on SVD were high, making misclassification less likely. White matter 
hyperintensities were automatically segmented using an in-house developed method 
that also limits the risk of misclassification. 
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Another form of information bias is recall bias that occurs when participants do not 
remember events (or details of the event) accurately. Self-reported questionnaires are 
prone to recall bias and in some studies described in this thesis, recall bias might have 
played a role. We used self-report questionnaires on recurrent vascular events (chapter 4) 
and pregnancy data (chapter 6 and 7). All questionnaires were used in a structured 
manner. In case of our report on recurrent vascular events, we reduced the impact of recall 
bias by verifying every patient-reported vascular event by a neurologist or cardiologist 
using information collected from the treating physician. Nevertheless, there remains a 
risk of random misclassification and thus underestimation of recurrent vascular events, 
especially when these events occurred many years ago. This recall bias also applies to 
our findings on the risk of pregnancy-related complications (chapter 6 and 7). However, 
we consider the risk of misclassification of pregnancy complications low as pregnancy 
(and its complications) is an important life-event that is unlikely to be forgotten. This 
reliability in self reported pregnancy complications was considered moderate to good in a 
large systematic review, with a specificity of >90% for hypertensive diseases in pregnancy.6
Confounding 
Confounding may arise when there is an association of a third factor with both the 
determinant and outcome of interest.1 This third factor is not part of the causal chain 
and unintentionally influences the association between determinant and outcome. In our 
studies we also identified some potential confounders, such as age, which we corrected 
for in our analyses where possible. 
In our analyses on the risk of pregnancy complications after stroke (chapter 6) we 
were not able to correct for confounders (such as cardiovascular risk factors) due to the 
small sample size. Thus, we can state that the prevalence of pregnancy complications is 
elevated in women with a stroke at a young age when compared to population data, but 
there are still multiple explanations for this observation. Also, the secondary preventive 
(antithrombotic) therapy that patients received after stroke can also prevent pregnancy 
complications such as preeclampsia.7 Thus, if the sample size was large enough, we would 
have adjusted for the presence of cardiovascular risk factors and the use of antithrombotic 
therapy.
Hypertension, smoking and age are important contributors to the risk of SVD and 
were therefore included in the analyses as confounding factors (chapter 7).8-11 However, 
especially hypertension can also be part of the causal chain which links hypertensive 
disorders of pregnancy (HDP) to the development of SVD, because the risk of developing 
hypertension is significantly elevated when a woman suffered HDP.12, 13 We therefore 
repeated the analyses without adjustment for hypertension which did not change our 
results. This suggests that hypertension did not play a major role in the relation between 
HDP and SVD.
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Precision
Precision stands for the repeatability of a measure and random errors negatively influence 
the precision.1 A solution to reduce random errors is the inclusion of a large sample size. 
The FUTURE study includes a large sample size, but especially the studies on pregnancy 
complications and the risk of SVD were performed in a smaller sample size, resulting in 
less power, thus these results should be interpreted with caution. 
To limit random error in the measurement of SVD, all participants underwent investigation 
on the same MRI-scanner, and we achieved high inter- and intrarater reliability on 
cerebral SVD markers. 
External validity
External validity reflects the generalizability of the study, e.g. the extent to which the 
results of this study can be generalized to the general population.1
The FUTURE-study is not a population-based study, thus there is a possibility that not 
every young patient with a stroke was included. However, data of all consecutive patients 
18 to 50 years who visited our hospital were prospectively collected. Thereby, stroke under 
the age of 50 years is a very specific diagnosis, for which almost every patient alive after 
stroke will be referred to an academic hospital at least once during the course of their 
disease. There is some possible loss in patients who were not referred to our centre. This 
would especially be the case when the patient received an unjustly alternative diagnosis 
such as migraine or when the patient died shortly after stroke. The risk of misdiagnosis 
is especially increased in the earlier years of inclusion when the appropriate imaging 
techniques such as an MRI were not readily available. However, immediate death after 
ischemic stroke or TIA is rare and therefore the loss of eligible patients in this thesis will 
be minimal. Thus, the included study population of the FUTURE study represents the 
whole sample of young stroke patients in our catchment area and we therefore feel our 
results can be generalized to the general Dutch young stroke population.
Classification of stroke
This thesis shows that young stroke patients have a variety of (presumed) risk factors 
and proposed mechanisms for stroke. However, despite these findings these patients 
are currently very likely to be classified as stroke of undetermined origin (in 30-50% of 
cases)14, 15 when adhering to classification systems such as the TOAST classification,16, 
17 which was originally built for categorization of stroke in the elderly. A classification 
system specifically designed for a young stroke population is urgently needed to be able 
to investigate prognosis and appropriate treatment strategies stratified by the cause. This 
will facilitate individualized decision making, which is one of the main goals in young 
stroke care. 
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 164
Chapter 10
164
Some new classification initiatives emerged to reduce the number of cases that were 
left with a cryptogenic stroke, such as the ASCO classification (Atherosclerosis, Small-
vessel disease, Cardioembolic and Other causes).18 Applying ASCO resulted in significantly 
less strokes of undetermined cause when compared to the TOAST classification (ASCO 
26.5% versus TOAST 41.1%).19 However, classifying a stroke into ASCO’s category “Other 
causes” will still result in a residual group. Within such residual groups are potentially 
very different etiologies of stroke.20 For instance, recently it was found that a considerable 
part of patients with undetermined cause of stroke are likely to have an embolic origin 
of (yet) unknown source.21 Also, there might be yet unknown risk factors present, for 
instance genetic risk factors or a genetic predisposition.22 It is also possible that within 
these residual groups are specific mechanisms of stroke present but not recognized or 
investigated as such, for example arteriopathies not caused by atherosclerosis but caused 
by vasoconstriction, inflammation of the vessel wall or an infection (e.g. varicella).23, 24 
These mechanisms are rare in stroke the elderly, but on the other side of the age-spectrum, 
namely in children with ischemic stroke, these are very frequent findings because children 
are eminently missing the traditional cardiovascular risk factors.25-27 Therefore, we applied 
a pediatric stroke risk factor categorization (IPSS)26 to our young stroke cohort, which 
demonstrated that young stroke patients show overlap with pediatric stroke categories 
such as these non-atherosclerotic arteriopathies, but also on cardiac disorders (excluding 
atrial fibrillation), prothrombotic disorders and chronic systemic conditions. This is 
relevant because the appropriate treatment and prognosis differs for specific etiological 
diagnoses. For example, in a cohort from Utrecht was found that 11% of young adults 
(16-50years) with an anterior circulation ischemic stroke (and appropriate imaging) 
had signs of a unilateral intracranial arteriopathy, a diagnosis that originated from the 
etiology of stroke in children.28, 29 Some of these arteriopathies in young adults were 
transient and monophasic (non-atherosclerotic unilateral focal cerebral arteriopathy), so 
that the expected outcome is good and recurrence risk was low,28 and lifelong secondary 
preventive treatment might not be necessary. 
Thus, in case of undetermined stroke in young adults, the application of a pediatric 
diagnostic risk factor classification scheme may be result in the recognition of a wider 
spectrum of possible etiological categories,25, 26 that would have gone unnoticed with the 
conventional classification schemes. However, for most of these causes, proper diagnostic 
approaches and treatment need to be investigated. We should also be aware of the fact 
that IPSS is a risk factor inventory rather than a classification system. Thus, whether a 
risk factor is only an associated factor increasing the susceptibility to stroke, or directly 
causal/related to a specific mechanism, remains a matter of debate. This is to a great 
extent inevitable because the true origin of the embolus (or development of a thrombosis) 
in general cannot be witnessed, and the cause of stroke could be multifactorial. 
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Pregnancy and stroke in young adults
This thesis showed that pregnancy complications, such as gestational hypertension and 
HELLP syndrome, are very common in women after stroke and are significantly more 
prevalent than in the general Dutch population. Overall, one third of all nulliparous 
women experiences at least one pregnancy complication after stroke. Also, stillbirths 
and (multiple) miscarriages are more prevalent in a young stroke population than in the 
general Dutch population. Our observations further highlight the interaction between 
stroke and pregnancy complications: in addition to the already known fact that many 
pregnancy complications are a risk factor for stroke and cardiovascular disease in 
general,30-32 we now found evidence that a stroke itself, or associated risk factors, are 
also risk factors for future complicated pregnancies. Maybe these patients are already 
susceptible for the development of cardiovascular disease early in life, of which the 
debut can either be ischemic stroke at a young age or the development of a hypertensive 
disorder during pregnancy.
We also found that after first stroke, no recurrent events occurred during a subsequent 
pregnancy, which is comparable to other studies (0% to 1.8% in subsequent pregnancies).33, 
34 This finding might be explained by the secondary preventive treatment (such as 
antihypertensive drugs and antiplatelets) initiated directly after the stroke. Aspirin not 
only reduces the risk of recurrent stroke but in large randomized controlled trials it was 
also found to reduce the risk of preeclampsia with 10-15% in high-risk patients when 
subscribed during pregnancy.35 As preeclampsia is also a risk factor for stroke during 
pregnancy,36 aspirin will contribute to the prevention of both stroke and preeclampsia. 
Another possibility is that high-risk patients may not proceed to another pregnancy or 
are discouraged to get pregnant, although systematic data on this matter are lacking. 
Knowledge about risk of pregnancy-related disorders after stroke is important because 
women who suffer a stroke at a reproductive age will seek information on the risk of 
subsequent pregnancy-related complications.
Risk of recurrent events and SVD after stroke, stratified by hypertensive disorders of 
pregnancy
This thesis showed that the increased risk of both SVD and recurrent vascular events after 
young stroke is not modified by a history of HDP. Thereby, the increased WMH volumes 
of women with young stroke compared to controls remained present after correction 
for cardiovascular risk factors. Also, the predictive value of the prediction model for 
recurrent vascular events remained moderate despite incorporation of many known risk 
factors. These observations imply that there must be other (yet unknown) risk factors 
present that explain these increased risks. Evidence is rising that a genetic predisposition, 
inflammation, and various lifestyle factors can contribute to these risks.37-41 On the other 
hand, it is not yet sufficiently excluded that the more severe manifestations of HDP play 
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a role in the risk of recurrent events: we observed that patients with a history of HELLP 
or (pre)eclampsia had a higher cumulative risk of recurrent vascular events compared to 
women without complicated pregnancies, but we lacked power because of a small sample 
size. This observation is consistent with another study, that also observed a possible 
increased risk of recurrent stroke based on previous severe pregnancy complications 
(preeclampsia), in patients with stroke due to antiphospholipid syndrome.42
Based on our results we could thus recommend to focus on other (unknown) risk factors, 
but also to further investigate the influence of severe pregnancy complications on 
vascular outcome measures in patients with young stroke.
Clinical relevance
Following the results of this thesis, the treating physician should be aware that other, rare 
mechanisms might be the cause of stroke at a young age, especially if the patient does 
not fit into a “classic” cardiovascular profile and/or is younger than 35 years. In that case, a 
targeted approach is justified, including: the patient’s extensive medical history, detection 
of cardiac disorders on echocardiography, screening for coagulation disorders and an MRI 
with MR-angiography to detect non-atherosclerotic vasculopathies. Advanced imaging or 
laboratory investigations are not always available in every hospital thus the patient could 
be referred to an academic hospital for further evaluation. It is important to accurately 
classify the stroke because the prognosis after stroke is dependent on the etiology, which 
might implicate different treatment strategies: the risk of recurrent vascular events is 
especially high in patients with stroke due to early atherosclerosis or cardio-embolism, 
thus these patients probably should receive lifelong secondary preventive treatment. 
On the other hand, patients with an unknown cause of stroke (according to TOAST) 
had a lower risk of recurrent vascular events. Maybe there are patients within this 
residual group who do not need treatment or only for a limited period, or who need other 
targeted therapy. However, none of these stratified treatment strategies are evidence 
based and until now all patients are routinely treated with standard secondary preventive 
medication. It is an important topic because life-long secondary prevention in young 
adults means multiple decades of medication use, has psychosocial as well as financial 
consequences and is also associated with a risk of hemorrhagic complications of the 
secondary prevention itself.43-45
Furthermore, we identified several risk factors for recurrent vascular events, such as poor 
kidney function and a history of peripheral artery disease. We also found that smoking, 
which is a modifiable risk factor, is independently associated with recurrent events, and 
therefore smoking cessation should be strongly advised. Clinicians should be aware of 
these predictors so that they can appropriately inform and counsel the patient.46 
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 167
General discussion
167
10
Stroke and pregnancy
Acute stroke treatment options during pregnancy, such as intravenous rt-PA or intra-arterial 
thrombectomy were never investigated in randomized controlled trials, thus physicians as 
well as the patient should be aware of this limitation. However, these effective treatments 
should not be withheld from a pregnant woman with a disabling ischemic stroke when 
benefits outweigh the risk.47-49 In case of a stroke with a proximal occlusion of the intracranial 
vessels, direct mechanical thrombectomy without intravenous rt-PA can be considered as 
preferred treatment,50 however objective data in pregnant women are lacking. 
Also, pregnancy should always be addressed after stroke in women who are at a 
reproductive age. Appropriate counseling by both neurologist and gynecologist is 
warranted to correctly inform and guide these women, also in the period before pregnancy. 
On the other hand, the risk of a recurrent stroke during pregnancy seems very low. This 
implies that a subsequent pregnancy is not without a risk but, in our opinion, should 
not be discouraged. We emphasize the continuation of aspirin (not clopidogrel) during 
pregnancy after stroke, as it is safe and may reduce the risk of both recurrent stroke and 
preeclampsia. 
Future directions
Focusing on treatment strategies based on the etiology of stroke in the individual patient 
should receive urgent attention, starting with further unraveling etiologies of stroke 
in young adults. We should consider incorporating more categories into an etiologic 
classification system to accommodate to more possible mechanisms, including non-
atherosclerotic arteriopathies, prothrombotic disorders and chronic systemic conditions. 
MRI with vessel wall imaging can provide additional information on a possible underlying 
arteriopathy. Collaboration between many hospitals and possibly researchers from a 
pediatric stroke field, especially in case of rare (genetic) diseases, is recommended because 
large sample sizes are needed in every separate category. A prospective cohort is best 
suited for investigating the association between potential risk factors and stroke, using 
a risk factor inventory such as IPSS. These identified risk factors might also contribute 
to the risk estimation of SVD and recurrent vascular events. A longitudinal prospective 
cohort with a long-term follow-up in a large population-based setting is suited to 
further investigate risk factors for SVD and recurrent vascular events, and for building a 
prediction model with better predictive value. 
The ODYSSEY-study was initiated largely based on these (remaining) important issues. 
ODYSSEY has a nationwide multicentre design and was specifically designed to collect 
data on all risk factors and acute trigger factors, to unravel possible mechanisms of stroke 
in young adults. Also, blood samples will be taken for genetic purposes, and all women 
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are asked about the course of pregnancies and outcome. A considerable proportion of 
patients will receive MRI with high-resolution vessel wall imaging to evaluate the specific 
vessel wall characteristics seen amongst different etiologies. Furthermore, patients will 
receive follow-up every six months, so that we will have information on mortality, 
recurrent vascular events and continuation, initiation or discontinuation of secondary 
prevention. Thereby, we will include at least 250 controls who will receive the same 
follow-up investigations as patients. 
Thus, we feel that after FUTURE, ODYSSEY can provide valuable information on risk 
factors, mechanisms and prognosis of stroke at a young age, so that these patients will 
know what to expect, also when they are expecting. 
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Nederlandse samenvatting | Dutch summary 
Een herseninfarct is doodsoorzaak nummer 2 wereldwijd en één van de meest voorkomende 
oorzaken van (blijvende) invaliditeit. Ondanks het feit dat een herseninfarct voornamelijk 
bij ouderen voorkomt, betreft het in 15% van alle herseninfarcten een jong persoon 
(18-50jaar) en is de incidentie stijgende. Jaarlijks worden er inmiddels ruim 13 miljoen 
mensen wereldwijd getroffen door een herseninfarct, waarvan dus bijna 2 miljoen jonge 
mensen tussen de 18 en 50 jaar. Mensen die op jonge leeftijd getroffen worden door een 
herseninfarct staan midden in het leven waarin gezin en werk centraal staan. Zij hebben 
daarom grote behoefte aan informatie over de risicofactoren en de prognose van een 
herseninfarct. Het is belangrijk om te realiseren dat jonge mensen andere vragen hebben 
over hun toekomst dan ouderen, bijvoorbeeld over de risico’s van een eventuele volgende 
zwangerschap. De levensverwachting van deze jonge patiënten is over het algemeen ook 
dusdanig lang, dat informatie over prognose op de zéér lange termijn nodig is. Echter, die 
informatie is tot op heden nog relatief schaars. 
Om die reden werd de FUTURE-studie gestart, een prospectief cohortonderzoek naar 
oorzaken en de gevolgen van een herseninfarct of TIA op jonge leeftijd. In deel I, 
hoofdstuk 2 wordt besproken hoe de FUTURE-studie is opgezet. We onderzochten 1005 
patiënten met een herseninfarct, hersenbloeding of TIA op jonge leeftijd (tussen de 18-
50jaar) die waren opgenomen in het Radboud ziekenhuis Nijmegen tussen 1 januari 1980 
en 1 november 2010. Deze patiënten kregen allemaal follow-up tussen 2009 en 2012 en 
tussen 2014 en 2015, met een follow-up duur van soms wel 30 jaar. 
De studies uit dit proefschrift beschrijven verschillende uitkomsten van de 
FUTURE-studie, gericht op de risicofactoren en de lange termijn prognose van een 
herseninfarct of TIA op jonge leeftijd, met een speciale aandacht voor zwangerschap en 
zwangerschapsgerelateerde complicaties. 
Risicofactoren en lange termijn gevolgen van een herseninfarct op jonge leeftijd
Deel II, hoofdstuk 3 richt zich op de risicofactoren van een herseninfarct op jonge 
leeftijd. De oorzaak van het herseninfarct blijft in 30-40% van de gevallen onbekend 
wanneer er gebruik wordt gemaakt van een classificatiesysteem dat eigenlijk ontworpen 
is voor ouderen (de TOAST-classificatie). We categoriseerden daarom de patiënten van 
de FUTURE-studie volgens een risicofactor inventarisatie die gebruikt wordt bij kinderen 
(IPSS), om te evalueren of dit leidt tot een betere identificatie van risicofactoren en 
oorzaken. Van alle 656 patiënten kon 94% in één of meerdere IPSS-categorieën worden 
ingedeeld. De gevonden risicofactoren wezen dikwijls in de richting van specifieke 
mechanismes, zoals niet-atherosclerotische arteriopathieën, stollingsstoornissen en 
migraine. In 88% van de patiënten bij wie de oorzaak van het herseninfarct 'onbekend' 
was volgens de TOAST-classificatie, werden aan de hand van IPSS toch potentiële 
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risicofactoren gevonden. Dit kan een eerste aanzet vormen voor toekomstige initiatieven 
om een classificatiesysteem te maken specifiek gericht op oorzaken van een herseninfarct 
op jonge leeftijd.
De zeer lange termijn prognose na een herseninfarct of TIA op jonge leeftijd wordt 
beschreven in deel II, hoofdstuk 4, waarin is onderzocht wat het risico is op nieuwe 
vasculaire events en wat daarvoor de belangrijkste voorspellers zijn. Na 25 jaar follow-
up was het cumulatieve risico op een vasculair event 45.4% (1 op 2 patiënten) en 30.1% 
voor een nieuw herseninfarct (1 op de 3 patiënten). Als de oorzaak van het herseninfarct 
“large vessel disease” of “cardiale embolie” was, was die kans nog veel hoger (met een 25 
jaar cumulatief risico van ongeveer 60%). De belangrijkste voorspellers voor een nieuw 
vasculair event waren roken, een slechte nierfunctie en een voorgeschiedenis van perifeer 
vaatlijden of myocardinfarct. De voorspellende waarde van het predictiemodel was matig, 
waaruit blijkt dat er mogelijk nog andere (vooralsnog) onbekende risicofactoren een rol 
spelen.
Zwangerschap en een herseninfarct op jonge leeftijd
Deel III, hoofdstuk 5 beschrijft in een praktisch overzicht de diagnostiek en behandeling 
van een herseninfarct tijdens de zwangerschap en de (medicamenteuze) begeleiding erna. 
Het risico op een herseninfarct rondom de zwangerschap is verhoogd, met name vanaf het 
3e trimester tot 6 weken postpartum. Een MRI is de beste optie voor diagnostiek naar een 
herseninfarct tijdens de zwangerschap, maar een (“low-dose”) CT-hersenen is een valide 
alternatief. Behandelingen van een acuut herseninfarct, zoals intraveneuze trombolyse 
of intra-arteriële trombectomie, zijn op effectiviteit en veiligheid niet onderzocht in 
zwangere vrouwen, maar moeten zeker ook overwogen worden bij zwangere patiënten 
met een matig tot ernstig herseninfarct, wanneer de voordelen opwegen tegen het risico. 
Aspirine is als secundaire preventie veilig voor patiënten die zwanger zijn of borstvoeding 
geven. Echter, over het gebruik van clopidogrel tijdens de zwangerschap en lactatie zijn te 
weinig gegevens bekend en wordt als secundaire preventie dus afgeraden. Te allen tijde 
is er een multidisciplinaire aanpak nodig, waarbij minstens neuroloog, gynaecoloog en 
eventueel (interventie)radioloog zijn betrokken. 
Deel III, hoofdstuk 6 beschrijft het vóórkomen van zwangerschapscomplicaties bij 223 
vrouwen met ook een herseninfarct op jonge leeftijd. Vergeleken met de gegevens van de 
algemene Nederlandse populatie hadden deze 223 vrouwen significant vaker (meerdere) 
miskramen (35.2% versus 13.5%) en intra-uteriene vruchtdood (6.1% versus 0.9%). Specifiek 
bij vrouwen die zwanger werden na het herseninfarct of TIA kwamen significant vaker 
hypertensieve aandoeningen in de zwangerschap (33.3% versus 12.2%), HELLP-syndroom 
(9.5% versus 0.5%) en vroeggeboorte (9.0% versus 1.4%) voor. In hoofdstuk 6 werd ook 
onderzocht of een hypertensieve aandoening in de zwangerschap een risicofactor is voor 
een nieuw vasculair event na een herseninfarct op jonge leeftijd: het 20 jaar cumulatief 
534679-L-sub01-bw-vanAlebeek
Processed on: 10-9-2019 PDF page: 177
Dutch summary | Nederlandse samenvatting
177
11
risico op een nieuw vasculair event was 35.2%, maar een voorgeschiedenis van een 
hypertensieve aandoening in de zwangerschap had hier geen invloed op. Geen enkele 
vrouw kreeg een recidief vasculair event tijdens een (volgende) zwangerschap, ook niet 
als het eerste herseninfarct tijdens de zwangerschap was opgetreden. 
In deel III, hoofdstuk 7 werd vervolgens onderzocht of een hypertensieve aandoening 
in de zwangerschap een risicofactor is voor het ontwikkelen van small vessel disease 
(SVD) bij patiënten met een herseninfarct of TIA op jonge leeftijd. We vonden dat zowel 
patiënten met als zonder hypertensieve aandoening in de zwangerschap meer witte 
stofafwijkingen hadden dan controles (1.70ml versus 1.44ml versus 0.61 ml), ook wanneer 
we corrigeerden voor bekende cardiovasculaire risicofactoren zoals hypertensie en roken. 
Echter, op geen enkele SVD-marker verschilden de patiënten met of zonder hypertensieve 
aandoening significant van elkaar. 
Toekomstperspectief
Deel IV, hoofdstuk 8, beschrijft het onderzoeksprotocol van een nieuwe studie bij patiënten met 
een beroerte op jonge leeftijd: de ODYSSEY-studie (Observational Dutch Young Symptomatic 
StrokE studY). Het betreft een nationaal multicenter prospectief cohortonderzoek met als 
doel om de prognose en etiologie van een TIA, herseninfarct of hersenbloeding bij patiënten 
tussen 18 en 50 jaar te onderzoeken. Deze patiënten worden halfjaarlijks vervolgd. De 
primaire uitkomstmaten zijn overlijden en het risico op nieuwe vasculaire events. Secundaire 
uitkomstmaten zijn daarnaast o.a. (het risico op) zwangerschapscomplicaties en cognitieve 
problemen. Het gebruik van secundaire preventie en eventuele medicatiewijzigingen zal 
worden geregistreerd. Ook zullen acute triggerfactoren, de 'klassieke' en minder klassieke 
risicofactoren geïnventariseerd worden. Van een gedeelte van de patiënten zal een uitgebreide 
MRI-scan worden gemaakt met vaatwandopnames. Ook wordt er van elke patiënt bloed 
afgenomen ten behoeve van eventuele genetische analyses. 
Conclusie
De studies in dit proefschrift laten zien dat patiënten die op jonge leeftijd getroffen worden 
door een herseninfarct of TIA een hogere kans hebben op het ontwikkelen van nieuwe 
vasculaire events, en dat bij vrouwen vaker zwangerschapscomplicaties voorkomen. De 
klassieke cardiovasculaire risicofactoren zijn van belang voor het risico op vasculaire 
events en het ontwikkelen van small vessel disease, maar hypertensieve aandoeningen 
in de zwangerschap lijken dit reeds verhoogde risico niet nog verder te verhogen. Voor 
toekomstige studies is het van belang om te kijken naar alle mogelijke mechanismen van 
herseninfarct op jonge leeftijd zodat er uiteindelijk op individueel niveau kan worden 
behandeld op basis van de onderliggende oorzaak en de daarbij behorende prognose. 
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Een proefschrift maken doe je nooit alleen. Een hoop mensen hebben allemaal op hun 
eigen manier meegewerkt aan de totstandkoming van dit proefschrift. En al die mensen 
ben ik heel dankbaar. Een aantal mensen wil ik heel graag in het bijzonder noemen. 
Allereerst gaat mijn grootste dank natuurlijk uit naar alle patiënten die vrijwillig hebben 
meegewerkt aan de FUTURE-studie of nu meewerken aan de ODYSSEY-studie. Zonder 
jullie was dit waardevolle onderzoek én dit boekje er niet geweest.  
Prof. dr. Frank-Erik de Leeuw, beste FE. Ooit kwam ik vragen of ik bij jou mijn 
wetenschappelijke stage kon doen, bijna 10 jaar later staan we nu hier. Van ongeschreven 
blad naar een vol proefschrift. Het was inspirerende, leerzame en soms ook hobbelige 
weg, maar het is gelukt! Jouw enthousiasme en positiviteit hebben hier ten volste aan 
bijgedragen, waarvoor duizendmaal dank! Ik koester goede herinneringen aan al onze 
ritjes per auto (of soms fiets) door uiteindelijk heel Nederland om alle ODYSSEY centra 
te bezoeken, en de uiteenlopende gesprekken die we tijdens deze ritten hebben gehad. 
Je kritische maar ook nuchtere blik heeft mij gedurende al die jaren onderzoek scherp 
gehouden. Begaan met mij als onderzoeker maar net zo met mij als mens, had ik me geen 
promotor kunnen bedenken die ik beter had kunnen treffen. 
Dr. Tuladhar. Anil, zo gingen we van samen AIOS (waar je me nog vreselijk genept 
hebt als Mol op het “wie-is-de-mol?” assistentenweekend, ik ben er nog steeds niet 
helemaal overheen), naar arts-assistent en supervisor, en uiteindelijk naar promovenda 
en copromotor. In al die “rollen” heb ik jou altijd bijzonder gewaardeerd. En ik ben blij 
dat ik van jouw waardevolle begeleiding en kennis gebruik heb mogen maken tijdens de 
verschillende fasen van mijn promotietraject. Bedankt!
Prof. Dr. Klijn, beste Karin, dank voor jouw inspirerende kennis en kunde in de wetenschap 
en de neurologie, maar ook voor jouw interesse in de mens achter de dokter, en bovenal 
je oprechte interesse in mij.
Dr. Post, beste Bart, de rol als opleider staat jou goed. Je hebt mij altijd alle ruimte 
gegeven om mij zowel persoonlijk als wetenschappelijk te ontplooien. Dank ook voor de 
inspirerende gesprekken en nuttige levenslessen die je met mij gedeeld hebt. Ooit zeg 
ik ze weer voort. 
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Dr. Kappelle, beste Arnoud, als mentor heb je mij pieken maar soms ook dalen zien 
bereiken. Op al die momenten stond jij als een soort doorgewinterde “hockey-vader” aan 
de zijlijn te juichen of me weer aan te moedigen. Ik heb ontzettend veel gehad aan jouw 
oneindige steun, support, adviezen en het feit dat ik altijd op jou kon (en kan) rekenen. 
Jij bent goud!
Alle coauteurs wil ik erg graag bedanken voor alle waardevolle toevoegingen en tips die 
ik heb gekregen om de manuscripten naar een hoger niveau te tillen. Roel, bedankt voor 
al jouw waardevolle gynaecologische aanvullingen.
Mijn dankbaarheid gaat ook uit naar alle betrokkenen die nu landelijk heel hard werken 
om de ODYSSEY-studie tot een goed “eind” te brengen! 
Veel dank ook voor alle ondersteuning die ik tijdens mijn onderzoekstraject heb gehad 
(en heb), waaronder van Karin (Kans), Sharon, Saskia, Annet, Astrid, Anneke, Han en 
Angelique! Onmisbaar waardevol!
Karin, jou wil ik toch even specifiek noemen. Ik zie jou toch eigenlijk wel een beetje als 
de “moeder” van de young stroke groep :-). We hebben samen heel wat congrestripjes 
gemaakt. Eindeloos gekletst. Samen patiënten gezien en gesproken op zowel polikliniek 
als afdeling. Jij bent, samen met Sharon en Saskia natuurlijk, de stille motor (nou ja 
stil..) achter heel veel goedlopende neurovasculaire zorgpaden en onderzoekslijnen. Mijn 
complimenten. Dat mag toch ook wel eens even gezegd worden!
Mede FUTURista’s (ik verzin dit ter plekke, maar het klonk wel goed :-)): Loes, Noortje, 
Pauline, Renate en Nathalie. Nog steeds prijs ik me erg gelukkig dat ik me destijds bij 
jullie hebben kunnen en mogen aansluiten. Of we nou moesten plannen, stickeren, 
scannen, honderden mensen moesten bellen of voor de 80e keer alle statussen moesten 
doorbladeren (waar zijn die dozen nou weer?), samen met jullie was het eigenlijk nooit 
een straf. Een beetje pragmatiek, voldoende humor en de juiste versnapering op zijn tijd 
doet wonderen. Renate, ik kan me geen onderwerp bedenken waar we het niet over gehad 
hebben. Ik kon altijd bij jou voor advies of uitleg terecht, jij bent een prachtig mens en 
goed in alles wat je doet! Lieve Nathalie, wat was het nou ook alweer...pragmatisch is 
kort door de goede bocht, toch? Ik nam soms toch die buitenbocht, maar heb veel van je 
geleerd :-). Noortje: Als jij ergens voor gaat, ga je er ook de volle 100 voor, daar heb ik zo 
veel respect voor! Pauline, betrokken en slim, een succesvolle combinatie voor een goede 
onderzoekster! Lieve Loes: slim, altijd geduldig en bereid om te helpen, jouw kennis en 
hulp hebben mij heel veel verder geholpen! Bedankt voor alles!
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Alle collega’s van de onderzoekskamer 5e, waaronder Nienke, Tessa, Nathalie, Carlijn, Ellen, 
Hanneke, Corinne, Anna, Kim, Lotte, Merel, Esther B, Esther v L, Inge, Annemieke, Tessa 
W, Bonnie, Melina, Hannah, en Marthe. Ja, als je er sinds 2012 af en aan zit zoals ik, heb je 
inmiddels héél wat groepssamenstellingen versleten. Sorry dus als ik iemand ben vergeten! 
Maar, zo’n gezellige onderzoekskamer maakt wel degelijk heel veel uit voor de hele “PhD 
experience”. Koffie en thee sessies, even ventileren bij die keiharde writer’s block, samen 
hoogwaardig sparren of juist slap ouwehoeren. Kerstbomen versieren. Wekelijks taarten 
bakken (en op een gegeven moment weer opdoeken want écht niet goed voor de lijn). 
Hele ontbijtsessies met sap en croissants. Freaky baby’s verstoppen (leuk hè Esther v L?). Ik 
denk nog steeds met een grote glimlach terug aan die ene opruimsessie waarbij we zoveel 
kleingeld vonden dat we de chips-automaat beneden hadden leeggekocht. Dat soort 
herinneringen maken die hele onderzoekservaring voor mij compleet! Dankjulliewel!
Esther B, Merel, Jamie en Mijntje, bedankt dat jullie het ODYSSEY stokje van mij en 
Renate hebben overgenomen. ODYSSEY voelt in zeer veilige handen bij jullie :-). Ik kijk 
uit naar alle resultaten die voort zullen komen uit de studie.
Esther v L, zo leuk dat wij de laatste periode (bijna) tegelijkertijd hebben kunnen afronden. 
Ok ok, ik liep iets uit. Je had een jaloersmakend goede verdediging, nu ik nog! Enne, lunch-
time is voor ons never over!!
Aan alle andere mensen van de vasculaire groep: de groep wordt nog steeds groter en 
dat is een goed teken! Bedankt voor alle waardevolle vasculaire meetings en leerzame en 
gezellige ESO/ESC trips. Fijn dat zo’n toegewijd team zich hard maakt voor de vasculaire 
neurologie. Daar mogen we trots op zijn!
Mijn zeer gewaardeerde collega AIOS, wat mogen wij trots zijn op ons team. 
Professionaliteit, collegialiteit en gezelligheid staan hoog in het vaandel hier! Ondanks 
de immer wisselende samenstelling in de jaren dat ik hier al werk, verandert daar gelukkig 
niets aan. Hou dit vast! 
Bas, Anouke en Joery: Bedankt voor een geweldige opleidingstijd samen. Nu iedereen 
langzaam aan het uitwaaieren is hoop ik dat we elkaar niet alleen nog maar zullen 
zien op de Biemond ;-). Enne, ons “nudisten” assistentenweekend 2013 blijft nog steeds 
onverminderd de beste! 
Lieve Tessa, als vaste poliwaarneemster heb je je altijd hard gemaakt voor “mijn” 
polipatiënten. Ook wij samen hebben er heel wat fijne gesprekken opzitten. Enne, ik heb 
jouw “grumpy cat” mints nog steeds in m’n tas hoor ;-). Ik gun jou alles. Ik hoop dat ik 
heel binnenkort ook op jouw promotie mag komen! 
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Lieve Myrthe, samen belden wij héél veel vrouwen om te vragen naar hun doorgemaakte 
zwangerschappen. Het ging ons soms best aan het hart om al die persoonlijke verhalen 
te horen. Bloed zweet en tranen om de klus geklaard te krijgen. Schrijven schrijven. Toen 
bleef het even liggen. Maar, een tijd na jouw wetenschappelijke stage kwam dat definitieve 
artikel er uiteindelijk gelukkig tóch. Ooit was ik jouw mentor, nu ben je misschien nog 
wel eerder klaar dan ik als neuroloog. Bedankt voor al je hulp en gezellige gesprekken! 
En een kus voor Maren!
Jeroen, aka Dillers: Als Brabanders onder elkaar hadden wij, zammazegge, gelijk een 
keimooi startpunt van waaruit een dierbare vriendschap is ontstaan. Gaan we binnenkort 
weer een keer friet (géén patat) eten en Bert Visscher kijken? Joe!
Dokter van Gaalen, lieve Judith, altijd in voor een goed gesprek, gezellige Arnhemse uitjes 
en Nijmeegse lunchdates. Lunch? 12.30u? Grote restaurant? Ok, zie je zo. 
Anke, a.k.a. dr. Rietvink. Tijdens onze (in principe ;-)) wekelijkse zwemsessies bespraken we 
alles wat los en vast zat. Al banenzwemmend analyseerden we de voortgang van artikelen, 
submit frustraties, opvoedkundige materie en dagelijkse beslommeringen op het werk. 
Alles is denk ik wel de revue gepasseerd. Van zwemmen kwam soms niet veel terecht, 
maar dat was voor mij toch het minst belangrijke punt van de hele avond. Je bent een 
topmens met een hart van goud. Ik kijk tegen jou op als professional en als persoon. Ik 
vind het zo jammer dat je binnenkort naar Frankrijk vertrekt, en misschien wel voorgoed. 
Beloof je dan wel dat er een logeerkamer is in jullie Franse maison? 
Co-groep 102: De harde kern: Erik, Marloes, Nikki, Lyvonne, Esther, Anne, Sandra, Monique 
en Robin.
Ik kijk met zoveel goede herinneringen terug op al die coschappen en al die vakanties die 
we samen hebben doorlopen. We waren allemaal serieus en toegewijd aan onze opleiding, 
maar het was toch ook geregeld één groot feest. Ik zal die gouden avondjes in de Malle 
Babbe niet gauw vergeten (en als ik dat wel doe, dan hebben we “gelukkig” de foto’s 
nog hahaha), evenmin die duizenden potjes die wij hebben getoept. Overal. Altijd. We 
begonnen ooit met z’n 10-en...toen kwamen de partners…toen de kinderen…en nu ben ik 
de tel kwijt. Het doet me goed dat we, ondanks al die wendingen in onze privé en werk 
situaties, toch nog steeds moeite doen om elkaar met enige regelmaat te zien. Dat is me 
heel veel waard. Ik kijk alweer reikhalzend uit naar co-weekend 2020! Enne, ik toep over. 
Lieve Nikki, ik vind het nog steeds een gelukje dat jullie “achter ons” zijn komen wonen 
in het mooie Velp! Ook zo leuk dat onze kids het zo goed kunnen vinden samen. Je bent 
altijd zo oprecht geïnteresseerd geweest in mijn onderzoek en mijn voortgang, dat stel 
ik echt heel erg op prijs. Dankjewel! Laten we snel weer even een thee-moment plannen.
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Team Ouderwets-gezellig, a.k.a. the Cargo Crew; Pascal, Guido en Nadine: Ondanks dat 
jullie redelijk ver weg tot zelfs aan de Zeeuwse kust wonen, is ons contact gelukkig nooit 
verwaterd :-). Ik denk ook niet dat dat nu nog zal gebeuren want dan was dat de afgelopen 
15 jaar al wel gebeurd. Laten we vooral ouderwets en gezellig blijven. BBQ Middelkoop 
2020 staat alweer in de agenda (de after eight is gekocht). 
En misschien "Vlissingen zingt" 2020 of "Cargolympics" 2020? ;-) Kom maar op met al die 
datumprikkers!
Allerliefste paranymf vriendinnetjes. Onze geschiedenis gaat way back, ik weet niet eens 
waar ik moet beginnen!
Lieve Nadine, als broekies op de middelbare school deelden we al gauw dezelfde humor en 
onze interesses, waaronder in reizen en cultuur. Daarna als studiegenootjes en uiteindelijk 
huisgenoten hebben we lief en leed gedeeld. Jij leerde mij het “vak” van het goed Sale-
shoppen en exquise nieuwe gerechten bedenken met kliekjes. Menig stedentrip en vakantie 
hebben we achter de rug, cultuursnuivend tot we er op de laatste dag achter kwamen dat 
we nog geen enkele dag bij het zwembad hadden gelegen. Nu wonen we ver uit elkaar, 
maar dat maakt de vriendschap niet minder sterk. Ik vind het supermooi om te zien hoe we 
samen gegroeid zijn, en jij nu als revalidatiearts ook precies op je plek terecht bent gekomen!
Lieve Lyvonne; ja, haal die bril maar vast uit dat tasje want dit stukje is voor jou! Tja tja tja, co-
groep 102 dat was het he. Al gauw ontdekten we dat wij een humor hadden die niet iedereen 
begreep. Ik weet niet of ik met iemand harder kan lachen dan met jou. Ook wij hebben er 
inmiddels heel wat vakanties, feestjes, meetings, etentjes, game -en cabaret-avonden opzitten. 
Ik heb er nog lang geen genoeg van! Nu we allebei de “geneugten” van het moeder-zijn hebben 
ontdekt, ontplooit zich weer een heel nieuw hoofdstuk met weer zeeën van inspiratie om 
zwartgallig en sarcastisch over te zijn. Tot we oud en verrimpeld zijn. Lyv: dankewol!
Verder wilde ik nog iets leuks zeggen, maar het boek zat al dicht. 
Lieve schoonouders, Ellen en Joop, bedankt dat jullie me met open armen hebben 
ontvangen en me als natuurlijk hebben opgenomen in de familie. Bedankt dat jullie zo 
openlijk trots op me zijn. De deur bij jullie staat altijd open, jullie staan altijd voor ons 
klaar en dat waardeer ik enorm! 
Renate, Maarten en Duuc en Demi: met jullie is het altijd gezellig! Binnenkort een feestje? 
Dan gaan we weer dansen!
Opa Klompenhouwer, ik vind het zeer bijzonder dat u en oma (†) altijd zoveel interesse 
hebben getoond in mijn promotietraject. Met plezier heb ik alle artikelen voor u uitgeprint 
en ik waardeer het enorm dat u ze ook allemaal hebt gelezen, ondanks dat het toch geen 
makkelijke kost is. Ik weet dat u er vandaag heel graag bij had willen zijn, maar ondanks 
uw vechtlust heeft u het toch net niet gehaald († 14-08-2019). Ik hoop dat u samen met 
Henny vanaf daarboven toch nog kunt meegenieten! 
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Rein a.k.a. Reinemans; mijn 9 jaar jongere maar toch 3 koppen grotere kleine boertje. Was 
ik maar half zo slim als jij. Als je wil heb je in no-time het wiskundig bewijs gevonden 
dat kaas toch echt worst is. Zo zorgzaam en toegewijd als jij tegelijkertijd bent, daar kan 
menig persoon nog een puntje aan zuigen! Hou die kwaliteiten vast, ze zouden nog wel 
eens van pas kunnen komen ;-).
1337.
Els en Wiljo. Mijn ouderts. Papsie en mamsie. Vadert en moedert. Jullie leerden mij 
alles wat ik moest leren om de volwassene te worden die ik nu ben. En nog steeds kan 
ik altijd terecht voor raad en daad. Jullie staan altijd voor mij klaar en hebben altijd 
onverminderd achter me gestaan. Ook als het even tegenzat. Even sip-lippen en weer 
doorgaan. Relativeren. Schouders eronder. Grapje ertussendoor. Snackje erbij :-). En door. 
Altijd positief en enthousiast. 
Ik ben zo gelukkig als ik zie dat Yrsa weer de dag van haar leven heeft gehad bij jullie in 
5-sterren Hotel “van Alebeek-Mulder” ;-). Het zal haar aan niets ontbreken zoals het aan 
mij ook nooit íets heeft ontbroken!
Enne, dear MoM, ik kan ‘t  niet op een beter moment zeggen dan nu:  All’s well that ends 
well.
Yrsa. Mijn lieve meisje, wat ben je toch leuk. En eigenwijs. En wat lijk je toch op je vader. 
Uiterlijk dan he. Hahahaha. Knuffel en een kus!
Lieve Rem(co), onze allereerste gesprekken kwamen ooit, via tuinkabouters en floaters, uit 
op de rode draad in het leven. Ik kan gerust zeggen dat jíj inmiddels die rode draad in mijn 
leven bent geworden. Samen de natuur in, de wijde wereld zien met een backpack, gewoon 
rondom ons eigen huis, fotograferen, snorkelen, vogelspotten, Netflix bingen, zwemmen, 
lachen, liggen, zitten, staan, lopen. Ik vind alles even leuk als het maar met jou is. Je was een 
enorme support de afgelopen jaren. De stabiele factor. De liefste vader voor Yrsa. Zorgzaam 
en bomvol (best rare) humor. Jij helpt mij nuchter nadenken (dat tegeltje he..). Het zijn die 
kleine dingen, zoals die joggingbroek die beneden klaarligt na een lange werkdag. Ik verbaas 
me wel eens dat dat allemaal in één persoon kan zitten. Lucky me! Lief jou!
Oh, Yrsa wil ook nog even “werke”, hier komt het:
“xxxxxxxxxxxxxxxxxxxxxxxxddddrrrrlhlhhhhhhhhhhhhghhhhhjj,4hhaggtt12345678
90nnnnnnnnnnnnnnnnnnnnnvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvcccccccccccccccccccccc
ccccccccccccczzzzzv bzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz knnnnnnllol loiolloiuuytdfewqw q.”
Bedankt lieverd, écht heel mooi gemaakt. 
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For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), which was 
officially recognised as a national graduate school in 2009. The Graduate School covers 
training at both Master’s and PhD level and provides an excellent educational context 
fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, e.g. 
Stanford University, University of Oxford, University of Cambridge, UCL London, MPI 
Leipzig, Hanyang University in South Korea, NTNU Norway, University of Illinois, North 
Western University, Northeastern University in Boston, ETH Zürich, University of Vienna 
etc.. Positions outside academia spread among the following sectors: specialists in a 
medical environment, mainly in genetics, geriatrics, psychiatry and neurology. Specialists 
in a psychological environment, e.g. as specialist in neuropsychology, psychological 
diagnostics or therapy. Positions in higher education as coordinators or lecturers. A 
smaller percentage enters business as research consultants, analysts or head of research 
and development. Fewer graduates stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the IT sector 
and management position in pharmaceutical industry. In general, the PhDs graduates 
almost invariably continue with high-quality positions that play an important role in 
our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
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